CA3158394A1 - Cellulose composition and tablet - Google Patents
Cellulose composition and tabletInfo
- Publication number
- CA3158394A1 CA3158394A1 CA3158394A CA3158394A CA3158394A1 CA 3158394 A1 CA3158394 A1 CA 3158394A1 CA 3158394 A CA3158394 A CA 3158394A CA 3158394 A CA3158394 A CA 3158394A CA 3158394 A1 CA3158394 A1 CA 3158394A1
- Authority
- CA
- Canada
- Prior art keywords
- cellulose
- mass
- tablet
- cellulose composition
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 183
- 239000001913 cellulose Substances 0.000 title claims abstract description 180
- 229920002678 cellulose Polymers 0.000 title claims abstract description 180
- 150000004043 trisaccharides Chemical class 0.000 claims abstract description 28
- 239000000126 substance Substances 0.000 claims description 88
- 239000000843 powder Substances 0.000 claims description 65
- 239000002245 particle Substances 0.000 claims description 63
- -1 fatty acid esters Chemical class 0.000 claims description 32
- FYGDTMLNYKFZSV-ZWSAEMDYSA-N cellotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-ZWSAEMDYSA-N 0.000 claims description 29
- 239000000314 lubricant Substances 0.000 claims description 22
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 15
- 229930195729 fatty acid Natural products 0.000 claims description 15
- 239000000194 fatty acid Substances 0.000 claims description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 229910052751 metal Inorganic materials 0.000 claims description 9
- 239000002184 metal Substances 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 4
- 235000013539 calcium stearate Nutrition 0.000 claims description 4
- 239000008116 calcium stearate Substances 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 239000000454 talc Substances 0.000 claims description 4
- 229910052623 talc Inorganic materials 0.000 claims description 4
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 description 165
- 239000003826 tablet Substances 0.000 description 107
- 238000000034 method Methods 0.000 description 73
- 239000006185 dispersion Substances 0.000 description 40
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- 238000002156 mixing Methods 0.000 description 30
- 238000001035 drying Methods 0.000 description 27
- 239000000284 extract Substances 0.000 description 26
- 238000005469 granulation Methods 0.000 description 25
- 230000003179 granulation Effects 0.000 description 25
- 238000004519 manufacturing process Methods 0.000 description 25
- 238000005259 measurement Methods 0.000 description 25
- 239000000546 pharmaceutical excipient Substances 0.000 description 25
- 239000002904 solvent Substances 0.000 description 25
- 230000002349 favourable effect Effects 0.000 description 21
- 230000009467 reduction Effects 0.000 description 18
- 238000003756 stirring Methods 0.000 description 18
- 239000000654 additive Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 239000003814 drug Substances 0.000 description 16
- 239000007787 solid Substances 0.000 description 15
- 230000000704 physical effect Effects 0.000 description 14
- 229940124531 pharmaceutical excipient Drugs 0.000 description 13
- 229920002472 Starch Polymers 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 12
- 239000008187 granular material Substances 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 235000002639 sodium chloride Nutrition 0.000 description 11
- 239000011230 binding agent Substances 0.000 description 10
- 238000000748 compression moulding Methods 0.000 description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 10
- 238000006386 neutralization reaction Methods 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000000465 moulding Methods 0.000 description 9
- 230000009257 reactivity Effects 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 8
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 238000000227 grinding Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000007921 spray Substances 0.000 description 8
- 238000005507 spraying Methods 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 7
- BNABBHGYYMZMOA-IIXPINMKSA-N Celloheptaose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3[C@H](O[C@@H](O[C@@H]4[C@H](O[C@@H](O[C@@H]5[C@H](O[C@@H](O[C@@H]6[C@H](O[C@@H](O)[C@H](O)[C@H]6O)CO)[C@H](O)[C@H]5O)CO)[C@H](O)[C@H]4O)CO)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O BNABBHGYYMZMOA-IIXPINMKSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- OCIBBXPLUVYKCH-FYTDUCIRSA-N beta-D-cellohexaose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3[C@H](O[C@@H](O[C@@H]4[C@H](O[C@@H](O[C@@H]5[C@H](O[C@@H](O)[C@H](O)[C@H]5O)CO)[C@H](O)[C@H]4O)CO)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O OCIBBXPLUVYKCH-FYTDUCIRSA-N 0.000 description 7
- 238000011088 calibration curve Methods 0.000 description 7
- OCIBBXPLUVYKCH-UHFFFAOYSA-N cellopentanose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(OC3C(OC(OC4C(OC(OC5C(OC(O)C(O)C5O)CO)C(O)C4O)CO)C(O)C3O)CO)C(O)C2O)CO)C(O)C1O OCIBBXPLUVYKCH-UHFFFAOYSA-N 0.000 description 7
- FTNIPWXXIGNQQF-XHCCAYEESA-N cellopentaose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3[C@H](O[C@@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FTNIPWXXIGNQQF-XHCCAYEESA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000012937 correction Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000003086 colorant Substances 0.000 description 6
- 239000007884 disintegrant Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000003599 food sweetener Nutrition 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 238000006116 polymerization reaction Methods 0.000 description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 6
- 238000001694 spray drying Methods 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 5
- PZUPAGRIHCRVKN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]-5-[3,4,5-trihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound OCC1OC(O)C(O)C(O)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(COC4C(C(O)C(O)CO4)O)O3)O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(COC2C(C(O)C(O)CO2)O)O1 PZUPAGRIHCRVKN-UHFFFAOYSA-N 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 5
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 5
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 5
- 229960003291 chlorphenamine Drugs 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 235000019700 dicalcium phosphate Nutrition 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 229960000304 folic acid Drugs 0.000 description 5
- 239000011724 folic acid Substances 0.000 description 5
- 235000019152 folic acid Nutrition 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 229960002477 riboflavin Drugs 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- LUEWUZLMQUOBSB-ZLBHSGTGSA-N alpha-maltotetraose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](O[C@H](O[C@@H]3[C@H](O[C@H](O)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-ZLBHSGTGSA-N 0.000 description 4
- 229940024545 aluminum hydroxide Drugs 0.000 description 4
- 229960003556 aminophylline Drugs 0.000 description 4
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000004927 clay Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- LPRLDRXGWKXRMQ-UHFFFAOYSA-N diphenylpyraline hydrochloride Chemical compound [Cl-].C1C[NH+](C)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 LPRLDRXGWKXRMQ-UHFFFAOYSA-N 0.000 description 4
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 4
- 229940090949 docosahexaenoic acid Drugs 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 229960001680 ibuprofen Drugs 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 229960001855 mannitol Drugs 0.000 description 4
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 4
- 235000019814 powdered cellulose Nutrition 0.000 description 4
- 229920003124 powdered cellulose Polymers 0.000 description 4
- 239000011164 primary particle Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 241000555678 Citrus unshiu Species 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 241000241413 Propolis Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 235000006886 Zingiber officinale Nutrition 0.000 description 3
- 244000273928 Zingiber officinale Species 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 229940023476 agar Drugs 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 3
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000001465 calcium Nutrition 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 229950008138 carmellose Drugs 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 235000017471 coenzyme Q10 Nutrition 0.000 description 3
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229960000913 crospovidone Drugs 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 3
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 3
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 description 3
- 229960000514 ethenzamide Drugs 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000008397 ginger Nutrition 0.000 description 3
- 229960002449 glycine Drugs 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229910001701 hydrotalcite Inorganic materials 0.000 description 3
- 229960001545 hydrotalcite Drugs 0.000 description 3
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 3
- 239000001095 magnesium carbonate Substances 0.000 description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 235000010449 maltitol Nutrition 0.000 description 3
- 239000000845 maltitol Substances 0.000 description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 3
- 229940035436 maltitol Drugs 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 3
- 235000019175 phylloquinone Nutrition 0.000 description 3
- 239000011772 phylloquinone Substances 0.000 description 3
- 229960001898 phytomenadione Drugs 0.000 description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229940069949 propolis Drugs 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 235000019192 riboflavin Nutrition 0.000 description 3
- 239000002151 riboflavin Substances 0.000 description 3
- 239000011163 secondary particle Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- 229920003169 water-soluble polymer Polymers 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- FLNXBVJLPJNOSI-UHFFFAOYSA-N 1-[2-[(4-chlorophenyl)-phenylmethoxy]ethyl]piperidine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 FLNXBVJLPJNOSI-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 2
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 2
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 2
- QPRQEDXDYOZYLA-UHFFFAOYSA-N 2-methylbutan-1-ol Chemical compound CCC(C)CO QPRQEDXDYOZYLA-UHFFFAOYSA-N 0.000 description 2
- QOLHOCYZKJILAV-UHFFFAOYSA-N 5-[(3-carboxy-4-hydroxyphenyl)methyl]-2-hydroxybenzoic acid;n,n-dimethyl-1-phenothiazin-10-ylpropan-2-amine Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1.C1=C(O)C(C(=O)O)=CC(CC=2C=C(C(O)=CC=2)C(O)=O)=C1 QOLHOCYZKJILAV-UHFFFAOYSA-N 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- 241000132012 Atractylodes Species 0.000 description 2
- 241000132011 Atractylodes lancea Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 206010004542 Bezoar Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- AKJDEXBCRLOVTH-UHFFFAOYSA-N Carbetapentane citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 AKJDEXBCRLOVTH-UHFFFAOYSA-N 0.000 description 2
- 240000003538 Chamaemelum nobile Species 0.000 description 2
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 2
- 235000001258 Cinchona calisaya Nutrition 0.000 description 2
- 244000037364 Cinnamomum aromaticum Species 0.000 description 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 2
- 240000009138 Curcuma zedoaria Species 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000218671 Ephedra Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 240000006927 Foeniculum vulgare Species 0.000 description 2
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 2
- 241000605372 Fritillaria Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 241001071795 Gentiana Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- 244000299507 Gossypium hirsutum Species 0.000 description 2
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241000208343 Panax Species 0.000 description 2
- 235000002791 Panax Nutrition 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 241000972673 Phellodendron amurense Species 0.000 description 2
- 241001127637 Plantago Species 0.000 description 2
- 235000006751 Platycodon Nutrition 0.000 description 2
- 244000274050 Platycodon grandiflorum Species 0.000 description 2
- 241000208966 Polygala Species 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 244000223014 Syzygium aromaticum Species 0.000 description 2
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 235000013832 Valeriana officinalis Nutrition 0.000 description 2
- 244000126014 Valeriana officinalis Species 0.000 description 2
- XWCYDHJOKKGVHC-UHFFFAOYSA-N Vitamin A2 Chemical compound OCC=C(C)C=CC=C(C)C=CC1=C(C)C=CCC1(C)C XWCYDHJOKKGVHC-UHFFFAOYSA-N 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 241000949456 Zanthoxylum Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- HZVVJJIYJKGMFL-UHFFFAOYSA-N almasilate Chemical compound O.[Mg+2].[Al+3].[Al+3].O[Si](O)=O.O[Si](O)=O HZVVJJIYJKGMFL-UHFFFAOYSA-N 0.000 description 2
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960004991 artesunate Drugs 0.000 description 2
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 229940106164 cephalexin Drugs 0.000 description 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229960002544 cloperastine Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- AQEDFGUKQJUMBV-UHFFFAOYSA-N copper;ethane-1,2-diamine Chemical compound [Cu].NCCN AQEDFGUKQJUMBV-UHFFFAOYSA-N 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 229960002448 dasatinib Drugs 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 2
- XLIDPNGFCHXNGX-UHFFFAOYSA-N dialuminum;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Al+3].[Al+3].[Si+4] XLIDPNGFCHXNGX-UHFFFAOYSA-N 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 229940015826 dihydroxyaluminum aminoacetate Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229960000520 diphenhydramine Drugs 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 2
- 229960004646 diphenhydramine tannate Drugs 0.000 description 2
- 229960002392 diphenylpyraline hydrochloride Drugs 0.000 description 2
- 238000002036 drum drying Methods 0.000 description 2
- 229960000980 entecavir Drugs 0.000 description 2
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 229960002568 ethinylestradiol Drugs 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 2
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 2
- 229960002867 griseofulvin Drugs 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 238000009775 high-speed stirring Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 239000001341 hydroxy propyl starch Substances 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960004400 levonorgestrel Drugs 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 229960000869 magnesium oxide Drugs 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 229960004708 noscapine Drugs 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 229960003893 phenacetin Drugs 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- 229960002695 phenobarbital Drugs 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 229940018492 plantago seed Drugs 0.000 description 2
- 229930189914 platycodon Natural products 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- 239000008262 pumice Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000013094 purity test Methods 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 229960000948 quinine Drugs 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 229940100486 rice starch Drugs 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 230000004799 sedative–hypnotic effect Effects 0.000 description 2
- 229940048730 senega Drugs 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 2
- 150000004044 tetrasaccharides Chemical class 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 229960005196 titanium dioxide Drugs 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000016788 valerian Nutrition 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 229940100445 wheat starch Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 1
- KTGRHKOEFSJQNS-BDQAORGHSA-N (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;oxalic acid Chemical compound OC(=O)C(O)=O.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 KTGRHKOEFSJQNS-BDQAORGHSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- AJZJIYUOOJLBAU-CEAXSRTFSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;n,n,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1.C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 AJZJIYUOOJLBAU-CEAXSRTFSA-N 0.000 description 1
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 1
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- 239000001096 (4-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol hydrochloride Substances 0.000 description 1
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 1
- ZGSZBVAEVPSPFM-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC ZGSZBVAEVPSPFM-FFHNEAJVSA-N 0.000 description 1
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- DJAHKBBSJCDSOZ-AJLBTXRUSA-N (5z,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one;(5e,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C/CCC(C)=O.CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O DJAHKBBSJCDSOZ-AJLBTXRUSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NNKXWRRDHYTHFP-HZQSTTLBSA-N (r)-[(2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;hydron;dichloride Chemical compound Cl.Cl.C([C@H]([C@H](C1)C=C)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 NNKXWRRDHYTHFP-HZQSTTLBSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- JWDYCNIAQWPBHD-UHFFFAOYSA-N 1-(2-methylphenyl)glycerol Chemical compound CC1=CC=CC=C1OCC(O)CO JWDYCNIAQWPBHD-UHFFFAOYSA-N 0.000 description 1
- UOTMYNBWXDUBNX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinolin-2-ium;chloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 UOTMYNBWXDUBNX-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- FBOUYBDGKBSUES-KEKNWZKVSA-N 1-azabicyclo[2.2.2]octan-3-yl (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(OC2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-KEKNWZKVSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
- NOXZRZKBAKQQAL-UHFFFAOYSA-M 2,2-diphenyl-4-piperidinomethyl-1,3-dioxolane methiodide Chemical compound [I-].C1OC(C=2C=CC=CC=2)(C=2C=CC=CC=2)OC1C[N+]1(C)CCCCC1 NOXZRZKBAKQQAL-UHFFFAOYSA-M 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- LZFZQYNTEZSWCP-UHFFFAOYSA-N 2,6-dibutyl-4-methylphenol Chemical compound CCCCC1=CC(C)=CC(CCCC)=C1O LZFZQYNTEZSWCP-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- WYUYEJNGHIOFOC-VVTVMFAVSA-N 2-[(z)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C\CN1CCCC1 WYUYEJNGHIOFOC-VVTVMFAVSA-N 0.000 description 1
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 description 1
- GZECPKFYQHSCEV-UHFFFAOYSA-N 2-[2-benzhydryloxyethyl(methyl)amino]-1-phenylpropan-1-ol;phosphoric acid Chemical compound OP(O)(O)=O.C=1C=CC=CC=1C(C=1C=CC=CC=1)OCCN(C)C(C)C(O)C1=CC=CC=C1 GZECPKFYQHSCEV-UHFFFAOYSA-N 0.000 description 1
- FBCDRHDULQYRTB-UHFFFAOYSA-N 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-1h-imidazo[5,1-f][1,2,4]triazin-4-one;trihydrate;hydrochloride Chemical compound O.O.O.Cl.CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 FBCDRHDULQYRTB-UHFFFAOYSA-N 0.000 description 1
- FSSICIQKZGUEAE-UHFFFAOYSA-N 2-[benzyl(pyridin-2-yl)amino]ethyl-dimethylazanium;chloride Chemical compound Cl.C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 FSSICIQKZGUEAE-UHFFFAOYSA-N 0.000 description 1
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- CMCCHHWTTBEZNM-UHFFFAOYSA-N 2-bromo-N-carbamoyl-3-methylbutanamide Chemical compound CC(C)C(Br)C(=O)NC(N)=O CMCCHHWTTBEZNM-UHFFFAOYSA-N 0.000 description 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- WQOYJMWVNIGIQR-UHFFFAOYSA-N 3-(dithiophen-2-ylmethylidene)-1-methylpiperidine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1N(C)CCCC1=C(C=1SC=CC=1)C1=CC=CS1 WQOYJMWVNIGIQR-UHFFFAOYSA-N 0.000 description 1
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 1
- GNKZMNRKLCTJAY-UHFFFAOYSA-N 4'-Methylacetophenone Chemical compound CC(=O)C1=CC=C(C)C=C1 GNKZMNRKLCTJAY-UHFFFAOYSA-N 0.000 description 1
- PBBGSZCBWVPOOL-HDICACEKSA-N 4-[(1r,2s)-1-ethyl-2-(4-hydroxyphenyl)butyl]phenol Chemical compound C1([C@H](CC)[C@H](CC)C=2C=CC(O)=CC=2)=CC=C(O)C=C1 PBBGSZCBWVPOOL-HDICACEKSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- FQUTYCCWVYCBGB-UHFFFAOYSA-N 4-butyl-1,2-diphenylpyrazolidine-3,5-dione;4-(dimethylamino)-1,5-dimethyl-2-phenylpyrazol-3-one Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1.O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 FQUTYCCWVYCBGB-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- OUTUZEBQXNEVGY-UHFFFAOYSA-N 5,5-diethyl-1,3-diazinane-2,4,6-trione;4-(dimethylamino)-1,5-dimethyl-2-phenylpyrazol-3-one Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O.O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 OUTUZEBQXNEVGY-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- PUHLHLQBIFRKRD-CSKARUKUSA-N 5-methyl-2-[(E)-2-phenylethenyl]-1,3-benzoxazole Chemical compound N=1C2=CC(C)=CC=C2OC=1\C=C\C1=CC=CC=C1 PUHLHLQBIFRKRD-CSKARUKUSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- NQPDXQQQCQDHHW-UHFFFAOYSA-N 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole Chemical compound ClC=1C=C2NC(SC)=NC2=CC=1OC1=CC=CC(Cl)=C1Cl NQPDXQQQCQDHHW-UHFFFAOYSA-N 0.000 description 1
- MPORYQCGWFQFLA-ONPDANIMSA-N 7-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid;trihydrate Chemical compound O.O.O.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 MPORYQCGWFQFLA-ONPDANIMSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 1
- TWHZNAUBXFZMCA-UHFFFAOYSA-N Acotiamide Chemical compound C1=C(OC)C(OC)=CC(O)=C1C(=O)NC1=NC(C(=O)NCCN(C(C)C)C(C)C)=CS1 TWHZNAUBXFZMCA-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241000906543 Actaea racemosa Species 0.000 description 1
- 241000222518 Agaricus Species 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 240000007474 Aloe arborescens Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000609240 Ambelania acida Species 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 239000009405 Ashwagandha Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- 241001106067 Atropa Species 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- CULUWZNBISUWAS-UHFFFAOYSA-N Benznidazole Chemical compound [O-][N+](=O)C1=NC=CN1CC(=O)NCC1=CC=CC=C1 CULUWZNBISUWAS-UHFFFAOYSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- XVGOZDAJGBALKS-UHFFFAOYSA-N Blonanserin Chemical compound C1CN(CC)CCN1C1=CC(C=2C=CC(F)=CC=2)=C(CCCCCC2)C2=N1 XVGOZDAJGBALKS-UHFFFAOYSA-N 0.000 description 1
- 240000008564 Boehmeria nivea Species 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- 239000002051 C09CA08 - Olmesartan medoxomil Substances 0.000 description 1
- 235000014161 Caesalpinia gilliesii Nutrition 0.000 description 1
- 244000003240 Caesalpinia gilliesii Species 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 235000006693 Cassia laevigata Nutrition 0.000 description 1
- 244000025596 Cassia laevigata Species 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 235000021508 Coleus Nutrition 0.000 description 1
- 244000061182 Coleus blumei Species 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- AVZIYZHXZAYGJS-UHFFFAOYSA-N Difenidol hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCCN1CCCCC1 AVZIYZHXZAYGJS-UHFFFAOYSA-N 0.000 description 1
- WKZITTRQXFNUNO-UHFFFAOYSA-N Difeterol hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)OCCN(C)C(C)C(O)C1=CC=CC=C1 WKZITTRQXFNUNO-UHFFFAOYSA-N 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 229920000875 Dissolving pulp Polymers 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- 241001632410 Eleutherococcus senticosus Species 0.000 description 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- XRHVZWWRFMCBAZ-UHFFFAOYSA-L Endothal-disodium Chemical compound [Na+].[Na+].C1CC2C(C([O-])=O)C(C(=O)[O-])C1O2 XRHVZWWRFMCBAZ-UHFFFAOYSA-L 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- OVGORFFCBUIFIA-UHFFFAOYSA-N Fenipentol Chemical compound CCCCC(O)C1=CC=CC=C1 OVGORFFCBUIFIA-UHFFFAOYSA-N 0.000 description 1
- 241000123326 Fomes Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 244000119461 Garcinia xanthochymus Species 0.000 description 1
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 241000208253 Gymnema sylvestre Species 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 240000000797 Hibiscus cannabinus Species 0.000 description 1
- 241000511976 Hoya Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 244000267823 Hydrangea macrophylla Species 0.000 description 1
- 235000014486 Hydrangea macrophylla Nutrition 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- CFIGYZZVJNJVDQ-LMJOQDENSA-N Indomethacin farnesil Chemical compound CC1=C(CC(=O)OC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CFIGYZZVJNJVDQ-LMJOQDENSA-N 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- BFSMWENDZZIWPW-UHFFFAOYSA-N Isopropamide iodide Chemical compound [I-].C=1C=CC=CC=1C(C(N)=O)(CC[N+](C)(C(C)C)C(C)C)C1=CC=CC=C1 BFSMWENDZZIWPW-UHFFFAOYSA-N 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- 240000000759 Lepidium meyenii Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 241000319062 Lycoris radiata Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 235000014837 Malpighia glabra Nutrition 0.000 description 1
- 240000003394 Malpighia glabra Species 0.000 description 1
- 239000009566 Mao-to Substances 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 235000017822 Melilotus officinalis Nutrition 0.000 description 1
- 240000000366 Melilotus officinalis Species 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- WRWBCPJQPDHXTJ-DTMQFJJTSA-N Methandriol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 WRWBCPJQPDHXTJ-DTMQFJJTSA-N 0.000 description 1
- DKMVJQCQTCLYIF-UHFFFAOYSA-M Methylbenactyzium bromide Chemical compound [Br-].C=1C=CC=CC=1C(O)(C(=O)OCC[N+](C)(CC)CC)C1=CC=CC=C1 DKMVJQCQTCLYIF-UHFFFAOYSA-M 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- YLXDSYKOBKBWJQ-LBPRGKRZSA-N N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide Chemical compound C1=C2OCCC2=C2[C@H](CCNC(=O)CC)CCC2=C1 YLXDSYKOBKBWJQ-LBPRGKRZSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- ARFHIAQFJWUCFH-IZZDOVSWSA-N Nifurtimox Chemical compound CC1CS(=O)(=O)CCN1\N=C\C1=CC=C([N+]([O-])=O)O1 ARFHIAQFJWUCFH-IZZDOVSWSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 240000005859 Orthosiphon aristatus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- WXAYTPABEADAAB-UHFFFAOYSA-N Oxyphencyclimine hydrochloride Chemical compound Cl.CN1CCCN=C1COC(=O)C(O)(C=1C=CC=CC=1)C1CCCCC1 WXAYTPABEADAAB-UHFFFAOYSA-N 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930195708 Penicillin V Natural products 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920001991 Proanthocyanidin Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 244000141353 Prunus domestica Species 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- JPRXYLQNJJVCMZ-UHFFFAOYSA-N Rizatriptan benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1.C1=C2C(CC[NH+](C)C)=CNC2=CC=C1CN1C=NC=N1 JPRXYLQNJJVCMZ-UHFFFAOYSA-N 0.000 description 1
- XDXHAEQXIBQUEZ-UHFFFAOYSA-N Ropinirole hydrochloride Chemical compound Cl.CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 XDXHAEQXIBQUEZ-UHFFFAOYSA-N 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N Ropinirole hydrochloride Natural products CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- 235000003500 Ruscus aculeatus Nutrition 0.000 description 1
- 240000000353 Ruscus aculeatus Species 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- 241000899950 Salix glauca Species 0.000 description 1
- 241000269851 Sarda sarda Species 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- KHNXRSIBRKBJDI-UHFFFAOYSA-N Sevelamer hydrochloride Chemical compound Cl.NCC=C.ClCC1CO1 KHNXRSIBRKBJDI-UHFFFAOYSA-N 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000020759 St. John’s wort extract Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- HRYJPHOTGFERGT-UHFFFAOYSA-N Thonzylamine hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=NC=CC=N1 HRYJPHOTGFERGT-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- HKDLNTKNLJPAIY-WKWWZUSTSA-N Ulipristal Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)C(C)=O)[C@]2(C)C1 HKDLNTKNLJPAIY-WKWWZUSTSA-N 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000001667 Vitex agnus castus Nutrition 0.000 description 1
- 244000063464 Vitex agnus-castus Species 0.000 description 1
- 235000001978 Withania somnifera Nutrition 0.000 description 1
- 240000004482 Withania somnifera Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- XGGHHHBGPSNXFE-XYPWUTKMSA-N [(1r,5s)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-propylpentanoate Chemical compound C1C(OC(=O)C(CCC)CCC)C[C@@H]2CC[C@H]1[N+]2(C)C XGGHHHBGPSNXFE-XYPWUTKMSA-N 0.000 description 1
- QWSHKNICRJHQCY-VBTXLZOXSA-N [(3as,4r,6ar)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] n-[(2s,3r)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate;ethanol Chemical compound CCO.C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 QWSHKNICRJHQCY-VBTXLZOXSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- VZMLEMYJUIIHNF-DQRAZIAOSA-N [4-[(z)-4-(4-propanoyloxyphenyl)hex-3-en-3-yl]phenyl] propanoate Chemical compound C1=CC(OC(=O)CC)=CC=C1C(\CC)=C(\CC)C1=CC=C(OC(=O)CC)C=C1 VZMLEMYJUIIHNF-DQRAZIAOSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- OMZAMQFQZMUNTP-UHFFFAOYSA-N acetic acid;1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol Chemical compound CC(O)=O.C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 OMZAMQFQZMUNTP-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229950005462 acotiamide Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960002669 albendazole Drugs 0.000 description 1
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 1
- 229960004601 aliskiren Drugs 0.000 description 1
- KLRSDBSKUSSCGU-KRQUFFFQSA-N aliskiren fumarate Chemical compound OC(=O)\C=C\C(O)=O.COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC.COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC KLRSDBSKUSSCGU-KRQUFFFQSA-N 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 229950009425 alloclamide Drugs 0.000 description 1
- UHWFVIPXDFZTFA-UHFFFAOYSA-N alloclamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(Cl)C=C1OCC=C UHWFVIPXDFZTFA-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- MANKSFVECICGLK-UHFFFAOYSA-K aloxiprin Chemical compound [OH-].[Al+3].CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O MANKSFVECICGLK-UHFFFAOYSA-K 0.000 description 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 229940103272 aluminum potassium sulfate Drugs 0.000 description 1
- RJZNFXWQRHAVBP-UHFFFAOYSA-I aluminum;magnesium;pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Al+3] RJZNFXWQRHAVBP-UHFFFAOYSA-I 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 229960002414 ambrisentan Drugs 0.000 description 1
- OUJTZYPIHDYQMC-LJQANCHMSA-N ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 229960001444 amodiaquine Drugs 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
- 229960001372 aprepitant Drugs 0.000 description 1
- KSUUMAWCGDNLFK-UHFFFAOYSA-N apronal Chemical compound C=CCC(C(C)C)C(=O)NC(N)=O KSUUMAWCGDNLFK-UHFFFAOYSA-N 0.000 description 1
- 229960004459 apronal Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 229960000981 artemether Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 239000010905 bagasse Substances 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N baicalein Chemical compound C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- 239000009616 bakumondo-to Substances 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 229960003713 bazedoxifene acetate Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- UDGHXQPQKQPSBB-UHFFFAOYSA-N benzenesulfonic acid;4-[4-[(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1.C1CN(CCCC(=O)O)CCC1OC(C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 UDGHXQPQKQPSBB-UHFFFAOYSA-N 0.000 description 1
- 229960004001 benznidazole Drugs 0.000 description 1
- 229960001105 bepotastine besilate Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 description 1
- 229960003003 biperiden Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- 229950002871 blonanserin Drugs 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 description 1
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 1
- 235000008207 calcium folinate Nutrition 0.000 description 1
- 239000011687 calcium folinate Substances 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- QEVLNUAVAONTEW-UZYHXJQGSA-L calcium;(2s)-4-[(3as,7ar)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxobutanoate;dihydrate Chemical compound O.O.[Ca+2].C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)[O-])C1=CC=CC=C1.C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)[O-])C1=CC=CC=C1 QEVLNUAVAONTEW-UZYHXJQGSA-L 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- XFOSOYZCQOPDSQ-XMYIDBJESA-K calcium;potassium;(1s,2s)-1,2-dihydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[Ca+2].[O-]C(=O)[C@@H](O)[C@](O)(C([O-])=O)CC([O-])=O XFOSOYZCQOPDSQ-XMYIDBJESA-K 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 229940098391 carbetapentane citrate Drugs 0.000 description 1
- 229960004205 carbidopa Drugs 0.000 description 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 1
- 229960000428 carbinoxamine Drugs 0.000 description 1
- GVNWHCVWDRNXAZ-BTJKTKAUSA-N carbinoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 GVNWHCVWDRNXAZ-BTJKTKAUSA-N 0.000 description 1
- 229960000456 carbinoxamine maleate Drugs 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000011472 cat’s claw Nutrition 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- XMLNCADGRIEXPK-KUMOIWDRSA-M chembl2146143 Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C)C(=O)C(CO)C1=CC=CC=C1 XMLNCADGRIEXPK-KUMOIWDRSA-M 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
- 229960002559 chlorotrianisene Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229940046374 chromium picolinate Drugs 0.000 description 1
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 235000005301 cimicifuga racemosa Nutrition 0.000 description 1
- QANQWUQOEJZMLL-PKLMIRHRSA-N cinacalcet hydrochloride Chemical compound Cl.N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 QANQWUQOEJZMLL-PKLMIRHRSA-N 0.000 description 1
- 229960000478 cinacalcet hydrochloride Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 229940038649 clavulanate potassium Drugs 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 229960003608 clomifene Drugs 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 229960004415 codeine phosphate Drugs 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 229960001127 colistin sulfate Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229940108924 conjugated linoleic acid Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- HWDGVJUIHRPKFR-UHFFFAOYSA-I copper;trisodium;18-(2-carboxylatoethyl)-20-(carboxylatomethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18-dihydroporphyrin-21,23-diide-2-carboxylate Chemical compound [Na+].[Na+].[Na+].[Cu+2].N1=C(C(CC([O-])=O)=C2C(C(C)C(C=C3C(=C(C=C)C(=C4)[N-]3)C)=N2)CCC([O-])=O)C(=C([O-])[O-])C(C)=C1C=C1C(CC)=C(C)C4=N1 HWDGVJUIHRPKFR-UHFFFAOYSA-I 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 235000020237 cranberry extract Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 229960003564 cyclizine Drugs 0.000 description 1
- UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 229960005449 daclatasvir Drugs 0.000 description 1
- FKRSSPOQAMALKA-CUPIEXAXSA-N daclatasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)=CN1 FKRSSPOQAMALKA-CUPIEXAXSA-N 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 1
- 229960005107 darunavir Drugs 0.000 description 1
- 229960004080 darunavir ethanolate Drugs 0.000 description 1
- NBRBXGKOEOGLOI-UHFFFAOYSA-N dasabuvir Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C=C1N1C=CC(=O)NC1=O NBRBXGKOEOGLOI-UHFFFAOYSA-N 0.000 description 1
- 229960001418 dasabuvir Drugs 0.000 description 1
- 229960001489 deferasirox Drugs 0.000 description 1
- FMSOAWSKCWYLBB-VBGLAJCLSA-N deferasirox Chemical compound C1=CC(C(=O)O)=CC=C1N(N\C(N\1)=C\2C(C=CC=C/2)=O)C/1=C\1C(=O)C=CC=C/1 FMSOAWSKCWYLBB-VBGLAJCLSA-N 0.000 description 1
- 229960003496 delamanid Drugs 0.000 description 1
- XDAOLTSRNUSPPH-XMMPIXPASA-N delamanid Chemical compound C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N(CC1)CCC1OC1=CC=C(OC(F)(F)F)C=C1 XDAOLTSRNUSPPH-XMMPIXPASA-N 0.000 description 1
- 229960004486 desoxycorticosterone acetate Drugs 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- HEQUOWMMDQTGCX-UHFFFAOYSA-L dicesium;oxalate Chemical compound [Cs+].[Cs+].[O-]C(=O)C([O-])=O HEQUOWMMDQTGCX-UHFFFAOYSA-L 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- GUBNMFJOJGDCEL-UHFFFAOYSA-N dicyclomine hydrochloride Chemical compound [Cl-].C1CCCCC1C1(C(=O)OCC[NH+](CC)CC)CCCCC1 GUBNMFJOJGDCEL-UHFFFAOYSA-N 0.000 description 1
- 229940110321 dicyclomine hydrochloride Drugs 0.000 description 1
- NFDFQCUYFHCNBW-SCGPFSFSSA-N dienestrol Chemical compound C=1C=C(O)C=CC=1\C(=C/C)\C(=C\C)\C1=CC=C(O)C=C1 NFDFQCUYFHCNBW-SCGPFSFSSA-N 0.000 description 1
- 229960003839 dienestrol Drugs 0.000 description 1
- 229960003309 dienogest Drugs 0.000 description 1
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 description 1
- CRVGKGJPQYZRPT-UHFFFAOYSA-N diethylamino acetate Chemical compound CCN(CC)OC(C)=O CRVGKGJPQYZRPT-UHFFFAOYSA-N 0.000 description 1
- RCKMWOKWVGPNJF-UHFFFAOYSA-N diethylcarbamazine Chemical compound CCN(CC)C(=O)N1CCN(C)CC1 RCKMWOKWVGPNJF-UHFFFAOYSA-N 0.000 description 1
- 229960003974 diethylcarbamazine Drugs 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 229960001111 diloxanide Drugs 0.000 description 1
- BDYYDXJSHYEDGB-UHFFFAOYSA-N diloxanide furoate Chemical compound C1=CC(N(C(=O)C(Cl)Cl)C)=CC=C1OC(=O)C1=CC=CO1 BDYYDXJSHYEDGB-UHFFFAOYSA-N 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 1
- 229960001051 dimercaprol Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229960005058 diphenidol hydrochloride Drugs 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 229960002819 diprophylline Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 235000019262 disodium citrate Nutrition 0.000 description 1
- 239000002526 disodium citrate Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229940005636 dl- methylephedrine Drugs 0.000 description 1
- 229960002542 dolutegravir Drugs 0.000 description 1
- RHWKPHLQXYSBKR-BMIGLBTASA-N dolutegravir Chemical compound C([C@@H]1OCC[C@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F RHWKPHLQXYSBKR-BMIGLBTASA-N 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- VHBABGAFHUKREU-ICKLFXEKSA-N duo-cotecxin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C.ClC1=CC=C2C(N3CCN(CC3)CCCN3CCN(CC3)C=3C4=CC=C(C=C4N=CC=3)Cl)=CC=NC2=C1 VHBABGAFHUKREU-ICKLFXEKSA-N 0.000 description 1
- 229960004199 dutasteride Drugs 0.000 description 1
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
- KSCFJBIXMNOVSH-UHFFFAOYSA-N dyphylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)CO)C=N2 KSCFJBIXMNOVSH-UHFFFAOYSA-N 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 229960003470 eletriptan hydrobromide Drugs 0.000 description 1
- UTINOWOSWSPFLJ-FSRHSHDFSA-N eletriptan hydrobromide Chemical compound Br.CN1CCC[C@@H]1CC(C1=C2)=CNC1=CC=C2CCS(=O)(=O)C1=CC=CC=C1 UTINOWOSWSPFLJ-FSRHSHDFSA-N 0.000 description 1
- 229960000366 emtricitabine Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003337 entacapone Drugs 0.000 description 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 1
- 229960001208 eplerenone Drugs 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 description 1
- 229960005073 erlotinib hydrochloride Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960005086 escitalopram oxalate Drugs 0.000 description 1
- 229960004770 esomeprazole Drugs 0.000 description 1
- KWORUUGOSLYAGD-YPPDDXJESA-N esomeprazole magnesium Chemical compound [Mg+2].C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C.C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-YPPDDXJESA-N 0.000 description 1
- 229950002007 estradiol benzoate Drugs 0.000 description 1
- GBBSUAFBMRNDJC-INIZCTEOSA-N eszopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-INIZCTEOSA-N 0.000 description 1
- 229960001578 eszopiclone Drugs 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 229960002001 ethionamide Drugs 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- QLGIFPJNYPWBMQ-UHFFFAOYSA-N ethyl piperidinoacetylaminobenzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1NC(=O)CN1CCCCC1 QLGIFPJNYPWBMQ-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 229950007454 fenethazine Drugs 0.000 description 1
- PFAXACNYGZVKMX-UHFFFAOYSA-N fenethazine Chemical compound C1=CC=C2N(CCN(C)C)C3=CC=CC=C3SC2=C1 PFAXACNYGZVKMX-UHFFFAOYSA-N 0.000 description 1
- 229960005035 fenipentol Drugs 0.000 description 1
- 239000010643 fennel seed oil Substances 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960002011 fludrocortisone Drugs 0.000 description 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960001469 fluticasone furoate Drugs 0.000 description 1
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000000989 food dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- JTLXCMOFVBXEKD-FOWTUZBSSA-N fursultiamine Chemical compound C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JTLXCMOFVBXEKD-FOWTUZBSSA-N 0.000 description 1
- 229950006836 fursultiamine Drugs 0.000 description 1
- QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 description 1
- 229960002024 galantamine hydrobromide Drugs 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 229960002146 guaifenesin Drugs 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 235000020717 hawthorn extract Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- 229950001996 hexestrol Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229940095066 hydroxytyrosol Drugs 0.000 description 1
- 235000003248 hydroxytyrosol Nutrition 0.000 description 1
- 229960003210 hyoscyamine Drugs 0.000 description 1
- SQKXYSGRELMAAU-UHFFFAOYSA-N imidafenacin Chemical compound CC1=NC=CN1CCC(C(N)=O)(C=1C=CC=CC=1)C1=CC=CC=C1 SQKXYSGRELMAAU-UHFFFAOYSA-N 0.000 description 1
- 229950005396 imidafenacin Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229960001543 isopropamide iodide Drugs 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- 229960003517 isothipendyl Drugs 0.000 description 1
- OQJBSDFFQWMKBQ-UHFFFAOYSA-N isothipendyl Chemical compound C1=CN=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 OQJBSDFFQWMKBQ-UHFFFAOYSA-N 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000008805 kakkon-to Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000009382 keishi-to Substances 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229950007634 kitasamycin Drugs 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000002655 kraft paper Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- AFCUGQOTNCVYSW-UHFFFAOYSA-H lanthanum(3+);tricarbonate;hydrate Chemical compound O.[La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O AFCUGQOTNCVYSW-UHFFFAOYSA-H 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- VRTWBAAJJOHBQU-KMWAZVGDSA-N ledipasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N([C@@H](C1)C=2NC(=CN=2)C=2C=C3C(F)(F)C4=CC(=CC=C4C3=CC=2)C=2C=C3NC(=NC3=CC=2)[C@H]2N([C@@H]3CC[C@H]2C3)C(=O)[C@@H](NC(=O)OC)C(C)C)CC21CC2 VRTWBAAJJOHBQU-KMWAZVGDSA-N 0.000 description 1
- 229960002461 ledipasvir Drugs 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- XYJOGTQLTFNMQG-KJHBSLKPSA-N leucomycin V Chemical compound CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1 XYJOGTQLTFNMQG-KJHBSLKPSA-N 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229960004002 levetiracetam Drugs 0.000 description 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 1
- 229960001508 levocetirizine Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 229950008325 levothyroxine Drugs 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229940008015 lithium carbonate Drugs 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- DYLGFOYVTXJFJP-MYYYXRDXSA-N lumefantrine Chemical compound C12=CC(Cl)=CC=C2C=2C(C(O)CN(CCCC)CCCC)=CC(Cl)=CC=2\C1=C/C1=CC=C(Cl)C=C1 DYLGFOYVTXJFJP-MYYYXRDXSA-N 0.000 description 1
- 229960004985 lumefantrine Drugs 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 229960003390 magnesium sulfate Drugs 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 229940075071 maitake extract Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229960003439 mebendazole Drugs 0.000 description 1
- BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 description 1
- 229960004934 mebhydrolin Drugs 0.000 description 1
- FQQIIPAOSKSOJM-UHFFFAOYSA-N mebhydrolin Chemical compound C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=CC=C1 FQQIIPAOSKSOJM-UHFFFAOYSA-N 0.000 description 1
- 229940018415 meclizine hydrochloride Drugs 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960001962 mefloquine Drugs 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960000967 memantine hydrochloride Drugs 0.000 description 1
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 description 1
- 235000009491 menaquinone-4 Nutrition 0.000 description 1
- 239000011676 menaquinone-4 Substances 0.000 description 1
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 1
- 229960005481 menatetrenone Drugs 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229960003861 mephenesin Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229960001833 methandriol Drugs 0.000 description 1
- 229960001397 methdilazine hydrochloride Drugs 0.000 description 1
- IEISBKIVLDXSMZ-UHFFFAOYSA-N methdilazine hydrochloride Chemical compound Cl.C1N(C)CCC1CN1C2=CC=CC=C2SC2=CC=CC=C21 IEISBKIVLDXSMZ-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- RAOHHYUBMJLHNC-UHFFFAOYSA-N methixene hydrochloride Chemical compound [H+].O.[Cl-].C1N(C)CCCC1CC1C2=CC=CC=C2SC2=CC=CC=C21 RAOHHYUBMJLHNC-UHFFFAOYSA-N 0.000 description 1
- 229940098953 methixene hydrochloride Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229950003018 methylbenactyzium bromide Drugs 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960001383 methylscopolamine Drugs 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229950011129 minodronic acid Drugs 0.000 description 1
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 229960003365 mitiglinide Drugs 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- BDRTVPCFKSUHCJ-UHFFFAOYSA-N molecular hydrogen;potassium Chemical compound [K].[H][H] BDRTVPCFKSUHCJ-UHFFFAOYSA-N 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229960001951 montelukast sodium Drugs 0.000 description 1
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- CKIPCLCBYTWUEZ-UHFFFAOYSA-N n,n-dimethyl-2-phenothiazin-10-ylethanamine;hydrochloride Chemical compound Cl.C1=CC=C2N(CCN(C)C)C3=CC=CC=C3SC2=C1 CKIPCLCBYTWUEZ-UHFFFAOYSA-N 0.000 description 1
- ZESIAEVDVPWEKB-ORCFLVBFSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O ZESIAEVDVPWEKB-ORCFLVBFSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
- 229940086319 nattokinase Drugs 0.000 description 1
- 108010073682 nattokinase Proteins 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- 229940000041 nervous system drug Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 229960001920 niclosamide Drugs 0.000 description 1
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960002644 nifurtimox Drugs 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 239000002661 non steroidal estrogen Substances 0.000 description 1
- 229940053934 norethindrone Drugs 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229960001199 olmesartan medoxomil Drugs 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 229960000518 ombitasvir Drugs 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 229960000251 oxyphencyclimine hydrochloride Drugs 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- GHZNWXGYWUBLLI-UHFFFAOYSA-N p-Lactophenetide Chemical compound CCOC1=CC=C(NC(=O)C(C)O)C=C1 GHZNWXGYWUBLLI-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229960001057 paliperidone Drugs 0.000 description 1
- 229940045258 pancrelipase Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 229960003207 papaverine hydrochloride Drugs 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960002754 paritaprevir Drugs 0.000 description 1
- UAUIUKWPKRJZJV-MDJGTQRPSA-N paritaprevir Chemical compound C1=NC(C)=CN=C1C(=O)N[C@@H]1C(=O)N2C[C@H](OC=3C4=CC=CC=C4C4=CC=CC=C4N=3)C[C@H]2C(=O)N[C@]2(C(=O)NS(=O)(=O)C3CC3)C[C@@H]2\C=C/CCCCC1 UAUIUKWPKRJZJV-MDJGTQRPSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229940056367 penicillin v Drugs 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229950006717 piperaquine Drugs 0.000 description 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 1
- 229960003073 pirfenidone Drugs 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- QFRKWSPTCBGLSU-UHFFFAOYSA-M potassium 4-hydroxy-3-methoxybenzene-1-sulfonate Chemical compound [K+].COC1=CC(S([O-])(=O)=O)=CC=C1O QFRKWSPTCBGLSU-UHFFFAOYSA-M 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229960004109 potassium acetate Drugs 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 description 1
- 229940069505 potassium guaiacolsulfonate Drugs 0.000 description 1
- FJWLWIRHZOHPIY-UHFFFAOYSA-N potassium;hydroiodide Chemical compound [K].I FJWLWIRHZOHPIY-UHFFFAOYSA-N 0.000 description 1
- 229960002957 praziquantel Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960005179 primaquine Drugs 0.000 description 1
- INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960002244 promethazine hydrochloride Drugs 0.000 description 1
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 229960005134 pyrantel Drugs 0.000 description 1
- YSAUAVHXTIETRK-AATRIKPKSA-N pyrantel Chemical compound CN1CCCN=C1\C=C\C1=CC=CS1 YSAUAVHXTIETRK-AATRIKPKSA-N 0.000 description 1
- 229960005206 pyrazinamide Drugs 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- 229960002290 pyridostigmine Drugs 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- DJUFPMUQJKWIJB-UHFFFAOYSA-N pyronaridine Chemical compound C12=NC(OC)=CC=C2N=C2C=C(Cl)C=CC2=C1NC(C=C(CN1CCCC1)C=1O)=CC=1CN1CCCC1 DJUFPMUQJKWIJB-UHFFFAOYSA-N 0.000 description 1
- 229950011262 pyronaridine Drugs 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229960001811 quinine hydrochloride Drugs 0.000 description 1
- BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical compound [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 description 1
- 229960002119 raloxifene hydrochloride Drugs 0.000 description 1
- 229960004742 raltegravir Drugs 0.000 description 1
- CZFFBEXEKNGXKS-UHFFFAOYSA-N raltegravir Chemical compound O1C(C)=NN=C1C(=O)NC(C)(C)C1=NC(C(=O)NCC=2C=CC(F)=CC=2)=C(O)C(=O)N1C CZFFBEXEKNGXKS-UHFFFAOYSA-N 0.000 description 1
- 229960001150 ramelteon Drugs 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960001520 ranitidine hydrochloride Drugs 0.000 description 1
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 description 1
- 229960002599 rifapentine Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960004789 rizatriptan benzoate Drugs 0.000 description 1
- 229960002349 ropinirole hydrochloride Drugs 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- 229960004796 rosuvastatin calcium Drugs 0.000 description 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940119485 safflower extract Drugs 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000008651 saiko-keishi-to Substances 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 229960004499 scopolamine hydrobromide Drugs 0.000 description 1
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 description 1
- CXYRUNPLKGGUJF-RAFJPFSSSA-M scopolamine methobromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 CXYRUNPLKGGUJF-RAFJPFSSSA-M 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 229940124513 senna glycoside Drugs 0.000 description 1
- 229940000634 serratiopeptidase Drugs 0.000 description 1
- 108010038132 serratiopeptidase Proteins 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229960003027 sevelamer hydrochloride Drugs 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000010243 sho-seiryu-to Substances 0.000 description 1
- 239000008485 shosaiko-to Substances 0.000 description 1
- 150000003377 silicon compounds Chemical class 0.000 description 1
- 229960004953 silodosin Drugs 0.000 description 1
- PNCPYILNMDWPEY-QGZVFWFLSA-N silodosin Chemical compound N([C@@H](CC=1C=C(C=2N(CCCO)CCC=2C=1)C(N)=O)C)CCOC1=CC=CC=C1OCC(F)(F)F PNCPYILNMDWPEY-QGZVFWFLSA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960003177 sitafloxacin Drugs 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- JWBPVFVNISJVEM-UHFFFAOYSA-M sodium caffeine benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2C JWBPVFVNISJVEM-UHFFFAOYSA-M 0.000 description 1
- 229940079841 sodium copper chlorophyllin Drugs 0.000 description 1
- 235000013758 sodium copper chlorophyllin Nutrition 0.000 description 1
- 229960002325 sodium dibunate Drugs 0.000 description 1
- XYEXKDCAGSHWSD-UHFFFAOYSA-M sodium dibunate Chemical compound [Na+].[O-]S(=O)(=O)C1=C(C(C)(C)C)C=CC2=CC(C(C)(C)C)=CC=C21 XYEXKDCAGSHWSD-UHFFFAOYSA-M 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 229940006186 sodium polystyrene sulfonate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 229940084026 sodium valproate Drugs 0.000 description 1
- QVGLHVDBDYLFON-UHFFFAOYSA-M sodium;1,3-dimethylpurin-7-ide-2,6-dione Chemical compound [Na+].O=C1N(C)C(=O)N(C)C2=C1[N-]C=N2 QVGLHVDBDYLFON-UHFFFAOYSA-M 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- VBDRTGFACFYFCT-UHFFFAOYSA-M sodium;hydroxy-[(1r)-1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphinate;hydrate Chemical compound O.[Na+].CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)([O-])=O VBDRTGFACFYFCT-UHFFFAOYSA-M 0.000 description 1
- KFLRWGSAMLBHBV-UHFFFAOYSA-M sodium;pyridine-3-carboxylate Chemical compound [Na+].[O-]C(=O)C1=CC=CN=C1 KFLRWGSAMLBHBV-UHFFFAOYSA-M 0.000 description 1
- 229960002063 sofosbuvir Drugs 0.000 description 1
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 description 1
- 229960001368 solifenacin succinate Drugs 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 229930188627 soysaponin Natural products 0.000 description 1
- ZPCCSZFPOXBNDL-RSMXASMKSA-N spiramycin II Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]([C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)OC(C)=O)[C@H]1CC[C@H](N(C)C)[C@H](C)O1 ZPCCSZFPOXBNDL-RSMXASMKSA-N 0.000 description 1
- 229950006796 spiramycin ii Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 229940099416 st. john's wort extract Drugs 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 229960005346 succimer Drugs 0.000 description 1
- ACTRVOBWPAIOHC-XIXRPRMCSA-N succimer Chemical compound OC(=O)[C@@H](S)[C@@H](S)C(O)=O ACTRVOBWPAIOHC-XIXRPRMCSA-N 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 description 1
- 229950006156 teprenone Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 229960003231 thioacetazone Drugs 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229960004636 thonzylamine hydrochloride Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229960000896 tipepidine Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- GYHCTFXIZSNGJT-UHFFFAOYSA-N tolvaptan Chemical compound CC1=CC=CC=C1C(=O)NC(C=C1C)=CC=C1C(=O)N1C2=CC=C(Cl)C=C2C(O)CCC1 GYHCTFXIZSNGJT-UHFFFAOYSA-N 0.000 description 1
- 229960001256 tolvaptan Drugs 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229960000323 triclabendazole Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 229960000732 tripelennamine hydrochloride Drugs 0.000 description 1
- 229960001593 triprolidine hydrochloride Drugs 0.000 description 1
- LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 description 1
- 229960005041 troleandomycin Drugs 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 229960000200 ulipristal Drugs 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 235000020767 valerian extract Nutrition 0.000 description 1
- 229960002149 valganciclovir Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- FHCUMDQMBHQXKK-CDIODLITSA-N velpatasvir Chemical compound C1([C@@H](NC(=O)OC)C(=O)N2[C@@H](C[C@@H](C2)COC)C=2NC(=CN=2)C=2C=C3C(C4=CC5=CC=C6NC(=NC6=C5C=C4OC3)[C@H]3N([C@@H](C)CC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)=CC=CC=C1 FHCUMDQMBHQXKK-CDIODLITSA-N 0.000 description 1
- 229960000863 velpatasvir Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- DBRXOUCRJQVYJQ-CKNDUULBSA-N withaferin A Chemical compound C([C@@H]1[C@H]([C@@H]2[C@]3(CC[C@@H]4[C@@]5(C)C(=O)C=C[C@H](O)[C@@]65O[C@@H]6C[C@H]4[C@@H]3CC2)C)C)C(C)=C(CO)C(=O)O1 DBRXOUCRJQVYJQ-CKNDUULBSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
- C08H8/00—Macromolecular compounds derived from lignocellulosic materials
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/15—Heterocyclic compounds having oxygen in the ring
- C08K5/151—Heterocyclic compounds having oxygen in the ring having one oxygen atom in the ring
- C08K5/1545—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
- C08L1/02—Cellulose; Modified cellulose
Abstract
Provided is a cellulose composition containing cellulose and cellooligosaccharides from trisaccharides to heptasaccharides, wherein the content of the cellooligosaccharides is 1.5-9.0 mg per 5 g of the cellulose composition. A tablet according to the present invention contains the aforementioned cellulose composition and one or more types of active components.
Description
DESCRIPTION
CELLULOSE COMPOSITION AND TABLET
TECHNICAL FIELD
[0001]
The present invention relates to a cellulose composition and a tablet.
BACKGROUND ART
CELLULOSE COMPOSITION AND TABLET
TECHNICAL FIELD
[0001]
The present invention relates to a cellulose composition and a tablet.
BACKGROUND ART
[0002]
Tableting of pharmaceuticals offers the advantages of high productivity and ease of handling during transport and use. During tableting, because many active component raw materials cannot be molded even when compressed, excipients are added to enable tableting, with these excipients requiring favorable moldability, flowability and disintegrability. Cellulose is widely used as an excipient.
Tableting of pharmaceuticals offers the advantages of high productivity and ease of handling during transport and use. During tableting, because many active component raw materials cannot be molded even when compressed, excipients are added to enable tableting, with these excipients requiring favorable moldability, flowability and disintegrability. Cellulose is widely used as an excipient.
[0003]
Patent Document 1 discloses a cellulose powder having an average degree of polymerization of at least 100 but not more than 350, a weight-average particle size of greater than 30 pm but not more than 250 pm. an apparent specific volume of at least 2 cm3/g but less than 15 cm3/g, and a particle size distribution sharpness of at least 1.5 but not more than 2.9. It is disclosed that using this cellulose powder provides excellent compression moldability, and has the effects of enabling traditional Chinese medicine components having high levels of stickiness and hygroscopicity and other components having adhesiveness to be retained in a uniform manner, providing a sharper particle size distribution for the granules due to the sharp particle size distribution of the cellulose Date Recue/Date Received 2022-04-20 powder, offering a shortened disintegration time, and imparting more stable disintegrability over a long period of time.
Patent Document 1 discloses a cellulose powder having an average degree of polymerization of at least 100 but not more than 350, a weight-average particle size of greater than 30 pm but not more than 250 pm. an apparent specific volume of at least 2 cm3/g but less than 15 cm3/g, and a particle size distribution sharpness of at least 1.5 but not more than 2.9. It is disclosed that using this cellulose powder provides excellent compression moldability, and has the effects of enabling traditional Chinese medicine components having high levels of stickiness and hygroscopicity and other components having adhesiveness to be retained in a uniform manner, providing a sharper particle size distribution for the granules due to the sharp particle size distribution of the cellulose Date Recue/Date Received 2022-04-20 powder, offering a shortened disintegration time, and imparting more stable disintegrability over a long period of time.
[0004]
On the other hand, when a cellulose powder of conventional technology is used, in order to ensure uniformity of active component content in each tablet, the raw material mixing time tends to require lengthening, and the reduction in tablet hardness accompanying this lengthening of mixing time can become problematic. However, satisfactory mixing is essential to prevent inaldistribution of the active component, and preventing any reduction in the tablet hardness caused by lengthening of the mixing time, while simultaneously preventing any deterioration in content uniformity has proven difficult.
PRIOR ART LITERATURE
Patent Document
On the other hand, when a cellulose powder of conventional technology is used, in order to ensure uniformity of active component content in each tablet, the raw material mixing time tends to require lengthening, and the reduction in tablet hardness accompanying this lengthening of mixing time can become problematic. However, satisfactory mixing is essential to prevent inaldistribution of the active component, and preventing any reduction in the tablet hardness caused by lengthening of the mixing time, while simultaneously preventing any deterioration in content uniformity has proven difficult.
PRIOR ART LITERATURE
Patent Document
[0005]
Patent Document 1: International Patent Publication No. WO 2013/180248 SUMMARY OF INVENTION
Problems to be Solved by the Invention
Patent Document 1: International Patent Publication No. WO 2013/180248 SUMMARY OF INVENTION
Problems to be Solved by the Invention
[0006]
The present invention has been developed in light of the above circumstances, and provides a cellulose composition having favorable hardness and good suppression of both deviation in the active component content and tableting failure during molding, as well as a tablet containing the cellulose composition.
Date Recue/Date Received 2022-04-20 Means for Solving the Problems
The present invention has been developed in light of the above circumstances, and provides a cellulose composition having favorable hardness and good suppression of both deviation in the active component content and tableting failure during molding, as well as a tablet containing the cellulose composition.
Date Recue/Date Received 2022-04-20 Means for Solving the Problems
[0007]
In other words, the present invention includes the following aspects.
(1) A cellulose composition comprising cellulose and cellooligosaccharides from trisaccharides to heptasaccharides, wherein the cellooligosaccharide content per 5 g of the cellulose composition is at least 1.5 mg but not more than 9.0 mg.
(2) The cellulose composition according to (1), wherein the water-soluble substance content per 5 g of the cellulose composition is at least 2.5 mg but not more than 12.5 mg.
(3) The cellulose composition according to (2), wherein the proportion of the cellooligosaccharides relative to the water-soluble substances is at least 47%
by mass but not more than 67% by mass.
(4) The cellulose composition according to any one of (1) to (3), wherein the cellulose composition is a powder, and the average particle size of the powder is at least 10ium but not more than 200 um.
(5) The cellulose composition according to (4), wherein the aspect ratio L/D of the powder is at least 1.8 but not more than 4Ø
(6) A tablet comprising the cellulose composition of any one of (1) to (5), and at least one active component.
(7) The tablet according to (6), wherein the lubricant content, relative to the total mass of the tablet, is at least 0.3% by mass but not more than 5% by mass.
In other words, the present invention includes the following aspects.
(1) A cellulose composition comprising cellulose and cellooligosaccharides from trisaccharides to heptasaccharides, wherein the cellooligosaccharide content per 5 g of the cellulose composition is at least 1.5 mg but not more than 9.0 mg.
(2) The cellulose composition according to (1), wherein the water-soluble substance content per 5 g of the cellulose composition is at least 2.5 mg but not more than 12.5 mg.
(3) The cellulose composition according to (2), wherein the proportion of the cellooligosaccharides relative to the water-soluble substances is at least 47%
by mass but not more than 67% by mass.
(4) The cellulose composition according to any one of (1) to (3), wherein the cellulose composition is a powder, and the average particle size of the powder is at least 10ium but not more than 200 um.
(5) The cellulose composition according to (4), wherein the aspect ratio L/D of the powder is at least 1.8 but not more than 4Ø
(6) A tablet comprising the cellulose composition of any one of (1) to (5), and at least one active component.
(7) The tablet according to (6), wherein the lubricant content, relative to the total mass of the tablet, is at least 0.3% by mass but not more than 5% by mass.
(8) The tablet according to (7), wherein the lubricant is at least one substance selected from the group consisting of fatty acid metal salts, fatty acid esters and fatty acid ester metal salts.
Date Recue/Date Received 2022-04-20
Date Recue/Date Received 2022-04-20
(9) The tablet according to (7) or (8), wherein the lubricant is at least one substance selected from the group consisting of magnesium stearate, calcium stearate, sodium stearyl fumarate, stearic acid, sucrose fatty acid esters, and talc.
(10) The tablet according to any one of (6) to (9), wherein the active component content, relative to the total mass of the tablet, is at least 0.01% by mass but less than 50% by mass.
Effects of the Invention [0008]
By using a cellulose composition of an aspect described above, a cellulose composition can be provided that has favorable hardness and good suppression of both deviation in the active component content and tableting failure during molding. A tablet of an aspect described above comprises the cellulose composition, and exhibits favorable hardness and good suppression of both deviation in the active component content and tableting failure during molding.
EMBODIMENTS FOR CARRYING OUT THE INVENTION
[0009]
Embodiments for implementing the present invention (hereafter referred to as simply "embodiments of the present invention") are described below in detail.
The present invention is not limited to the following embodiments, and various modifications may be made within the scope of the present invention.
[0010]
<Cellulose Composition>
Date Recue/Date Received 2022-04-20 A cellulose composition of an embodiment of the present invention contains cellulose and cellooligosaccharides from trisaccharides to heptasaccharides (hereafter sometimes abbreviated as "cellooligosaccharides (3 to 7)"). The cellooligosaccharide (3 to 7) content per 5 g of the cellulose composition is at least 1.5 mg but not more than 9.0 mg, and is preferably at least 2.0 mg but not more than 8.0 mg, more preferably at least 3.0 mg but not more than 7.5mg, even more preferably at least 4.0 mg but not more than 7.5 lug, and particularly preferably at least 5.0 mg but not more than 7.5 mg.
By ensuring that the cellooligosaccharide (3 to 7) content per 5 g of the cellulose composition falls within the above range, any reduction in tablet hardness accompanying lengthening of the mixing time can be effectively prevented. In those cases where the cellulose composition is a powder, it is preferable that each single particle contains cellulose and the cellooligosaccharides (3 to 7).
Effects of the Invention [0008]
By using a cellulose composition of an aspect described above, a cellulose composition can be provided that has favorable hardness and good suppression of both deviation in the active component content and tableting failure during molding. A tablet of an aspect described above comprises the cellulose composition, and exhibits favorable hardness and good suppression of both deviation in the active component content and tableting failure during molding.
EMBODIMENTS FOR CARRYING OUT THE INVENTION
[0009]
Embodiments for implementing the present invention (hereafter referred to as simply "embodiments of the present invention") are described below in detail.
The present invention is not limited to the following embodiments, and various modifications may be made within the scope of the present invention.
[0010]
<Cellulose Composition>
Date Recue/Date Received 2022-04-20 A cellulose composition of an embodiment of the present invention contains cellulose and cellooligosaccharides from trisaccharides to heptasaccharides (hereafter sometimes abbreviated as "cellooligosaccharides (3 to 7)"). The cellooligosaccharide (3 to 7) content per 5 g of the cellulose composition is at least 1.5 mg but not more than 9.0 mg, and is preferably at least 2.0 mg but not more than 8.0 mg, more preferably at least 3.0 mg but not more than 7.5mg, even more preferably at least 4.0 mg but not more than 7.5 lug, and particularly preferably at least 5.0 mg but not more than 7.5 mg.
By ensuring that the cellooligosaccharide (3 to 7) content per 5 g of the cellulose composition falls within the above range, any reduction in tablet hardness accompanying lengthening of the mixing time can be effectively prevented. In those cases where the cellulose composition is a powder, it is preferable that each single particle contains cellulose and the cellooligosaccharides (3 to 7).
[0011]
Conventionally, from the viewpoint of quality assurance, pharmaceutical additives and food additives have required substances of high purity, and conventional cellulose powders used as pharmaceutical additives are formed from pure cellulose with an extremely high degree of purity. In contrast, the cellulose composition of an embodiment of the present invention may contain a specified amount of the types of water-soluble substances that have conventionally been removed. These water-soluble substances are composed mainly of monosaccharides such as glucose and sorbitol, and cellooligosaccharides such as cellobiose, cellotriose, cellotetraose, cellopentaose, cellohexaose and celloheptaose. Among these constituent components, it is important that the total amount of cellotriose, cellotetraose, cellopentaose, cellohexaose and celloheptaose (hereafter, these components are jointly referred to as the "cellooligosaccharides (3 to 7)" falls within a specific range. When mixing the raw Date Recue/Date Received 2022-04-20 materials of a tablet, it is thought that abrasion between particles and the generation of powders and the like result in a deterioration in the binding properties between the particles, causing a reduction in the tablet hardness, but it is thought that by using a cellulose composition for which the cellooligosaccharide content is within the range described above, the binding between particles can be appropriately enhanced, enabling any reduction in the tablet hardness to be effectively suppressed.
Conventionally, from the viewpoint of quality assurance, pharmaceutical additives and food additives have required substances of high purity, and conventional cellulose powders used as pharmaceutical additives are formed from pure cellulose with an extremely high degree of purity. In contrast, the cellulose composition of an embodiment of the present invention may contain a specified amount of the types of water-soluble substances that have conventionally been removed. These water-soluble substances are composed mainly of monosaccharides such as glucose and sorbitol, and cellooligosaccharides such as cellobiose, cellotriose, cellotetraose, cellopentaose, cellohexaose and celloheptaose. Among these constituent components, it is important that the total amount of cellotriose, cellotetraose, cellopentaose, cellohexaose and celloheptaose (hereafter, these components are jointly referred to as the "cellooligosaccharides (3 to 7)" falls within a specific range. When mixing the raw Date Recue/Date Received 2022-04-20 materials of a tablet, it is thought that abrasion between particles and the generation of powders and the like result in a deterioration in the binding properties between the particles, causing a reduction in the tablet hardness, but it is thought that by using a cellulose composition for which the cellooligosaccharide content is within the range described above, the binding between particles can be appropriately enhanced, enabling any reduction in the tablet hardness to be effectively suppressed.
[0012]
As illustrated in the examples described below, the cellooligosaccharide (3 to 7) content within 5 g of the cellulose composition is measured by liquid chromatography /
mass spectrometry (LC/MS). In those cases where the composition contains other components that are likely to overlap with the peaks attributable to the cellooligosaccharides (3 to 7), the conditions for the liquid chromatography are first adjusted appropriately to ensure that peak separation is possible. If peak separation is impossible, then within the mass spectrometry, an extracted ion chromatogram of the base peak ions attributable to the cellooligosaccharides (3 to 7) can be used to determine the peak surface area attributable to the cellooligosaccharides (3 to 7).
As illustrated in the examples described below, the cellooligosaccharide (3 to 7) content within 5 g of the cellulose composition is measured by liquid chromatography /
mass spectrometry (LC/MS). In those cases where the composition contains other components that are likely to overlap with the peaks attributable to the cellooligosaccharides (3 to 7), the conditions for the liquid chromatography are first adjusted appropriately to ensure that peak separation is possible. If peak separation is impossible, then within the mass spectrometry, an extracted ion chromatogram of the base peak ions attributable to the cellooligosaccharides (3 to 7) can be used to determine the peak surface area attributable to the cellooligosaccharides (3 to 7).
[0013]
The cellooligosaccharide (3 to 7) content within the cellulose composition can be adjusted, for example, by adding the cellooligosaccharides (3 to 7) during production of the cellulose composition. Commercially available products may be procured and used as the cellooligosaccharides (3 to 7), or the cellooligosaccharides (3 to 7) can be obtained by appropriate hydrolysis of a natural cellulose material such as pulp, and then extraction, separation and purification of the desired cellooligosaccharides from the obtained hydrolysate.
The cellooligosaccharide (3 to 7) content within the cellulose composition can be adjusted, for example, by adding the cellooligosaccharides (3 to 7) during production of the cellulose composition. Commercially available products may be procured and used as the cellooligosaccharides (3 to 7), or the cellooligosaccharides (3 to 7) can be obtained by appropriate hydrolysis of a natural cellulose material such as pulp, and then extraction, separation and purification of the desired cellooligosaccharides from the obtained hydrolysate.
[0014]
Date Recue/Date Received 2022-04-20 In the cellulose composition of an embodiment of the present invention, the water-soluble substance content per 5 g of the cellulose composition is preferably at least 0.5 mg but not more than 12.5 mg, more preferably at least 2.5 mg but not more than 12.5 mg, even more preferably at least 5.0 mg but not more than 12.5 mg, and particularly preferably at least 6.0 mg but not more than 12.0 mg.
By ensuring that the water-soluble substance content falls within the above range, the tablet hardness can be adjusted to a more favorable level. Further, reactivity with the active component(s) can be effectively suppressed.
Date Recue/Date Received 2022-04-20 In the cellulose composition of an embodiment of the present invention, the water-soluble substance content per 5 g of the cellulose composition is preferably at least 0.5 mg but not more than 12.5 mg, more preferably at least 2.5 mg but not more than 12.5 mg, even more preferably at least 5.0 mg but not more than 12.5 mg, and particularly preferably at least 6.0 mg but not more than 12.0 mg.
By ensuring that the water-soluble substance content falls within the above range, the tablet hardness can be adjusted to a more favorable level. Further, reactivity with the active component(s) can be effectively suppressed.
[0015]
As described below in the examples, the water-soluble substance content can be measured in accordance with the crystalline cellulose purity test (2) method described in the 17th edition of the Japanese Pharmacopoeia, thus enabling measurement of the water-soluble substance content per 5 g of the cellulose composition.
As described below in the examples, the water-soluble substance content can be measured in accordance with the crystalline cellulose purity test (2) method described in the 17th edition of the Japanese Pharmacopoeia, thus enabling measurement of the water-soluble substance content per 5 g of the cellulose composition.
[0016]
in the cellulose composition of an embodiment of the present invention, the proportion of the cellooligosaccharides (3 to 7) relative to all the water-soluble substances is at least 47% by mass but not more than 68% by mass, preferably at least 50% by mass but not more than 67% by mass, even more preferably at least 55%
by mass but not more than 66% by mass, and particularly preferably at least 60%
by mass but not more than 65% by mass.
By ensuring that the proportion of the cellooligosaccharides (3 to 7) relative to the water-soluble substances falls within the above range, any reduction in hardness due to lengthening of the mixing time can be effectively suppressed. Further, reactivity with the active component(s) can also be suppressed to a low level, meaning the storage stability is also inore favorable.
Date Recue/Date Received 2022-04-20 The water-soluble substances in the cellulose composition of an embodiment of the present invention can be measured using the method described in the examples below.
in the cellulose composition of an embodiment of the present invention, the proportion of the cellooligosaccharides (3 to 7) relative to all the water-soluble substances is at least 47% by mass but not more than 68% by mass, preferably at least 50% by mass but not more than 67% by mass, even more preferably at least 55%
by mass but not more than 66% by mass, and particularly preferably at least 60%
by mass but not more than 65% by mass.
By ensuring that the proportion of the cellooligosaccharides (3 to 7) relative to the water-soluble substances falls within the above range, any reduction in hardness due to lengthening of the mixing time can be effectively suppressed. Further, reactivity with the active component(s) can also be suppressed to a low level, meaning the storage stability is also inore favorable.
Date Recue/Date Received 2022-04-20 The water-soluble substances in the cellulose composition of an embodiment of the present invention can be measured using the method described in the examples below.
[0017]
<Form of Cellulose Composition>
The cellulose composition according to an embodiment of the present invention preferably exists in the form of a powder, granules, a paste, or a wet cake.
From the viewpoint of the handling properties, a cellulose powder is preferred. A
cellulose powder is typically described as a crystalline cellulose or a powdered cellulose or the like, and can be used favorably as a pharmaceutical additive or food additive.
Known examples of crystalline celluloses include the microcrystalline cellulose specified by the Joint FAO/WHO Expert Committee on Food Additives (JECFA), the microcrystalline cellulose disclosed in the 8th edition of the Japanese Standards of Food Additives, the crystalline cellulose disclosed in the Japanese Pharmacopoeia (17th edition), and crystalline celluloses disclosed in the United States Pharmacopoeia and the European Pharmacopoeia.
From the viewpoint of achieving a favorable balance between moldability, flowability and disintegrability, the average degree of polymerization of the cellulose in the cellulose composition is preferably not more than 400, and is more preferably 350 or lower. The lower limit for the average degree of polymerization is preferably at least 100. The average degree of polymerization of the cellulose can be measured using the copper ethylenediamine solution viscosity method disclosed in the crystalline cellulose confirmation test (3) or the powdered cellulose confirmation test (3) described in the Japanese Pharmacopoeia.
<Form of Cellulose Composition>
The cellulose composition according to an embodiment of the present invention preferably exists in the form of a powder, granules, a paste, or a wet cake.
From the viewpoint of the handling properties, a cellulose powder is preferred. A
cellulose powder is typically described as a crystalline cellulose or a powdered cellulose or the like, and can be used favorably as a pharmaceutical additive or food additive.
Known examples of crystalline celluloses include the microcrystalline cellulose specified by the Joint FAO/WHO Expert Committee on Food Additives (JECFA), the microcrystalline cellulose disclosed in the 8th edition of the Japanese Standards of Food Additives, the crystalline cellulose disclosed in the Japanese Pharmacopoeia (17th edition), and crystalline celluloses disclosed in the United States Pharmacopoeia and the European Pharmacopoeia.
From the viewpoint of achieving a favorable balance between moldability, flowability and disintegrability, the average degree of polymerization of the cellulose in the cellulose composition is preferably not more than 400, and is more preferably 350 or lower. The lower limit for the average degree of polymerization is preferably at least 100. The average degree of polymerization of the cellulose can be measured using the copper ethylenediamine solution viscosity method disclosed in the crystalline cellulose confirmation test (3) or the powdered cellulose confirmation test (3) described in the Japanese Pharmacopoeia.
[0018]
Date Recue/Date Received 2022-04-20 <Preferred Form for Cellulose Powder>
In those cases where the cellulose composition of an embodiment of the present invention is a powder, the average particle size of the powder is at least 10 pm but not more than 200 pm, and is preferably at least 15 pm but not more than 100 pm, more preferably at least 20 pm but not more than 90 pm, even more preferably at least 30 pm but not more than 70 pm, and particularly preferably at least 40 pm but not more than 60 pm.
By ensuring that the average particle size is not higher than the above upper limit, the cellulose powder can be mixed more uniformly with active components such as drugs, and the moldability also improves. In particular, provided the average particle size is at least 20 pm, the flowability of the powder tends to be more favorable.
Date Recue/Date Received 2022-04-20 <Preferred Form for Cellulose Powder>
In those cases where the cellulose composition of an embodiment of the present invention is a powder, the average particle size of the powder is at least 10 pm but not more than 200 pm, and is preferably at least 15 pm but not more than 100 pm, more preferably at least 20 pm but not more than 90 pm, even more preferably at least 30 pm but not more than 70 pm, and particularly preferably at least 40 pm but not more than 60 pm.
By ensuring that the average particle size is not higher than the above upper limit, the cellulose powder can be mixed more uniformly with active components such as drugs, and the moldability also improves. In particular, provided the average particle size is at least 20 pm, the flowability of the powder tends to be more favorable.
[0019]
The average particle size of the cellulose powder is the particle size at a cumulative volume of 50% measured using a laser diffraction particle size distribution meter (LA950 V2 (brand name), manufactured by Horiba, Ltd.).
The average particle size of the cellulose powder is the particle size at a cumulative volume of 50% measured using a laser diffraction particle size distribution meter (LA950 V2 (brand name), manufactured by Horiba, Ltd.).
[0020]
In those cases where the cellulose composition of an embodiment of the present invention is a powder, the loose bulk density is preferably at least 0.11 g/mL
but not more than 0.35 g/mL, more preferably at least 0.13 g/mL but not more than 0.33 g/mL, and even more preferably at least 0.18 g/mL but not more than 0.31 g/mL.
By ensuring that the loose bulk density is at least as high as the above lower limit, the compression moldability can be improved. On the other hand, by ensuring that the loose bulk density is not more than the above upper limit, the packing properties can be improved.
Date Recue/Date Received 2022-04-20 The loose bulk density can be measured using the method disclosed in the examples described below.
In those cases where the cellulose composition of an embodiment of the present invention is a powder, the loose bulk density is preferably at least 0.11 g/mL
but not more than 0.35 g/mL, more preferably at least 0.13 g/mL but not more than 0.33 g/mL, and even more preferably at least 0.18 g/mL but not more than 0.31 g/mL.
By ensuring that the loose bulk density is at least as high as the above lower limit, the compression moldability can be improved. On the other hand, by ensuring that the loose bulk density is not more than the above upper limit, the packing properties can be improved.
Date Recue/Date Received 2022-04-20 The loose bulk density can be measured using the method disclosed in the examples described below.
[0021]
In those cases where the cellulose composition of an embodiment of the present invention is a powder, the packed bulk density is preferably at least 0.25 g/mL but not more than 0.50 g/mL, more preferably at least 0.30 g/mL but not more than 0.45 g/mL, and even more preferably at least 0.32 g/mL but not more than 0.42 g/mL.
By ensuring that the packed bulk density is at least as high as the above lower limit, the powder can be mixed more uniformly with active components such as drugs, and the handling properties also improve. On the other hand, by ensuring that the packed bulk density is not more than the above upper limit, any maldistribution resulting from the density difference from the active component(s) or other additives can be more effectively suppressed.
The packed bulk density can be measured using the method disclosed in the examples described below.
In those cases where the cellulose composition of an embodiment of the present invention is a powder, the packed bulk density is preferably at least 0.25 g/mL but not more than 0.50 g/mL, more preferably at least 0.30 g/mL but not more than 0.45 g/mL, and even more preferably at least 0.32 g/mL but not more than 0.42 g/mL.
By ensuring that the packed bulk density is at least as high as the above lower limit, the powder can be mixed more uniformly with active components such as drugs, and the handling properties also improve. On the other hand, by ensuring that the packed bulk density is not more than the above upper limit, any maldistribution resulting from the density difference from the active component(s) or other additives can be more effectively suppressed.
The packed bulk density can be measured using the method disclosed in the examples described below.
[0022]
Further, in those cases where the loose bulk density and the packed bulk density simultaneously satisfy the ranges described above, the tablets obtained by compression molding tend to exhibit superior moldability and disintegrability.
Further, in those cases where the loose bulk density and the packed bulk density simultaneously satisfy the ranges described above, the tablets obtained by compression molding tend to exhibit superior moldability and disintegrability.
[0023]
In those cases where the cellulose composition of an embodiment of the present invention is a powder, the compressibility is preferably at least 25% but not more than 58%, more preferably at least 30% but not more than 58%, and even more preferably at least 35% but not more than 58%.
Date Recue/Date Received 2022-04-20 Provided the compressibility falls within the above range, the flowability of the cellulose powder itself can be improved, and maldistribution of components in the powder can be more effectively suppressed.
The compressibility can be calculated using the method disclosed in the examples described below.
In those cases where the cellulose composition of an embodiment of the present invention is a powder, the compressibility is preferably at least 25% but not more than 58%, more preferably at least 30% but not more than 58%, and even more preferably at least 35% but not more than 58%.
Date Recue/Date Received 2022-04-20 Provided the compressibility falls within the above range, the flowability of the cellulose powder itself can be improved, and maldistribution of components in the powder can be more effectively suppressed.
The compressibility can be calculated using the method disclosed in the examples described below.
[0024]
In those cases where the cellulose composition of an embodiment of the present invention is a powder, the primary particle-equivalent average particle size (hereafter sometimes abbreviated as the "primary particle-equivalent particle size") is preferably at least 15 pm but not more than 30 pm, more preferably at least 16 pm but not more than 29 pm, and even more preferably at least 16 pm but not more than 27 pm.
By ensuring that the primary particle-equivalent particle size falls within the above range, the cellulose powder can be mixed more uniformly with active components such as drugs, and the disintegrability when formed as a tablet becomes more favorable.
A primary particle refers to a unit particle, and an aggregate or agglomerate of primary particles is termed a secondary particle. Secondary particle aggregates can be broken down and retuned to primary particles by dispersion in water. The primary particle-equivalent average particle size can be measured using the method disclosed in the examples described below.
In those cases where the cellulose composition of an embodiment of the present invention is a powder, the primary particle-equivalent average particle size (hereafter sometimes abbreviated as the "primary particle-equivalent particle size") is preferably at least 15 pm but not more than 30 pm, more preferably at least 16 pm but not more than 29 pm, and even more preferably at least 16 pm but not more than 27 pm.
By ensuring that the primary particle-equivalent particle size falls within the above range, the cellulose powder can be mixed more uniformly with active components such as drugs, and the disintegrability when formed as a tablet becomes more favorable.
A primary particle refers to a unit particle, and an aggregate or agglomerate of primary particles is termed a secondary particle. Secondary particle aggregates can be broken down and retuned to primary particles by dispersion in water. The primary particle-equivalent average particle size can be measured using the method disclosed in the examples described below.
[0025]
In those cases where the cellulose composition of an embodiment of the present invention is a powder, the ratio of the long axis relative to the short axis of the cellulose particles, namely, the aspect ratio (L/D), is preferably at least 1.8 but not more than 4.0, more preferably at least 2.1 but not more than 3.5, and even more preferably at least 2.2 but not more than 3.1.
Date Recue/Date Received 2022-04-20 By ensuring that the aspect ratio falls within the above range, the mixability with active components is also favorable, and the degree of intertwining of elongated particles is also appropriate, resulting in an excellent balance between moldability and disintegrability.
The aspect ratio (L/D) can be measured using the method disclosed in the examples described below.
In those cases where the cellulose composition of an embodiment of the present invention is a powder, the ratio of the long axis relative to the short axis of the cellulose particles, namely, the aspect ratio (L/D), is preferably at least 1.8 but not more than 4.0, more preferably at least 2.1 but not more than 3.5, and even more preferably at least 2.2 but not more than 3.1.
Date Recue/Date Received 2022-04-20 By ensuring that the aspect ratio falls within the above range, the mixability with active components is also favorable, and the degree of intertwining of elongated particles is also appropriate, resulting in an excellent balance between moldability and disintegrability.
The aspect ratio (L/D) can be measured using the method disclosed in the examples described below.
[0026]
<Method for Producing Cellulose Composition>
One example of a method for producing the cellulose composition of an embodiment of the present invention is described below.
The cellulose composition of an embodiment of the present invention can be obtained, for example, using a method that includes a step of dispersing a hydrolyzed natural cellulose-based substance in a suitable solvent to obtain a cellulose aqueous dispersion, and a step of drying the cellulose aqueous dispersion. There are no particular limitations on the solid fraction concentration of the cellulose aqueous dispersion, and the concentration may be set, for example, to at least 1% by mass but not more than 30%
by mass. in such cases, the solid fraction containing the hydrolyzed cellulose-based substance may be isolated from the hydrolysis reaction solution obtained from the hydrolysis treatment, and a dispersion prepared by dispersing this solid fraction in a suitable solvent may then be dried. Further, in order to ensure that the cellooligosaccharide (3 to 7) content in the cellulose composition falls within the specified range, cellooligosaccharides may be added to and mixed with the cellulose dispersion before drying is conducted. Furthermore, in those cases where the hydrolysis solution itself forms a cellulose dispersion, this dispersion may be dried directly.
<Method for Producing Cellulose Composition>
One example of a method for producing the cellulose composition of an embodiment of the present invention is described below.
The cellulose composition of an embodiment of the present invention can be obtained, for example, using a method that includes a step of dispersing a hydrolyzed natural cellulose-based substance in a suitable solvent to obtain a cellulose aqueous dispersion, and a step of drying the cellulose aqueous dispersion. There are no particular limitations on the solid fraction concentration of the cellulose aqueous dispersion, and the concentration may be set, for example, to at least 1% by mass but not more than 30%
by mass. in such cases, the solid fraction containing the hydrolyzed cellulose-based substance may be isolated from the hydrolysis reaction solution obtained from the hydrolysis treatment, and a dispersion prepared by dispersing this solid fraction in a suitable solvent may then be dried. Further, in order to ensure that the cellooligosaccharide (3 to 7) content in the cellulose composition falls within the specified range, cellooligosaccharides may be added to and mixed with the cellulose dispersion before drying is conducted. Furthermore, in those cases where the hydrolysis solution itself forms a cellulose dispersion, this dispersion may be dried directly.
[0027]
Date Recue/Date Received 2022-04-20 The natural cellulose-based substance may be plant-based or animal-based, and examples include natural material-derived fibrous substances containing cellulose such as timber, bamboo, cotton, ramie, hoya, bagasse, kenaf and bacteria cellulose, although the substance preferably has a cellulose I crystal structure. One of the above natural cellulose-based substances may be used as the raw material, or a mixture of two or more substances may be used. Further, it is preferable that the substance is used in the form of a purified pulp, but there are no particular limitations on the pulp purification method used, and any pulp such as dissolving pulp, kraft pulp or NBKP pulp may be used.
Date Recue/Date Received 2022-04-20 The natural cellulose-based substance may be plant-based or animal-based, and examples include natural material-derived fibrous substances containing cellulose such as timber, bamboo, cotton, ramie, hoya, bagasse, kenaf and bacteria cellulose, although the substance preferably has a cellulose I crystal structure. One of the above natural cellulose-based substances may be used as the raw material, or a mixture of two or more substances may be used. Further, it is preferable that the substance is used in the form of a purified pulp, but there are no particular limitations on the pulp purification method used, and any pulp such as dissolving pulp, kraft pulp or NBKP pulp may be used.
[0028]
In the above production method, water is preferred as the solvent used when dispersing the solid fraction containing the natural cellulose-based substance in a suitable solvent, but any industrially used solvent may be used without any particular limitations, and for example, organic solvents may also be used. Examples of such organic solvents include alcohols such as methanol, ethanol, isopropyl alcohol, butyl alcohol, methylbutyl alcohol and benzyl alcohol; hydrocarbons such as pentane, hexane, heptane and cyclohexane; and ketones such as acetone and methyl ethyl ketone. Organic solvents used in pharmaceuticals are particularly preferred, and examples of such solvents include those classified as solvents in "Pharmaceutical Excipients Directory 2016"
(published by Yakuji Nippo, Ltd.). Either water or a single organic solvent may be used alone, or a mixture of two or more solvents may be used, and the substance may also be first dispersed in one solvent, and following removal of that solvent, subsequently dispersed in another solvent.
In the above production method, water is preferred as the solvent used when dispersing the solid fraction containing the natural cellulose-based substance in a suitable solvent, but any industrially used solvent may be used without any particular limitations, and for example, organic solvents may also be used. Examples of such organic solvents include alcohols such as methanol, ethanol, isopropyl alcohol, butyl alcohol, methylbutyl alcohol and benzyl alcohol; hydrocarbons such as pentane, hexane, heptane and cyclohexane; and ketones such as acetone and methyl ethyl ketone. Organic solvents used in pharmaceuticals are particularly preferred, and examples of such solvents include those classified as solvents in "Pharmaceutical Excipients Directory 2016"
(published by Yakuji Nippo, Ltd.). Either water or a single organic solvent may be used alone, or a mixture of two or more solvents may be used, and the substance may also be first dispersed in one solvent, and following removal of that solvent, subsequently dispersed in another solvent.
[0029]
For example, pulp fibers having an average width of at least 2 pm but not more than 30 pm and an average thickness of at least 0.5 pm but not more than 5 pm may be Date Recue/Date Received 2022-04-20 hydrolyzed while agitating with a stirrer under pressure in hydrochloric acid of at least 0.05% by mass but not more than 1.5% by mass at a temperature of at least 70 C
but not more than 140 C.
The degree of progression of the hydrolysis can be controlled by adjusting the motor output of the stirrer (P: units W) and the stirring volume (L: units L).
For example, by adjusting the P/V value represented by the formula shown below, the average particle size of the finally obtained cellulose particles can be controlled to a value of not more than 200 m.
For example, pulp fibers having an average width of at least 2 pm but not more than 30 pm and an average thickness of at least 0.5 pm but not more than 5 pm may be Date Recue/Date Received 2022-04-20 hydrolyzed while agitating with a stirrer under pressure in hydrochloric acid of at least 0.05% by mass but not more than 1.5% by mass at a temperature of at least 70 C
but not more than 140 C.
The degree of progression of the hydrolysis can be controlled by adjusting the motor output of the stirrer (P: units W) and the stirring volume (L: units L).
For example, by adjusting the P/V value represented by the formula shown below, the average particle size of the finally obtained cellulose particles can be controlled to a value of not more than 200 m.
[0030]
P/V (W/L) = [Actual power output of stirrer motor (W)] / [Stirring volume (L)]
P/V (W/L) = [Actual power output of stirrer motor (W)] / [Stirring volume (L)]
[0031]
There are no particular limitations on the drying method used when drying the cellulose aqueous dispersion to obtain a cellulose composition. For example, freeze drying, spray drying, drum drying, rack drying, convection drying, or vacuum drying may be used, and either a single drying method or a combination of two or more drying methods may be used. In the case of spray drying, the spraying method may employ any of disk spraying, pressurized nozzle spraying. pressurized two-fluid nozzle spraying and pressurized four-fluid nozzle spraying, and either one of these methods or a combination of two or more methods may be used.
In the case of the spray drying mentioned above, a trace amount of a water-soluble polymer or surfactant may be added for the purpose of lowering the surface tension of the dispersion, and a foaming agent or gas may be added to the dispersion for the purpose of accelerating the solvent vaporization rate.
There are no particular limitations on the drying method used when drying the cellulose aqueous dispersion to obtain a cellulose composition. For example, freeze drying, spray drying, drum drying, rack drying, convection drying, or vacuum drying may be used, and either a single drying method or a combination of two or more drying methods may be used. In the case of spray drying, the spraying method may employ any of disk spraying, pressurized nozzle spraying. pressurized two-fluid nozzle spraying and pressurized four-fluid nozzle spraying, and either one of these methods or a combination of two or more methods may be used.
In the case of the spray drying mentioned above, a trace amount of a water-soluble polymer or surfactant may be added for the purpose of lowering the surface tension of the dispersion, and a foaming agent or gas may be added to the dispersion for the purpose of accelerating the solvent vaporization rate.
[0032]
Date Recue/Date Received 2022-04-20 By controlling the acid concentration and the stirring conditions during preparation of the cellulose aqueous dispersion, a cellulose aqueous dispersion can be obtained which contains cellulose dispersed particles with an average particle size that satisfies a specific size, water-soluble substances which are incorporated within the cellulose particles in an amount that falls within a specific range, and cellooligosaccharides (3 to 7) which are incorporated within the water-soluble substances in an amount that falls within a specific range, and by also adjusting the solid fraction concentration of the cellulose aqueous dispersion and the drying conditions when drying this cellulose aqueous dispersion, the average particle size and compressibility of the obtained cellulose composition can be controlled. For example, when the drying of the cellulose aqueous dispersion is conducted by disk spray drying, by ensuring that the stirring power when preparing the cellulose aqueous dispersion falls within the specified range, and that the conditions for the solid fraction concentration of the cellulose aqueous dispersion and the rotational rate for the disk spray drying during the spray drying process satisfy the specified ranges, a cellulose composition for which the average particle size and the compressibility fall within the prescribed ranges can be obtained.
Date Recue/Date Received 2022-04-20 By controlling the acid concentration and the stirring conditions during preparation of the cellulose aqueous dispersion, a cellulose aqueous dispersion can be obtained which contains cellulose dispersed particles with an average particle size that satisfies a specific size, water-soluble substances which are incorporated within the cellulose particles in an amount that falls within a specific range, and cellooligosaccharides (3 to 7) which are incorporated within the water-soluble substances in an amount that falls within a specific range, and by also adjusting the solid fraction concentration of the cellulose aqueous dispersion and the drying conditions when drying this cellulose aqueous dispersion, the average particle size and compressibility of the obtained cellulose composition can be controlled. For example, when the drying of the cellulose aqueous dispersion is conducted by disk spray drying, by ensuring that the stirring power when preparing the cellulose aqueous dispersion falls within the specified range, and that the conditions for the solid fraction concentration of the cellulose aqueous dispersion and the rotational rate for the disk spray drying during the spray drying process satisfy the specified ranges, a cellulose composition for which the average particle size and the compressibility fall within the prescribed ranges can be obtained.
[0033]
Furthermore, as disclosed in the following examples, a cellulose composition for which the cellooligosaccharide (3 to 7) content falls within the specified range may be obtained by adding and mixing cellooligosaccharides with the cellulose aqueous dispersion, and then drying the resulting dispersion.
Furthermore, as disclosed in the following examples, a cellulose composition for which the cellooligosaccharide (3 to 7) content falls within the specified range may be obtained by adding and mixing cellooligosaccharides with the cellulose aqueous dispersion, and then drying the resulting dispersion.
[0034]
Even in those cases where the average particle size of the cellulose composition following drying is greater than 200 pm, the average particle size can be adjusted to a Date Recue/Date Received 2022-04-20 value of at least 10 pm but not more than 200 pm by supplying the composition to a grinding step described below.
Even in those cases where the average particle size of the cellulose composition following drying is greater than 200 pm, the average particle size can be adjusted to a Date Recue/Date Received 2022-04-20 value of at least 10 pm but not more than 200 pm by supplying the composition to a grinding step described below.
[0035]
The grinding step can be conducted by grinding the dried cellulose composition with a grinder such as an Ultra Centrifugal Mill (ZM-200, manufactured by Retsch GmbH), a Jet Mill (STJ-200, manufactured by Seishin Enterprise Co., Ltd.), a Hannner Mill (H-12, manufactured by Hosokawa Micron Corporation, or HM-600, manufactured by Nara Machinery Co., Ltd.), a Bantam Mill (AP-B, manufactured by Hosokawa Micron Corporation), a Pin Mill (160Z, manufactured by Powrex Corporation), a Feather Mill (FM, manufactured by Hosokawa Micron Corporation), a Flash Mill (FL-250N, manufactured by Dalton Corporation), a Ball Mill (Einax, manufactured by Retsch GmbH), a Vibrating Ball Mill (2C, manufactured by TRU Tech Systems Inc.), or a Screen Mill in which the composition is passed through a screen (U30, manufactured by Powrex Corporation). In particular, the Jet Mill (STJ-200, manufactured by Seishin Enterprise Co., Ltd.) is a convection-type grinder in which grinding is conducted while the particles are caused to collide with one another under high air pressure, thus facilitating the breakup of secondary particles into primary particles, and is consequently preferred.
The grinding step can be conducted by grinding the dried cellulose composition with a grinder such as an Ultra Centrifugal Mill (ZM-200, manufactured by Retsch GmbH), a Jet Mill (STJ-200, manufactured by Seishin Enterprise Co., Ltd.), a Hannner Mill (H-12, manufactured by Hosokawa Micron Corporation, or HM-600, manufactured by Nara Machinery Co., Ltd.), a Bantam Mill (AP-B, manufactured by Hosokawa Micron Corporation), a Pin Mill (160Z, manufactured by Powrex Corporation), a Feather Mill (FM, manufactured by Hosokawa Micron Corporation), a Flash Mill (FL-250N, manufactured by Dalton Corporation), a Ball Mill (Einax, manufactured by Retsch GmbH), a Vibrating Ball Mill (2C, manufactured by TRU Tech Systems Inc.), or a Screen Mill in which the composition is passed through a screen (U30, manufactured by Powrex Corporation). In particular, the Jet Mill (STJ-200, manufactured by Seishin Enterprise Co., Ltd.) is a convection-type grinder in which grinding is conducted while the particles are caused to collide with one another under high air pressure, thus facilitating the breakup of secondary particles into primary particles, and is consequently preferred.
[0036]
Among the grinding conditions for the Jet Mill grinder, the amount of powder supplied and the grinding pressure are important, and the supply amount when using the Jet Mill grinder (STJ-200, manufactured by Seishin Enterprise Co., Ltd.) is preferably at least 10 kg/hour but not more than 20 kg/hour, and more preferably at least 15 kg/hour but not more than 20 kg/hour. Further, the grinding pressure is preferably at least 0.15 MPa but not more than 0.70 MPa, and more preferably at least 0.30 MPa but not more Date Recue/Date Received 2022-04-20 than 0.50 MPa. Provided the supply amount of the powder and the grinding pressure satisfy the above ranges, the average particle size tends to be more easily adjusted to a value within the desired range of at least 10 pm but not more than 200 pm.
Even in those cases where the average particle size of the dried cellulose powder is less than 100 pm, by subjecting the cellulose powder to a granulation method such as stirring granulation or fluidized bed granulation, the average particle size can be adjusted to a value within the desired range from at least 100 pm to not more than about 200 pm.
Among the grinding conditions for the Jet Mill grinder, the amount of powder supplied and the grinding pressure are important, and the supply amount when using the Jet Mill grinder (STJ-200, manufactured by Seishin Enterprise Co., Ltd.) is preferably at least 10 kg/hour but not more than 20 kg/hour, and more preferably at least 15 kg/hour but not more than 20 kg/hour. Further, the grinding pressure is preferably at least 0.15 MPa but not more than 0.70 MPa, and more preferably at least 0.30 MPa but not more Date Recue/Date Received 2022-04-20 than 0.50 MPa. Provided the supply amount of the powder and the grinding pressure satisfy the above ranges, the average particle size tends to be more easily adjusted to a value within the desired range of at least 10 pm but not more than 200 pm.
Even in those cases where the average particle size of the dried cellulose powder is less than 100 pm, by subjecting the cellulose powder to a granulation method such as stirring granulation or fluidized bed granulation, the average particle size can be adjusted to a value within the desired range from at least 100 pm to not more than about 200 pm.
[0037]
<Usage Applications>
By blending the cellulose composition of an embodiment of the present invention with a composition containing an active component, tablets can be obtained which have favorable hardness and good suppression of both reduction in the tablet hardness caused by lengthening of the mixing time and deviation in the active component content. These effects are particularly marked in tablets for which the active component content is less than 50% by mass.
In the following description, when discussing production of a tablet, the mixtures obtained by mixing at least one active component, the cellulose composition of an embodiment of the present invention and any other optional additives is referred to as a "tablet mixture".
<Usage Applications>
By blending the cellulose composition of an embodiment of the present invention with a composition containing an active component, tablets can be obtained which have favorable hardness and good suppression of both reduction in the tablet hardness caused by lengthening of the mixing time and deviation in the active component content. These effects are particularly marked in tablets for which the active component content is less than 50% by mass.
In the following description, when discussing production of a tablet, the mixtures obtained by mixing at least one active component, the cellulose composition of an embodiment of the present invention and any other optional additives is referred to as a "tablet mixture".
[0038]
The blend proportion of the cellulose composition described above in the tablet mixture, expressed relative to the total mass of the obtained tablet, is normally at least 1% by mass but not more than 90% by mass, preferably at least 1% by mass but not more than 50% by mass, more preferably at least 1% by mass but not more than 30% by mass, Date Recue/Date Received 2022-04-20 even more preferably at least 3% by mass but not more than 20% by mass, and particularly preferably at least 5% by mass but not more than 15% by mass.
The blend proportion of the cellulose composition described above in the tablet mixture, expressed relative to the total mass of the obtained tablet, is normally at least 1% by mass but not more than 90% by mass, preferably at least 1% by mass but not more than 50% by mass, more preferably at least 1% by mass but not more than 30% by mass, Date Recue/Date Received 2022-04-20 even more preferably at least 3% by mass but not more than 20% by mass, and particularly preferably at least 5% by mass but not more than 15% by mass.
[0039]
[Active Component]
Examples of components that are ideal as the active component for inclusion in the tablet mixture are described below.
The pharmaceutical medicinal component is preferably an active component of an orally administered pharmaceutical. Examples of orally administered pharmaceuticals include antipyretic analgesic anti-inflammatory drugs, sedative hypnotic drugs, anti-drowsiness drugs, anti-vertiginous drugs, pediatric analgesics, stomachic drugs, antacids, digestive drugs, cardiotonic drugs, arrhythmia drugs, antihypertensive drugs, vasodilators, diuretics, antiulcer drugs, intestinal regulators, osteoporosis treatments, antitussive drugs, anti-asthmatic drugs, antibacterial agents, pollakiuria improvement agents, nourishing tonics, and vitamins. Any of these medicinal components may be used individually, or a combination of two or more components may be used.
[Active Component]
Examples of components that are ideal as the active component for inclusion in the tablet mixture are described below.
The pharmaceutical medicinal component is preferably an active component of an orally administered pharmaceutical. Examples of orally administered pharmaceuticals include antipyretic analgesic anti-inflammatory drugs, sedative hypnotic drugs, anti-drowsiness drugs, anti-vertiginous drugs, pediatric analgesics, stomachic drugs, antacids, digestive drugs, cardiotonic drugs, arrhythmia drugs, antihypertensive drugs, vasodilators, diuretics, antiulcer drugs, intestinal regulators, osteoporosis treatments, antitussive drugs, anti-asthmatic drugs, antibacterial agents, pollakiuria improvement agents, nourishing tonics, and vitamins. Any of these medicinal components may be used individually, or a combination of two or more components may be used.
[0040]
Specific examples of medicinal components include aspirin, aspirin aluminum, acetaminophen, ethenzamide, sasapyrine, salicylamide, lactylphenetidine, isothipendyl hydrochloride, diphenylpyraline hydrochloride, diphenhydramine hydrochloride, difeterol hydrochloride, triprolidine hydrochloride, tripelennamine hydrochloride, thonzylamine hydrochloride, fenethazine hydrochloride, methdilazine hydrochloride, diphenhydramine salicylate, carbinoxamine diphenyldisulfonate, alimemazine tartrate, diphenhydramine tannate, diphenylpyraline teoclate, mebhydrolin napadisilate, promethazine methylenedisalicylate, carbinoxamine maleate, chlorpheniramine dl-maleate, chlorpheniramine d-maleate, difeterol phosphate, alloclamide hydrochloride, Date Recue/Date Received 2022-04-20 cloperastine hydrochloride, pentoxyverine citrate (carbetapentane citrate), tipepidine citrate, sodium dibunate, dextromethorphan hydrobromide, dextromethorphan phenolphthalate, tipepidine hibenzate, cloperastine fendizoate, codeine phosphate, dihydrocodeine phosphate, noscapine hydrochloride, noscapine, dl-inethylephedrine hydrochloride, dl-methylephedrine saccharin salt, potassium guaiacolsulfonate, guaifenesin, caffeine sodium benzoate, caffeine, anhydrous caffeine, vitamin B1 and derivatives and salts thereof, vitamin B2 and derivatives and salts thereof, vitamin C and derivatives and salts thereof, hesperidin and derivatives and salts thereof, vitamin B6 and derivatives and salts thereof, nicotinamide, calcium pantothenate, aminoacetic acid, magnesium silicate, synthetic aluminum silicate, synthetic hydrotalcite, magnesium oxide, dihydroxyaluminum aminoacetate (aluminum glycinate), aluminum hydroxide gel, dried aluminum hydroxide gel, mixed dry gel of aluminum hydroxide and magnesium carbonate, co-precipitated product of aluminum hydroxide and sodium hydrogen carbonate, co-precipitated product of aluminum hydroxide, calcium carbonate and magnesi urn carbonate, co-precipitated product of magnesi urn hydroxide and aluminum potassium sulfate, magnesium carbonate, magnesium aluminometasilicate, ranitidine hydrochloride, cimetidine, famotidine, naproxen, diclofenac sodium, piroxicum, azulene, indomethacin, ketoprofen, ibuprofen, diphenidol hydrochloride, diphenylpyraline hydrochloride, diphenhydramine hydrochloride, promethazine hydrochloride, meclizine hydrochloride, dimenhydrinate, diphenhydramine tannate, phenethazine tannate, diphenylpyraline teoclate, diphenhydramine fumarate, promethazine methylenedisalicylate, scopolamine hydrobromide, oxyphencyclimine hydrochloride, dicyclomine hydrochloride, methixene hydrochloride, methylatropine bromide, methylanisotropine bromide, methylscopolamine bromide, methyl-l-hyoscyamine bromide, methylbenactyzium bromide, belladonna extract, isopropamide iodide, Date Recue/Date Received 2022-04-20 diphenylpiperidinomethyldioxolan iodide, papaverine hydrochloride, aminobenzoic acid, cesium oxalate, ethyl piperidylacetylaminobenzoate, aminophylline, diprophylline, theophylline, sodium hydrogen carbonate, fursultiamine, isosorbide mononitrate, ephedrine, cephalexin, ampicillin, sulfisoxazole, sucralfate, allylisopropylacetylurea, bromvalerylurea; as well as ephedra, nantenzitu, oohi, polygala root, glycyrrhiza, platycodon, plantago seed, plantago herb, senega, fritillaria, fennel, phellodendron bark, coptis rhizome, curcuma zedoaria, chamomile, cassia bark, gentian, oriental bezoar, animal bile (including bear bile), syazin, ginger, atractylodes lancea rhizome, clove, citrus unshiu, atractylodes rhizome, ziryuu, panax rhizome, ginseng. Japanese valerian, moutan bark, zanthoxylum, and extracts of these plants; and pharmaceutical medicinal components disclosed in the "Japanese Pharmacopoeia", "Japanese Pharmaceutical Codex", "United States Pharmacopoeia (USP)", "National Formulary (NF)" and "European Pharmacopoeia (EP)", such as insulin, vasopressin, interferon, urokinase, serratiopeptidase and somatostatin. A single substance selected from among the above substances may be used alone, or a combination of two or more substances may be used.
Specific examples of medicinal components include aspirin, aspirin aluminum, acetaminophen, ethenzamide, sasapyrine, salicylamide, lactylphenetidine, isothipendyl hydrochloride, diphenylpyraline hydrochloride, diphenhydramine hydrochloride, difeterol hydrochloride, triprolidine hydrochloride, tripelennamine hydrochloride, thonzylamine hydrochloride, fenethazine hydrochloride, methdilazine hydrochloride, diphenhydramine salicylate, carbinoxamine diphenyldisulfonate, alimemazine tartrate, diphenhydramine tannate, diphenylpyraline teoclate, mebhydrolin napadisilate, promethazine methylenedisalicylate, carbinoxamine maleate, chlorpheniramine dl-maleate, chlorpheniramine d-maleate, difeterol phosphate, alloclamide hydrochloride, Date Recue/Date Received 2022-04-20 cloperastine hydrochloride, pentoxyverine citrate (carbetapentane citrate), tipepidine citrate, sodium dibunate, dextromethorphan hydrobromide, dextromethorphan phenolphthalate, tipepidine hibenzate, cloperastine fendizoate, codeine phosphate, dihydrocodeine phosphate, noscapine hydrochloride, noscapine, dl-inethylephedrine hydrochloride, dl-methylephedrine saccharin salt, potassium guaiacolsulfonate, guaifenesin, caffeine sodium benzoate, caffeine, anhydrous caffeine, vitamin B1 and derivatives and salts thereof, vitamin B2 and derivatives and salts thereof, vitamin C and derivatives and salts thereof, hesperidin and derivatives and salts thereof, vitamin B6 and derivatives and salts thereof, nicotinamide, calcium pantothenate, aminoacetic acid, magnesium silicate, synthetic aluminum silicate, synthetic hydrotalcite, magnesium oxide, dihydroxyaluminum aminoacetate (aluminum glycinate), aluminum hydroxide gel, dried aluminum hydroxide gel, mixed dry gel of aluminum hydroxide and magnesium carbonate, co-precipitated product of aluminum hydroxide and sodium hydrogen carbonate, co-precipitated product of aluminum hydroxide, calcium carbonate and magnesi urn carbonate, co-precipitated product of magnesi urn hydroxide and aluminum potassium sulfate, magnesium carbonate, magnesium aluminometasilicate, ranitidine hydrochloride, cimetidine, famotidine, naproxen, diclofenac sodium, piroxicum, azulene, indomethacin, ketoprofen, ibuprofen, diphenidol hydrochloride, diphenylpyraline hydrochloride, diphenhydramine hydrochloride, promethazine hydrochloride, meclizine hydrochloride, dimenhydrinate, diphenhydramine tannate, phenethazine tannate, diphenylpyraline teoclate, diphenhydramine fumarate, promethazine methylenedisalicylate, scopolamine hydrobromide, oxyphencyclimine hydrochloride, dicyclomine hydrochloride, methixene hydrochloride, methylatropine bromide, methylanisotropine bromide, methylscopolamine bromide, methyl-l-hyoscyamine bromide, methylbenactyzium bromide, belladonna extract, isopropamide iodide, Date Recue/Date Received 2022-04-20 diphenylpiperidinomethyldioxolan iodide, papaverine hydrochloride, aminobenzoic acid, cesium oxalate, ethyl piperidylacetylaminobenzoate, aminophylline, diprophylline, theophylline, sodium hydrogen carbonate, fursultiamine, isosorbide mononitrate, ephedrine, cephalexin, ampicillin, sulfisoxazole, sucralfate, allylisopropylacetylurea, bromvalerylurea; as well as ephedra, nantenzitu, oohi, polygala root, glycyrrhiza, platycodon, plantago seed, plantago herb, senega, fritillaria, fennel, phellodendron bark, coptis rhizome, curcuma zedoaria, chamomile, cassia bark, gentian, oriental bezoar, animal bile (including bear bile), syazin, ginger, atractylodes lancea rhizome, clove, citrus unshiu, atractylodes rhizome, ziryuu, panax rhizome, ginseng. Japanese valerian, moutan bark, zanthoxylum, and extracts of these plants; and pharmaceutical medicinal components disclosed in the "Japanese Pharmacopoeia", "Japanese Pharmaceutical Codex", "United States Pharmacopoeia (USP)", "National Formulary (NF)" and "European Pharmacopoeia (EP)", such as insulin, vasopressin, interferon, urokinase, serratiopeptidase and somatostatin. A single substance selected from among the above substances may be used alone, or a combination of two or more substances may be used.
[0041]
There are no particular limitations on health food active components that may be used, provided the component is added for the purpose of enhancing health, and examples include green juice powder, aglycone, agaricus, ashwagandha, astaxanthin, acerola, amino acids (such as valine, leucine, isoleucine, lysine, methionine, phenylalanine, threonine, tryptophan, histidine, cystine, tyrosine, arginine, alanine, aspartic acid, seaweed powder, glutamine, glutamic acid, glycine, proline, and serine), alginic acid, gingko leaf extract, sardine peptide, turmeric, uronic acid, echinacea, eleuthero, oligosaccharides, oleic acid, nuclear proteins, bonito peptide, catechin, potassium, calcium, carotenoids, garcinia, L-carnitine, chitosan, conjugated linoleic acid, Date Recue/Date Received 2022-04-20 krantz aloe, gymnema sylvestre extract, citric acid, orthosiphon stamineus, glycerides, glycenol, glucagon, curcumin, glucosamine, L-glutamine, chlorella, cranberry extract, cat's claw, germanium, enzymes, ginseng extract, coenzyme Q10, collagen, collagen peptides, coleus forskolin, chondroitin, psyllium husk powder, hawthorn extract, saponin, lipids, L-cystine, perilla extract, citrimax, fatty acids, plant sterols, seed extracts, spirulina, squalane, white willow, ceramides, selenium, St. John's wort extract, soy isoflavone, soy saponin, soy peptide, soy lecithin, monosaccharides, proteins, chaste tree extract, iron, copper, docosahexaenoic acid, tocotrienol, natto kinase, bacillus natto culture extract, niacin sodium, nicotinic acid, disaccharides, lactic acid bacteria, garlic, saw plametto, sprouted rice, adlay extract, herb extracts, valerian extract, pantothenic acid, hyaluronic acid, biotin, chromium picolinate, vitamin A, vitamin A2, vitamin Bl, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, hydroxytyrosol, bifidus, beer yeast, fructooligosaccharides, flavonoids, butcher's broom extract, black cohosh, blueberry, prune extract, proanthocyanidin, proteins, propolis, bromelain, probiotics, phosphatidylcholine, phosphatidylserine, 3-carotene, peptides, safflower extract, maitake extract, maca extract, magnesium, milk thistle, manganese, mitochondria, minerals, mucopolysaccharides, melatonin, fomes yucatensis, melilot extract powder, molybdenum, vegetable powders. folic acid, lactose, lycopene, linoleic acid, lipoic acid, phosphorus, lutein, lecithin, rosmarinic acid, royal jelly, DHA, and EPA.
There are no particular limitations on health food active components that may be used, provided the component is added for the purpose of enhancing health, and examples include green juice powder, aglycone, agaricus, ashwagandha, astaxanthin, acerola, amino acids (such as valine, leucine, isoleucine, lysine, methionine, phenylalanine, threonine, tryptophan, histidine, cystine, tyrosine, arginine, alanine, aspartic acid, seaweed powder, glutamine, glutamic acid, glycine, proline, and serine), alginic acid, gingko leaf extract, sardine peptide, turmeric, uronic acid, echinacea, eleuthero, oligosaccharides, oleic acid, nuclear proteins, bonito peptide, catechin, potassium, calcium, carotenoids, garcinia, L-carnitine, chitosan, conjugated linoleic acid, Date Recue/Date Received 2022-04-20 krantz aloe, gymnema sylvestre extract, citric acid, orthosiphon stamineus, glycerides, glycenol, glucagon, curcumin, glucosamine, L-glutamine, chlorella, cranberry extract, cat's claw, germanium, enzymes, ginseng extract, coenzyme Q10, collagen, collagen peptides, coleus forskolin, chondroitin, psyllium husk powder, hawthorn extract, saponin, lipids, L-cystine, perilla extract, citrimax, fatty acids, plant sterols, seed extracts, spirulina, squalane, white willow, ceramides, selenium, St. John's wort extract, soy isoflavone, soy saponin, soy peptide, soy lecithin, monosaccharides, proteins, chaste tree extract, iron, copper, docosahexaenoic acid, tocotrienol, natto kinase, bacillus natto culture extract, niacin sodium, nicotinic acid, disaccharides, lactic acid bacteria, garlic, saw plametto, sprouted rice, adlay extract, herb extracts, valerian extract, pantothenic acid, hyaluronic acid, biotin, chromium picolinate, vitamin A, vitamin A2, vitamin Bl, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, hydroxytyrosol, bifidus, beer yeast, fructooligosaccharides, flavonoids, butcher's broom extract, black cohosh, blueberry, prune extract, proanthocyanidin, proteins, propolis, bromelain, probiotics, phosphatidylcholine, phosphatidylserine, 3-carotene, peptides, safflower extract, maitake extract, maca extract, magnesium, milk thistle, manganese, mitochondria, minerals, mucopolysaccharides, melatonin, fomes yucatensis, melilot extract powder, molybdenum, vegetable powders. folic acid, lactose, lycopene, linoleic acid, lipoic acid, phosphorus, lutein, lecithin, rosmarinic acid, royal jelly, DHA, and EPA.
[0042]
The active component may be water-soluble, or may be sparingly water-soluble.
The term "sparingly water-soluble" is defined in the 17th edition of the Japanese Pharmacopoeia as requiring 30 mL or more of water to dissolve 1 g of solute.
Date Recue/Date Received 2022-04-20 Examples of sparingly water-soluble solid active components include pharmaceutical medicinal components disclosed in the "Japanese Pharmacopoeia", "Japanese Pharmaceutical Codex", "USP", "NF" and "EP", including antipyretic analgesics, nervous system drugs, sedative hypnotic drugs, muscle relaxants, hypotensive agent and antihistamines such as acetaminophen, ibuprofen, benzoic acid, ethenzamide, caffeine, camphor, quinine, calcium gluconate, dimercaprol, sulfamine, theophylline, theobromine, riboflavin, mephenesin, phenobarbital, aminophylline, thioacetazone, quercetin, rutin, salicylic acid, theophylline sodium, pyrabital, quinine hydrochloride, irgapyrin, digitoxin, griseofulvin, and phenacetin; antibiotics such as acetylspiramycin, ampicillin, erythromycin, kitasamycin, chloramphenicol, triacetyloleandomycin, nystatin, and colistin sulfate; steroid hormones such as methyltestosterone, methylandrostenediol, progesterone, estradiol benzoate, ethinylestradiol, deoxycorticosterone acetate, cortisone acetate, hydrocortisone, hydrocortisone acetate, and prednisolone; non-steroidal estrogen hormones such as dienestrol, hexestrol, diethylstilbesterol, diethylstilbestrol dipropionate, and chlorotrianisene; and other fat-soluble vitamins and the like. A single substance selected from among the above substances may be used alone, or a combination of two or more substances may be used. If the substance is sparingly water-soluble, then regardless of the sublimability and degree of surface polarity, the effects of the present invention can be achieved by blending the active component with the tablet mixture.
The active component may be water-soluble, or may be sparingly water-soluble.
The term "sparingly water-soluble" is defined in the 17th edition of the Japanese Pharmacopoeia as requiring 30 mL or more of water to dissolve 1 g of solute.
Date Recue/Date Received 2022-04-20 Examples of sparingly water-soluble solid active components include pharmaceutical medicinal components disclosed in the "Japanese Pharmacopoeia", "Japanese Pharmaceutical Codex", "USP", "NF" and "EP", including antipyretic analgesics, nervous system drugs, sedative hypnotic drugs, muscle relaxants, hypotensive agent and antihistamines such as acetaminophen, ibuprofen, benzoic acid, ethenzamide, caffeine, camphor, quinine, calcium gluconate, dimercaprol, sulfamine, theophylline, theobromine, riboflavin, mephenesin, phenobarbital, aminophylline, thioacetazone, quercetin, rutin, salicylic acid, theophylline sodium, pyrabital, quinine hydrochloride, irgapyrin, digitoxin, griseofulvin, and phenacetin; antibiotics such as acetylspiramycin, ampicillin, erythromycin, kitasamycin, chloramphenicol, triacetyloleandomycin, nystatin, and colistin sulfate; steroid hormones such as methyltestosterone, methylandrostenediol, progesterone, estradiol benzoate, ethinylestradiol, deoxycorticosterone acetate, cortisone acetate, hydrocortisone, hydrocortisone acetate, and prednisolone; non-steroidal estrogen hormones such as dienestrol, hexestrol, diethylstilbesterol, diethylstilbestrol dipropionate, and chlorotrianisene; and other fat-soluble vitamins and the like. A single substance selected from among the above substances may be used alone, or a combination of two or more substances may be used. If the substance is sparingly water-soluble, then regardless of the sublimability and degree of surface polarity, the effects of the present invention can be achieved by blending the active component with the tablet mixture.
[0043]
The active component may also be a sparingly water-soluble oil or liquid.
Examples of sparingly water-soluble oil or liquid components that may be used as active components include pharmaceutical medicinal components disclosed in the "Japanese Pharmacopoeia", "Japanese Pharmaceutical Codex", "USP", "NF" and "EP", including Date Recue/Date Received 2022-04-20 vitamins such as teprenone, indometacin farnesil, menatetrenone, phytonadione, vitamin A oil, fenipentol, vitamin D and vitamin E, higher unsaturated fatty acids such as DHA
(docosahexaenoic acid), EPA (eicosapentaenoic acid) and cod liver oil, coenzyme Q
substances, and oil-soluble flavorings such as orange oil, lemon oil and peppermint oil.
Vitamin E has various homologues and derivatives, but there are no particular limitations on the form of the vitamin, provided it is liquid at normal temperatures.
Specific examples include dl-a-tocopherol, dl-a-tocopherol acetate, d-a-tocopherol, and d-a-tocopherol acetate. A single substance selected from among the above substances may be used alone, or a combination of two or more substances may be used.
The active component may also be a sparingly water-soluble oil or liquid.
Examples of sparingly water-soluble oil or liquid components that may be used as active components include pharmaceutical medicinal components disclosed in the "Japanese Pharmacopoeia", "Japanese Pharmaceutical Codex", "USP", "NF" and "EP", including Date Recue/Date Received 2022-04-20 vitamins such as teprenone, indometacin farnesil, menatetrenone, phytonadione, vitamin A oil, fenipentol, vitamin D and vitamin E, higher unsaturated fatty acids such as DHA
(docosahexaenoic acid), EPA (eicosapentaenoic acid) and cod liver oil, coenzyme Q
substances, and oil-soluble flavorings such as orange oil, lemon oil and peppermint oil.
Vitamin E has various homologues and derivatives, but there are no particular limitations on the form of the vitamin, provided it is liquid at normal temperatures.
Specific examples include dl-a-tocopherol, dl-a-tocopherol acetate, d-a-tocopherol, and d-a-tocopherol acetate. A single substance selected from among the above substances may be used alone, or a combination of two or more substances may be used.
[0044]
The active component may also be a sparingly water-soluble semisolid active component. Among the various active components, examples of sparingly water-soluble semisolid active components include traditional Chinese medicines and crude drug extracts such as ziryuu, glycyrrhiza, cassia bark, Chinese peony, moutan bark, Japanese valerian, zanthoxylum, ginger, citrus unshiu, ephedra, nantenzitsu, oohi, polygala root, platycodon root, plantago seed, plantago herb, lycoris radiata bulb, senega, fritillaria bulb, fennel, phellodendron bark, coptis rhizome, curcuma zedoaria, chamomile, gentian, oriental bezoar, animal bile, syazin, ginger, atractylodes lancea rhizome, clove, citrus unshiu, atractylodes rhizome, panax rhizome, ginseng, kakkon-to, keishi-to, kousosan, saiko-keishi-to, sho-saiko-to, sho-seiryu-to, bakumondo-to, hange-koboku-to, and mao-to; as well as oyster meat extract, propolis and propolis extract, and coenzyme Q
substances. A single substance selected from among the above substances may be used alone, or a combination of two or more substances may be used.
The active component may also be a sparingly water-soluble semisolid active component. Among the various active components, examples of sparingly water-soluble semisolid active components include traditional Chinese medicines and crude drug extracts such as ziryuu, glycyrrhiza, cassia bark, Chinese peony, moutan bark, Japanese valerian, zanthoxylum, ginger, citrus unshiu, ephedra, nantenzitsu, oohi, polygala root, platycodon root, plantago seed, plantago herb, lycoris radiata bulb, senega, fritillaria bulb, fennel, phellodendron bark, coptis rhizome, curcuma zedoaria, chamomile, gentian, oriental bezoar, animal bile, syazin, ginger, atractylodes lancea rhizome, clove, citrus unshiu, atractylodes rhizome, panax rhizome, ginseng, kakkon-to, keishi-to, kousosan, saiko-keishi-to, sho-saiko-to, sho-seiryu-to, bakumondo-to, hange-koboku-to, and mao-to; as well as oyster meat extract, propolis and propolis extract, and coenzyme Q
substances. A single substance selected from among the above substances may be used alone, or a combination of two or more substances may be used.
[0045]
Date Recue/Date Received 2022-04-20 The active component may be a sublimable. Examples of such components include sublimable pharmaceutical medicinal components disclosed in the "Japanese Pharmacopoeia", "Japanese Pharmaceutical Codex", "USP", "NF" and "EP", including benzoic acid, ethenzamide, caffeine, camphor, salicylic acid, phenacetin and ibuprofen.
A single substance selected from these substances may be used alone, or a combination of two or more substances may be used. In this description, there are no particular limitations on the sublimable component, provided it exhibits sublimability, and the component may be any one of a solid, a liquid or a semisolid at normal temperatures.
Date Recue/Date Received 2022-04-20 The active component may be a sublimable. Examples of such components include sublimable pharmaceutical medicinal components disclosed in the "Japanese Pharmacopoeia", "Japanese Pharmaceutical Codex", "USP", "NF" and "EP", including benzoic acid, ethenzamide, caffeine, camphor, salicylic acid, phenacetin and ibuprofen.
A single substance selected from these substances may be used alone, or a combination of two or more substances may be used. In this description, there are no particular limitations on the sublimable component, provided it exhibits sublimability, and the component may be any one of a solid, a liquid or a semisolid at normal temperatures.
[0046]
Further, medicinal components for which the maximum blend amount per tablet is small can be used particularly favorably as the active component.
Examples of medicinal components for which the maximum blend amount per tablet is small include the following medicinal components which are added in amounts of not more than 100 mg or not more than 10 mg.
Further, medicinal components for which the maximum blend amount per tablet is small can be used particularly favorably as the active component.
Examples of medicinal components for which the maximum blend amount per tablet is small include the following medicinal components which are added in amounts of not more than 100 mg or not more than 10 mg.
[0047]
Examples of medicinal components for which the maximum blend amount per tablet exceeds 100 mg include Abacavir, Acetazolamide, Acetylsalicylic acid, Aciclovir, Albendazole, Aliskiren Fumarate. Allopurinol, Amiodarone, Amodiaquine, Amoxicllin, Aprepitant, Artemether, Artesunate, Atazanavir, Calcium, Capecitabine, Carbamazepine, Carbidopa, Cefalexin, Cefixime, Celecoxib, Chloroquine, Ciprofloxacin, Clarithromycin, Clavulanate Potassium, Clopidogrel, Clozapine, Cycloserine, Darunavir, Darunavir ethanolate, Dasabuvir, Dasatinib, Deferasirox, Dihydroartemisinin piperaquine phosphate, Diloxanide, Efavirenz, Emtricitabine, Erlotinib hydrochloride, Ethambutol, Ethionamide, Famciclovir, Gefitinib, Griseofulvin, Hydroxycarbamide, Hydroxychloroquine, Ibuprofen, Imatinb, Irbesartan, Isoniazid, Lamivudine, Date Recue/Date Received 2022-04-20 Lamotrigine, Lanthanum carbonate hydrate, Ledipasvir, Lev amisole, Levetiracetam, Levodopa, Levofloxacin, Linezolid, Lithium carbonate, Lopinavir, Lumefantrine, Mebendazole, Mefloquine, Mesna, Metformin, Methyldopa, Metronidazole, Morphine, Moxifloxacin, Nevirapine, Niclosamide, Nifurtimox, Ombitasvir, p-Aminosalicylic acid, Paracetamol, Paritaprevir, Penicillamine, Pentamidine, Phenoxymethylpenicillin, Pirfenidone, Praziquantel, Pyrantel, Pyrazinamide, Pyronaridine tetraphosphate, Quinine, Raltegravir, Ranitidine, Ribavirin, Rifampicin, Rifapentine, Sevelamer hydrochloride, Sofosbuvir, Sorafenib tosilate, Sulfadiazine, Sulfamethoxazole, Sulfasalazine, Tenofovir, Tenofovir disoproxil fumarate, Triclabendazole, Trimethoprim, Valganciclovir, Valproic acid, Velpatasvir, Sodium valproate, Voriconazole and Zidovudine.
Examples of medicinal components for which the maximum blend amount per tablet exceeds 100 mg include Abacavir, Acetazolamide, Acetylsalicylic acid, Aciclovir, Albendazole, Aliskiren Fumarate. Allopurinol, Amiodarone, Amodiaquine, Amoxicllin, Aprepitant, Artemether, Artesunate, Atazanavir, Calcium, Capecitabine, Carbamazepine, Carbidopa, Cefalexin, Cefixime, Celecoxib, Chloroquine, Ciprofloxacin, Clarithromycin, Clavulanate Potassium, Clopidogrel, Clozapine, Cycloserine, Darunavir, Darunavir ethanolate, Dasabuvir, Dasatinib, Deferasirox, Dihydroartemisinin piperaquine phosphate, Diloxanide, Efavirenz, Emtricitabine, Erlotinib hydrochloride, Ethambutol, Ethionamide, Famciclovir, Gefitinib, Griseofulvin, Hydroxycarbamide, Hydroxychloroquine, Ibuprofen, Imatinb, Irbesartan, Isoniazid, Lamivudine, Date Recue/Date Received 2022-04-20 Lamotrigine, Lanthanum carbonate hydrate, Ledipasvir, Lev amisole, Levetiracetam, Levodopa, Levofloxacin, Linezolid, Lithium carbonate, Lopinavir, Lumefantrine, Mebendazole, Mefloquine, Mesna, Metformin, Methyldopa, Metronidazole, Morphine, Moxifloxacin, Nevirapine, Niclosamide, Nifurtimox, Ombitasvir, p-Aminosalicylic acid, Paracetamol, Paritaprevir, Penicillamine, Pentamidine, Phenoxymethylpenicillin, Pirfenidone, Praziquantel, Pyrantel, Pyrazinamide, Pyronaridine tetraphosphate, Quinine, Raltegravir, Ranitidine, Ribavirin, Rifampicin, Rifapentine, Sevelamer hydrochloride, Sofosbuvir, Sorafenib tosilate, Sulfadiazine, Sulfamethoxazole, Sulfasalazine, Tenofovir, Tenofovir disoproxil fumarate, Triclabendazole, Trimethoprim, Valganciclovir, Valproic acid, Velpatasvir, Sodium valproate, Voriconazole and Zidovudine.
[0048]
Examples of medicinal components for which the maximum blend amount per tablet exceeds 10 mg but is not more than 100 mg include Aripiprazole, Artesunate, Ascorbic acid, Azathioprine, Bazedoxifene acetate, Bicalutamide, Calcium folinate, Clomifene, Cyclizine, Cyclophosphamide, Dasatinib hydrate, Delamanid, Dolutegravir, Eletriptan hydrobromide, Febuxostat, Fluoxetine, Furosemide, Galantamine Hydrobromide, Hydralazine, Hydrochlorothiazide, Hydrocortisone, Memantine Hydrochloride, Mercaptopurine, Midazolam, Miltefosine, Minodronic Acid Hydrate, Mirtazapine, Neostigmine, Nicotineamide, Olmesartan Medoxomil, Omeprazole, Ondansetron, Pancrelipase, Potassium iodine, Prednisolone, Primaquine, Primethamine, Propranolol, Propylthiouracil, Pyridoxine, Simvastatin, Sitafloxacin hydrate, Spironolactone, Tadalafil, Tamoxifen, Thiamine, Tioguanine, Tolvaptan, Ulipristal, Vardenafil Hydrochloride Hydrate, Zinc sulfate, Acotiamide hydrochloride hydrate, Amitriptyline, Bedaquline, Benznidazole, Bosentan hydrate, Chlorpromazine, Cinacalcet hydrochloride, Daclatasvir, Dapsone, Diethylcarbamazine, Doxycycline, Entacapone, Date Recue/Date Received 2022-04-20 Eplerenone, Ferrous sulfate, Gliclazide, Ibandronate Sodium Hydrate, Losartan, Miglitol, Nitrofurantoin, Phenobarbital, Phenytoin, Pyridostigmine, Raloxifene Hydrochloride, Ritonavir, Succimer, Telmisartan, Topiramate and Verapamil.
Examples of medicinal components for which the maximum blend amount per tablet exceeds 10 mg but is not more than 100 mg include Aripiprazole, Artesunate, Ascorbic acid, Azathioprine, Bazedoxifene acetate, Bicalutamide, Calcium folinate, Clomifene, Cyclizine, Cyclophosphamide, Dasatinib hydrate, Delamanid, Dolutegravir, Eletriptan hydrobromide, Febuxostat, Fluoxetine, Furosemide, Galantamine Hydrobromide, Hydralazine, Hydrochlorothiazide, Hydrocortisone, Memantine Hydrochloride, Mercaptopurine, Midazolam, Miltefosine, Minodronic Acid Hydrate, Mirtazapine, Neostigmine, Nicotineamide, Olmesartan Medoxomil, Omeprazole, Ondansetron, Pancrelipase, Potassium iodine, Prednisolone, Primaquine, Primethamine, Propranolol, Propylthiouracil, Pyridoxine, Simvastatin, Sitafloxacin hydrate, Spironolactone, Tadalafil, Tamoxifen, Thiamine, Tioguanine, Tolvaptan, Ulipristal, Vardenafil Hydrochloride Hydrate, Zinc sulfate, Acotiamide hydrochloride hydrate, Amitriptyline, Bedaquline, Benznidazole, Bosentan hydrate, Chlorpromazine, Cinacalcet hydrochloride, Daclatasvir, Dapsone, Diethylcarbamazine, Doxycycline, Entacapone, Date Recue/Date Received 2022-04-20 Eplerenone, Ferrous sulfate, Gliclazide, Ibandronate Sodium Hydrate, Losartan, Miglitol, Nitrofurantoin, Phenobarbital, Phenytoin, Pyridostigmine, Raloxifene Hydrochloride, Ritonavir, Succimer, Telmisartan, Topiramate and Verapamil.
[0049]
Examples of medicinal components for which the maximum blend amount per tablet is not more than 10 mg include Anastrozole, Dienogest, Digoxin, Dutasteride, Entecavir, Entecavir hydrate, Ethinylestradiol, Finasteride, Fludrocortisone, Glyceryl trinitrate, Imidafenacin, Levothyroxine, Levonorgestrel, Misoprostol, Repaglinide, Ambrisentan, Amiloride, Amlodipine, Bepotastine Besilate, Biperiden, Bisoprolol, Blonanserin, Chlorambucil, Dexamethasone, Diazepam, Enalapril, Ergocalciferol, Escitalopram Oxalate, Esomeprazole magnesium hydrate, Eszopiclone, Ezetimibe, Fludarabine, Fluticasone furoate, Folic acid, Haloperidol, Isosorbide dinitrate, Ivermectin, Lenalidomide hydrate, Levocetirizine hydrochloride, Levonorgestrel, Loperamide, Loratadine, Medroxyprogesterone acetate, Methadone, Methotrexate, Metoclopramide, Mitiglinide Calcium Hydrate, Montelukast Sodium, Norethisterone, Paliperidone, Phytomenadione or Phytonadione, Ramelteon, Riboflavin, Risperidone, Rizatriptan benzoate, Ropinirole hydrochloride, Rosuvastatin Calcium, Senna, Silodosin, Solifenacin succinate and Warfarin.
Examples of medicinal components for which the maximum blend amount per tablet is not more than 10 mg include Anastrozole, Dienogest, Digoxin, Dutasteride, Entecavir, Entecavir hydrate, Ethinylestradiol, Finasteride, Fludrocortisone, Glyceryl trinitrate, Imidafenacin, Levothyroxine, Levonorgestrel, Misoprostol, Repaglinide, Ambrisentan, Amiloride, Amlodipine, Bepotastine Besilate, Biperiden, Bisoprolol, Blonanserin, Chlorambucil, Dexamethasone, Diazepam, Enalapril, Ergocalciferol, Escitalopram Oxalate, Esomeprazole magnesium hydrate, Eszopiclone, Ezetimibe, Fludarabine, Fluticasone furoate, Folic acid, Haloperidol, Isosorbide dinitrate, Ivermectin, Lenalidomide hydrate, Levocetirizine hydrochloride, Levonorgestrel, Loperamide, Loratadine, Medroxyprogesterone acetate, Methadone, Methotrexate, Metoclopramide, Mitiglinide Calcium Hydrate, Montelukast Sodium, Norethisterone, Paliperidone, Phytomenadione or Phytonadione, Ramelteon, Riboflavin, Risperidone, Rizatriptan benzoate, Ropinirole hydrochloride, Rosuvastatin Calcium, Senna, Silodosin, Solifenacin succinate and Warfarin.
[0050]
These active components and medicinal components may be blended in a finely ground state, together with the cellulose composition of an embodiment of the present invention, into the tablet mixture. For example, the active component used in the present invention may be finely ground to an average particle size of at least 1 pm but not more than 40 pm for purposes such as improving the dispersibility of the active component or improving the mixing uniformity of an active component having a medicinal effect at Date Recue/Date Received 2022-04-20 very small amounts. The average particle size of the active component is more preferably at least 1 pm but not more than 20 p m, and even more preferably at least 1 jim but not more than 10 pm.
These active components and medicinal components may be blended in a finely ground state, together with the cellulose composition of an embodiment of the present invention, into the tablet mixture. For example, the active component used in the present invention may be finely ground to an average particle size of at least 1 pm but not more than 40 pm for purposes such as improving the dispersibility of the active component or improving the mixing uniformity of an active component having a medicinal effect at Date Recue/Date Received 2022-04-20 very small amounts. The average particle size of the active component is more preferably at least 1 pm but not more than 20 p m, and even more preferably at least 1 jim but not more than 10 pm.
[0051]
The blend proportion of the above active component relative to the tablet mixture, expressed relative to the total mass of the obtained tablet, is typically less than 50% by mass, and is preferably not more than 40% by mass, more preferably not more than 30%
by mass, even more preferably not more than 20% by mass, and particularly preferably 10% by mass or less. A lower limit of 0.01% by mass is practically applicable.
If the proportion of the active component is less than 50% by mass, then maldistribution tends to occur more easily, requiring an accompanying lengthening of the mixing time.
However, by using the cellulose composition of an embodiment of the present invention, because any reduction in the tablet hardness caused by lengthening of the mixing time can be effectively suppressed, the cellulose composition of an embodiment of the present invention exhibits particularly marked effects when used in tablets for which the active component content falls within the range described above.
The blend proportion of the above active component relative to the tablet mixture, expressed relative to the total mass of the obtained tablet, is typically less than 50% by mass, and is preferably not more than 40% by mass, more preferably not more than 30%
by mass, even more preferably not more than 20% by mass, and particularly preferably 10% by mass or less. A lower limit of 0.01% by mass is practically applicable.
If the proportion of the active component is less than 50% by mass, then maldistribution tends to occur more easily, requiring an accompanying lengthening of the mixing time.
However, by using the cellulose composition of an embodiment of the present invention, because any reduction in the tablet hardness caused by lengthening of the mixing time can be effectively suppressed, the cellulose composition of an embodiment of the present invention exhibits particularly marked effects when used in tablets for which the active component content falls within the range described above.
[0052]
[Lubricant]
The tablet mixture preferably contains a lubricant in addition to the active component described above.
One or more compounds selected from the group consisting of fatty acid metal salts, fatty acid esters and fatty acid ester metal salts may be used as the lubricant, and specific examples include those compounds classified as lubricants in "Pharmaceutical Excipients Directory 2016" (published by Yakuji Nippo, Ltd.), such as magnesium stearate, calcium stearate, stearic acid, sucrose fatty acid esters, and talc.
One compound Date Recue/Date Received 2022-04-20 selected from among the above lubricants may be used alone, or a combination of two or more lubricants may be used.
[Lubricant]
The tablet mixture preferably contains a lubricant in addition to the active component described above.
One or more compounds selected from the group consisting of fatty acid metal salts, fatty acid esters and fatty acid ester metal salts may be used as the lubricant, and specific examples include those compounds classified as lubricants in "Pharmaceutical Excipients Directory 2016" (published by Yakuji Nippo, Ltd.), such as magnesium stearate, calcium stearate, stearic acid, sucrose fatty acid esters, and talc.
One compound Date Recue/Date Received 2022-04-20 selected from among the above lubricants may be used alone, or a combination of two or more lubricants may be used.
[0053]
The blend proportion of the above lubricant in the tablet mixture, expressed relative to the total mass of the obtained tablet, is typically at least 0.3%
by mass but not more than 5% by mass, and preferably at least 0.5% by mass but not more than 3% by mass.
The blend proportion of the above lubricant in the tablet mixture, expressed relative to the total mass of the obtained tablet, is typically at least 0.3%
by mass but not more than 5% by mass, and preferably at least 0.5% by mass but not more than 3% by mass.
[0054]
[Other Additives]
The tablet mixture may also contain other additives in addition to the active component described above.
Examples of these other additives include excipients, disintegrants, binders, fluidizing agents, flavorings, fragrances, colorants and sweeteners.
[Other Additives]
The tablet mixture may also contain other additives in addition to the active component described above.
Examples of these other additives include excipients, disintegrants, binders, fluidizing agents, flavorings, fragrances, colorants and sweeteners.
[0055]
Examples of excipients other than the cellulose composition include those substances classified as excipients in "Pharmaceutical Excipients Directory 2016"
(published by Yakuji Nippo, Ltd.), such as starch acrylate, L-aspartic acid, aminoethylsulfonic acid, aminoacetic acid, corn syrup (powder), gum arabic, gum arabic powder, alginic acid, sodium alginate, pregelatinized starch, pumice particles, inositol, ethylcellulose, ethylene-vinyl acetate copolymer, sodium chloride, olive oil, kaolin, cacao butter, casein, fructose, pumice particles, carmellose, carmellose sodium, hydrated silicone dioxide, dried yeast, dried aluminum hydroxide gel, dried sodium sulfate, dried magnesium sulfate, agar, agar powder, xylitol, citric acid, sodium citrate, disodium citrate, glycerol, calcium glycerophosphate, sodium gluconate, L-glutamine, clay, clay 3, clay particles, croscarmellose sodium, crospovidone, magnesium aluminosilicate, Date Recue/Date Received 2022-04-20 calcium silicate, magnesium silicate, light anhydrous silicate, light liquid paraffin, cinnamon powder, crystalline cellulose, crystalline cellulose carmellose sodium, crystalline cellulose (particles), brown rice koji, synthetic aluminum silicate, synthetic hydrotalcite, sesame oil, wheat flour, wheat starch, wheat germ flour, rice flour, rice starch, potassium acetate, calcium acetate, cellulose acetate phthalate, safflower oil, white beeswax, zinc oxide, titanium oxide, magnesium oxide, f3-cyclodextrin, dihydroxyaluminum aminoacetate, 2,6-di-butyl-4-methylphenol, dimethylpolysiloxane, tartaric acid, potassium hydrogen Emirate, calcined gypsum, sucrose fatty acid ester, magnesium aluminum hydroxide, aluminum hydroxide gel, co-precipitates of aluminum hydroxide and sodium hydrogen carbonate, magnesium hydroxide, squalane, stearyl alcohol, stearic acid, calcium stearate, polyoxyl stearate, magnesium stearate, hardened soybean oil, purified gelatin, purified shellac, purified white sugar, purified white sugar granules, cetostearyl alcohol, polyethylene glycol 1000 monocetyl ether, gelatin, sorbitan fatty acid ester, D-sorbitol, tribasic calcium phosphate, soybean oil, unsaponified soybean, soybean lecithin, defatted milk powder, talc, ammonium carbonate, calcium carbonate, magnesium carbonate, neutral anhydrous sodium sulfate, low-substituted hydroxypropyl cellulose, dextran, dextrin, natural aluminum silicate, corn starch, tragacanth powder, silicon dioxide, calcium lactate, lactose, lactose granules, Perfiller 101, white shellac, white vaseline, white clay, white sugar, white sugar-starch granules, rye green leaf extract powder, dried powder of rye bud juice, honey. paraffin, potato starch, semi-digested starch, human serum albumin, hydroxypropyl starch, hydroxypropyl cellulose, hydroxypropyl methylcellulose phthalate, phytic acid, glucose, glucose hydrate, partially pregelatinized starch, pullulan, propylene glycol, reduced maltose starch syrup powder, powdered cellulose, pectin, bentonite, sodium polyacrylate, polyoxyethylene alkyl ether, polyoxyethylene hardened castor oil, polyoxyethylene (105) Date Recue/Date Received 2022-04-20 polyoxypropylene (5) glycol, polyoxyethylene (160) polyoxypropylene (30) glycol, sodium polystyrenesulfonate, polysorbate 80, polyvinylacetal diethylamino acetate, polyvinyl pyn-olidone, polyethylene glycol, maltitol, maltose, D-mannitol, starch syrup, isopropyl myristate, anhydrous lactose, anhydrous calcium hydrogen phosphate, anhydrous calcium phosphate granules, magnesium aluminometasilicate, methylcellulose, cotton seed powder, cotton seed oil, wood wax, aluminum monostearate, glycerol monostearate, sorbitan monostearate, medical charcoal, peanut oil, aluminum sulfate, calcium sulfate, granular corn starch, liquid paraffin, dl-malic acid, calcium monohydrogen phosphate, calcium hydrogen phosphate, calcium hydrogen phosphate granules, sodium hydrogen phosphate, potassium dihydrogen phosphate, calcium dihydrogen phosphate and sodium dihydrogen phosphate. One of these excipients may be used alone, or a combination of two or more excipients may be used.
Examples of excipients other than the cellulose composition include those substances classified as excipients in "Pharmaceutical Excipients Directory 2016"
(published by Yakuji Nippo, Ltd.), such as starch acrylate, L-aspartic acid, aminoethylsulfonic acid, aminoacetic acid, corn syrup (powder), gum arabic, gum arabic powder, alginic acid, sodium alginate, pregelatinized starch, pumice particles, inositol, ethylcellulose, ethylene-vinyl acetate copolymer, sodium chloride, olive oil, kaolin, cacao butter, casein, fructose, pumice particles, carmellose, carmellose sodium, hydrated silicone dioxide, dried yeast, dried aluminum hydroxide gel, dried sodium sulfate, dried magnesium sulfate, agar, agar powder, xylitol, citric acid, sodium citrate, disodium citrate, glycerol, calcium glycerophosphate, sodium gluconate, L-glutamine, clay, clay 3, clay particles, croscarmellose sodium, crospovidone, magnesium aluminosilicate, Date Recue/Date Received 2022-04-20 calcium silicate, magnesium silicate, light anhydrous silicate, light liquid paraffin, cinnamon powder, crystalline cellulose, crystalline cellulose carmellose sodium, crystalline cellulose (particles), brown rice koji, synthetic aluminum silicate, synthetic hydrotalcite, sesame oil, wheat flour, wheat starch, wheat germ flour, rice flour, rice starch, potassium acetate, calcium acetate, cellulose acetate phthalate, safflower oil, white beeswax, zinc oxide, titanium oxide, magnesium oxide, f3-cyclodextrin, dihydroxyaluminum aminoacetate, 2,6-di-butyl-4-methylphenol, dimethylpolysiloxane, tartaric acid, potassium hydrogen Emirate, calcined gypsum, sucrose fatty acid ester, magnesium aluminum hydroxide, aluminum hydroxide gel, co-precipitates of aluminum hydroxide and sodium hydrogen carbonate, magnesium hydroxide, squalane, stearyl alcohol, stearic acid, calcium stearate, polyoxyl stearate, magnesium stearate, hardened soybean oil, purified gelatin, purified shellac, purified white sugar, purified white sugar granules, cetostearyl alcohol, polyethylene glycol 1000 monocetyl ether, gelatin, sorbitan fatty acid ester, D-sorbitol, tribasic calcium phosphate, soybean oil, unsaponified soybean, soybean lecithin, defatted milk powder, talc, ammonium carbonate, calcium carbonate, magnesium carbonate, neutral anhydrous sodium sulfate, low-substituted hydroxypropyl cellulose, dextran, dextrin, natural aluminum silicate, corn starch, tragacanth powder, silicon dioxide, calcium lactate, lactose, lactose granules, Perfiller 101, white shellac, white vaseline, white clay, white sugar, white sugar-starch granules, rye green leaf extract powder, dried powder of rye bud juice, honey. paraffin, potato starch, semi-digested starch, human serum albumin, hydroxypropyl starch, hydroxypropyl cellulose, hydroxypropyl methylcellulose phthalate, phytic acid, glucose, glucose hydrate, partially pregelatinized starch, pullulan, propylene glycol, reduced maltose starch syrup powder, powdered cellulose, pectin, bentonite, sodium polyacrylate, polyoxyethylene alkyl ether, polyoxyethylene hardened castor oil, polyoxyethylene (105) Date Recue/Date Received 2022-04-20 polyoxypropylene (5) glycol, polyoxyethylene (160) polyoxypropylene (30) glycol, sodium polystyrenesulfonate, polysorbate 80, polyvinylacetal diethylamino acetate, polyvinyl pyn-olidone, polyethylene glycol, maltitol, maltose, D-mannitol, starch syrup, isopropyl myristate, anhydrous lactose, anhydrous calcium hydrogen phosphate, anhydrous calcium phosphate granules, magnesium aluminometasilicate, methylcellulose, cotton seed powder, cotton seed oil, wood wax, aluminum monostearate, glycerol monostearate, sorbitan monostearate, medical charcoal, peanut oil, aluminum sulfate, calcium sulfate, granular corn starch, liquid paraffin, dl-malic acid, calcium monohydrogen phosphate, calcium hydrogen phosphate, calcium hydrogen phosphate granules, sodium hydrogen phosphate, potassium dihydrogen phosphate, calcium dihydrogen phosphate and sodium dihydrogen phosphate. One of these excipients may be used alone, or a combination of two or more excipients may be used.
[0056]
Examples of disintegrants include those substances classified as disintegrants in "Pharmaceutical Excipients Directory 2016" (published by Yakuji Nippo, Ltd.), including celluloses such as croscarmellose sodium, carmellose, carmellose calcium, carmellose sodium and low-substituted hydroxypropyl cellulose; starches such as sodium carboxymethyl starch, hydroxypropyl starch, rice starch, wheat starch, corn starch, potato starch and partially pregelatinized starch; and synthetic polymers such as crospovidone and crospovidone copolymers. One substance selected from among the above disintegrants may be used alone, or a combination of two or more disintegrants may be used.
Examples of disintegrants include those substances classified as disintegrants in "Pharmaceutical Excipients Directory 2016" (published by Yakuji Nippo, Ltd.), including celluloses such as croscarmellose sodium, carmellose, carmellose calcium, carmellose sodium and low-substituted hydroxypropyl cellulose; starches such as sodium carboxymethyl starch, hydroxypropyl starch, rice starch, wheat starch, corn starch, potato starch and partially pregelatinized starch; and synthetic polymers such as crospovidone and crospovidone copolymers. One substance selected from among the above disintegrants may be used alone, or a combination of two or more disintegrants may be used.
[0057]
Examples of binders include those substances classified as binders in "Pharmaceutical Excipients Directory 2016" (published by Yakuji Nippo, Ltd.), Date Recue/Date Received 2022-04-20 including sugars such as white sugar, glucose, lactose and fructose; sugar alcohols such as mannitol, xylitol, maltitol, erythritol and sorbitol; water-soluble polysaccharides such as gelatin, pullulan, carrageenan, locust bean gum, agar, glucomannan, xanthan gum, tamarind gum, pectin, sodium alginate and gum arabic; celluloses such as crystalline cellulose, powdered cellulose, hydroxypropyl cellulose and methylcellulose;
starches such as pregelatinized starch and starch paste; synthetic polymers such as polyvinylpyrrolidone, carboxyvinyl polymer and polyvinyl alcohol; and inorganic compounds such as calcium hydrogen phosphate, calcium carbonate, synthetic hydrotalcite and magnesium aluminosilicate. One substance selected from among the above binders may be used alone, or a combination of two or more binders may be used.
Examples of binders include those substances classified as binders in "Pharmaceutical Excipients Directory 2016" (published by Yakuji Nippo, Ltd.), Date Recue/Date Received 2022-04-20 including sugars such as white sugar, glucose, lactose and fructose; sugar alcohols such as mannitol, xylitol, maltitol, erythritol and sorbitol; water-soluble polysaccharides such as gelatin, pullulan, carrageenan, locust bean gum, agar, glucomannan, xanthan gum, tamarind gum, pectin, sodium alginate and gum arabic; celluloses such as crystalline cellulose, powdered cellulose, hydroxypropyl cellulose and methylcellulose;
starches such as pregelatinized starch and starch paste; synthetic polymers such as polyvinylpyrrolidone, carboxyvinyl polymer and polyvinyl alcohol; and inorganic compounds such as calcium hydrogen phosphate, calcium carbonate, synthetic hydrotalcite and magnesium aluminosilicate. One substance selected from among the above binders may be used alone, or a combination of two or more binders may be used.
[0058]
Examples of fluidizing agents include those substances classified as fluidizing agents in "Pharmaceutical Excipients Directory 2016" (published by Yakuji Nippo, Ltd.), including silicon compounds such as hydrated silicon dioxide and light anhydrous silicate. One substance selected from among the above fluidizing agents may be used alone, or a combination of two or more fluidizing agents may be used.
Examples of fluidizing agents include those substances classified as fluidizing agents in "Pharmaceutical Excipients Directory 2016" (published by Yakuji Nippo, Ltd.), including silicon compounds such as hydrated silicon dioxide and light anhydrous silicate. One substance selected from among the above fluidizing agents may be used alone, or a combination of two or more fluidizing agents may be used.
[0059]
Examples of flavorings include those substances classified as flavorings in "Pharmaceutical Excipients Directory 2016" (published by Yakuji Nippo, Ltd.), such as glutamic acid, furnaric acid, succinic acid, citric acid, sodium citrate, tartaric acid, malic acid, ascorbic acid, sodium chloride and 1-menthol. One substance selected from among the above flavorings may be used alone, or a combination of two or more flavorings may be used.
Examples of flavorings include those substances classified as flavorings in "Pharmaceutical Excipients Directory 2016" (published by Yakuji Nippo, Ltd.), such as glutamic acid, furnaric acid, succinic acid, citric acid, sodium citrate, tartaric acid, malic acid, ascorbic acid, sodium chloride and 1-menthol. One substance selected from among the above flavorings may be used alone, or a combination of two or more flavorings may be used.
[0060]
Date Recue/Date Received 2022-04-20 Examples of fragrances include those substances classified as fragrances in "Pharmaceutical Excipients Directory 2016" (published by Yakuji Nippo, Ltd.), including oils such as orange, vanilla, strawberry, yogurt, menthol, fennel oil, cinnamon oil, picea oil and peppermint oil, and green tea powder. One substance selected from among the above fragrances may be used alone, or a combination of two or more fragrances may be used.
Date Recue/Date Received 2022-04-20 Examples of fragrances include those substances classified as fragrances in "Pharmaceutical Excipients Directory 2016" (published by Yakuji Nippo, Ltd.), including oils such as orange, vanilla, strawberry, yogurt, menthol, fennel oil, cinnamon oil, picea oil and peppermint oil, and green tea powder. One substance selected from among the above fragrances may be used alone, or a combination of two or more fragrances may be used.
[0061]
Examples of colorants include those substances classified as colorants in "Pharmaceutical Excipients Directory 2016" (published by Yakuji Nippo, Ltd.), including food dyes such as food red No. 3, food yellow No. 5 and food blue No. 1, as well as sodium copper chlorophyllin, titanium oxide and riboflavin. One substance selected from among the above colorants may be used alone, or a combination of two or more colorants may be used.
Examples of colorants include those substances classified as colorants in "Pharmaceutical Excipients Directory 2016" (published by Yakuji Nippo, Ltd.), including food dyes such as food red No. 3, food yellow No. 5 and food blue No. 1, as well as sodium copper chlorophyllin, titanium oxide and riboflavin. One substance selected from among the above colorants may be used alone, or a combination of two or more colorants may be used.
[0062]
Examples of sweeteners include those substances classified as sweeteners in "Pharmaceutical Excipients Directory 2016" (published by Yakuji Nippo, Ltd.), such as aspartame, saccharin, dipotassium glycyrrhizinate, stevia, maltose, maltitol, starch syrup and sweet hydrangea leaf powder. One substance selected from among the above sweeteners may be used alone, or a combination of two or more sweeteners may be used.
Examples of sweeteners include those substances classified as sweeteners in "Pharmaceutical Excipients Directory 2016" (published by Yakuji Nippo, Ltd.), such as aspartame, saccharin, dipotassium glycyrrhizinate, stevia, maltose, maltitol, starch syrup and sweet hydrangea leaf powder. One substance selected from among the above sweeteners may be used alone, or a combination of two or more sweeteners may be used.
[0063]
<Method for Producing Tablet>
A method for producing a tablet by compressing the above tablet mixture (a method for producing a tablet according to an embodiment of the present invention) is described below in detail, but this method is merely one example, and the effects of embodiments of the present invention are not limited to the method described below.
Date Recue/Date Received 2022-04-20
<Method for Producing Tablet>
A method for producing a tablet by compressing the above tablet mixture (a method for producing a tablet according to an embodiment of the present invention) is described below in detail, but this method is merely one example, and the effects of embodiments of the present invention are not limited to the method described below.
Date Recue/Date Received 2022-04-20
[0064]
A method in which the active component and the cellulose composition of an embodiment of the present invention are mixed together and then subjected to compression molding may be used as the method for producing a tablet. During this process, besides the active component, other additives may also be blended into the mixture according to need. Examples of these additives include one or more components selected from among components such as the lubricants, excipients, disintegrants, binders, fluidizing agents, flavorings, fragrances, colorants, sweeteners and solubilizers described above.
A method in which the active component and the cellulose composition of an embodiment of the present invention are mixed together and then subjected to compression molding may be used as the method for producing a tablet. During this process, besides the active component, other additives may also be blended into the mixture according to need. Examples of these additives include one or more components selected from among components such as the lubricants, excipients, disintegrants, binders, fluidizing agents, flavorings, fragrances, colorants, sweeteners and solubilizers described above.
[0065]
There are no particular limitations on the order in which the various components are added, and any one of (i) a method in which the active component, the cellulose composition of an embodiment of the present invention, and any other additives that are required are mixed in a single batch, and the resulting mixture is then subjected to compression molding, (ii) a method in which the active component and certain optional additives are premixed, the resulting premixture is then mixed with the cellulose composition of an embodiment of the present invention and other optional additives, and the resulting mixture is then subjected to compression molding, and (iii) a method in which the active component, the cellulose composition of an embodiment of the present invention, and other additives that are required are premixed, the resulting premixture is then mixed with other additives as required, and the obtained mixture is then subjected to compression molding. The method (i) is preferred from the viewpoint of operational simplicity. There are no particular limitations on the method used for adding each of the components, and any typically used method may be employed to add the components either continuously or in batches, using a small suction transport device, air transport Date Recue/Date Received 2022-04-20 device, bucket conveyer, pressure-fed transport device, vacuum conveyer, quantitative vibration feeder, sprayer, or funnel or the like. Examples of spraying methods that may be used include methods for spraying a solution or dispersion of the active component using a pressure nozzle, two-fluid nozzle, four-fluid nozzle, rotating disk, or ultrasonic nozzle or the like, and methods for dripping a solution or dispersion of the active component from a tube-like nozzle.
There are no particular limitations on the order in which the various components are added, and any one of (i) a method in which the active component, the cellulose composition of an embodiment of the present invention, and any other additives that are required are mixed in a single batch, and the resulting mixture is then subjected to compression molding, (ii) a method in which the active component and certain optional additives are premixed, the resulting premixture is then mixed with the cellulose composition of an embodiment of the present invention and other optional additives, and the resulting mixture is then subjected to compression molding, and (iii) a method in which the active component, the cellulose composition of an embodiment of the present invention, and other additives that are required are premixed, the resulting premixture is then mixed with other additives as required, and the obtained mixture is then subjected to compression molding. The method (i) is preferred from the viewpoint of operational simplicity. There are no particular limitations on the method used for adding each of the components, and any typically used method may be employed to add the components either continuously or in batches, using a small suction transport device, air transport Date Recue/Date Received 2022-04-20 device, bucket conveyer, pressure-fed transport device, vacuum conveyer, quantitative vibration feeder, sprayer, or funnel or the like. Examples of spraying methods that may be used include methods for spraying a solution or dispersion of the active component using a pressure nozzle, two-fluid nozzle, four-fluid nozzle, rotating disk, or ultrasonic nozzle or the like, and methods for dripping a solution or dispersion of the active component from a tube-like nozzle.
[0066]
There are no particular limitations on the mixing method, and any typically used method may be employed, using a rotating vessel mixer such as a V-type mixer, W-type mixer, double cone type mixer or container tack mixer; a stirring mixer such as a high-speed stirring mixer, universal stirring mixer, ribbon mixer, pug mixer, or nauta mixer; or a super mixer, a drum mixer, or a fluidized bed mixer or the like. Further, a shaken vessel mixer such as a shaker or the like may also be used.
There are no particular limitations on the mixing method, and any typically used method may be employed, using a rotating vessel mixer such as a V-type mixer, W-type mixer, double cone type mixer or container tack mixer; a stirring mixer such as a high-speed stirring mixer, universal stirring mixer, ribbon mixer, pug mixer, or nauta mixer; or a super mixer, a drum mixer, or a fluidized bed mixer or the like. Further, a shaken vessel mixer such as a shaker or the like may also be used.
[0067]
There are no particular limitations on the compression molding method used on the composition, and any typically used method may be employed, including methods that use a mortar and pestle to achieve compression molding into the desired shape, and methods in which the composition is first compression molded into sheet form, and the sheet is then cut into the desired shape. Examples of compression molding devices that may be used include roller-type presses such as a hydrostatic press, a briquetting roller press, or a smooth roller press, and compressors such as a single-punch tableting machine or a rotary tableting machine.
There are no particular limitations on the compression molding method used on the composition, and any typically used method may be employed, including methods that use a mortar and pestle to achieve compression molding into the desired shape, and methods in which the composition is first compression molded into sheet form, and the sheet is then cut into the desired shape. Examples of compression molding devices that may be used include roller-type presses such as a hydrostatic press, a briquetting roller press, or a smooth roller press, and compressors such as a single-punch tableting machine or a rotary tableting machine.
[0068]
There are no particular limitations on the method used for dissolving or dispersing the active component in a medium, and typically used dissolution or Date Recue/Date Received 2022-04-20 dispersion methods may be used, including stirred mixing methods using a stiffing blade such as a one-way rotational blade, multi-shaft rotating blade, reciprocating and reversing blade, vertically moving blade, rotating and vertically moving blade or tube-like blade, such as a portable mixer, spatial mixer or side surface mixer, jet-type stirred mixing methods such as a line mixer, gas blowing stirred fluxing methods, mixing methods using a high-shear homogenizer, high-pressure homogenizer, or ultrasonic homogenizer, or the like, and shaken vessel mixing methods using a shaker.
There are no particular limitations on the method used for dissolving or dispersing the active component in a medium, and typically used dissolution or Date Recue/Date Received 2022-04-20 dispersion methods may be used, including stirred mixing methods using a stiffing blade such as a one-way rotational blade, multi-shaft rotating blade, reciprocating and reversing blade, vertically moving blade, rotating and vertically moving blade or tube-like blade, such as a portable mixer, spatial mixer or side surface mixer, jet-type stirred mixing methods such as a line mixer, gas blowing stirred fluxing methods, mixing methods using a high-shear homogenizer, high-pressure homogenizer, or ultrasonic homogenizer, or the like, and shaken vessel mixing methods using a shaker.
[0069]
There are no particular limitations on the solvent used in the production method described above, provided the solvent is suitable for use in pharmaceuticals, and for example, at least one of water and an organic solvent may be used. Examples of organic solvents include those compounds classified as solvents in "Pharmaceutical Excipients Directory 2016" (published by Yakuji Nippo, Ltd.), including alcohols such as methanol, ethanol, isopropyl alcohol, butyl alcohol, 2-methylbutyl alcohol and benzyl alcohol;
hydrocarbons such as pentane, hexane, heptane and cyclohexane; and ketones such as acetone and ethyl methyl ketone. One of these solvents may be used alone, a combination of two or more solvents may be used, or initial dispersion may be performed in one solvent, and that solvent may then be removed and the product dispersed in a different solvent.
There are no particular limitations on the solvent used in the production method described above, provided the solvent is suitable for use in pharmaceuticals, and for example, at least one of water and an organic solvent may be used. Examples of organic solvents include those compounds classified as solvents in "Pharmaceutical Excipients Directory 2016" (published by Yakuji Nippo, Ltd.), including alcohols such as methanol, ethanol, isopropyl alcohol, butyl alcohol, 2-methylbutyl alcohol and benzyl alcohol;
hydrocarbons such as pentane, hexane, heptane and cyclohexane; and ketones such as acetone and ethyl methyl ketone. One of these solvents may be used alone, a combination of two or more solvents may be used, or initial dispersion may be performed in one solvent, and that solvent may then be removed and the product dispersed in a different solvent.
[0070]
When dissolving the active component in a medium, a water-soluble polymer, oil or fat, or surfactant or the like may be used as a solubilizer. Examples of water-soluble polymers, oils and fats, and surfactants that may be used as solubilizers include those substances disclosed in "Pharmaceutical Excipients Directory 2016" (published by Date Recue/Date Received 2022-04-20 Yakuji Nippo, Ltd.). One of these solubilizers may be used alone, or a combination of two or more solubilizers may be used.
When dissolving the active component in a medium, a water-soluble polymer, oil or fat, or surfactant or the like may be used as a solubilizer. Examples of water-soluble polymers, oils and fats, and surfactants that may be used as solubilizers include those substances disclosed in "Pharmaceutical Excipients Directory 2016" (published by Date Recue/Date Received 2022-04-20 Yakuji Nippo, Ltd.). One of these solubilizers may be used alone, or a combination of two or more solubilizers may be used.
[0071]
In this description, the term "molded body" refers to a body in the form of a granule, fine grain, slug, or tablet or the like, containing the cellulose composition of an embodiment of the present invention, at least one active component, and other additives as required.
Examples of the method used for molding tablets include direct tableting methods in which a mixture prepared by mixing at least one active component and the cellulose composition of an embodiment of the present invention, or a mixture prepared by mixing at least one active component, the cellulose composition of an embodiment of the present invention and other additives as required is subjected to compression molding.
Other production methods may also be used, including a production method for polynuclear tablets in which a tablet that has undergone compression molding in advance is used as an inner nucleus, and a production method for multi-layer tablets in which a plurality of pre-compressed molded bodies are stacked together and recompressed. The direct tableting method is preferred from the viewpoints of productivity and ease of process control.
In this description, the term "molded body" refers to a body in the form of a granule, fine grain, slug, or tablet or the like, containing the cellulose composition of an embodiment of the present invention, at least one active component, and other additives as required.
Examples of the method used for molding tablets include direct tableting methods in which a mixture prepared by mixing at least one active component and the cellulose composition of an embodiment of the present invention, or a mixture prepared by mixing at least one active component, the cellulose composition of an embodiment of the present invention and other additives as required is subjected to compression molding.
Other production methods may also be used, including a production method for polynuclear tablets in which a tablet that has undergone compression molding in advance is used as an inner nucleus, and a production method for multi-layer tablets in which a plurality of pre-compressed molded bodies are stacked together and recompressed. The direct tableting method is preferred from the viewpoints of productivity and ease of process control.
[0072]
The compression molded tablet (molded body) may be subjected to additional coating. Examples of coating agents that may be used in such cases include the coating agents disclosed in "Pharmaceutical Excipients Directory 2016" (published by Yakuji Nippo, Ltd.). One of these coating agents may be used alone, or a combination of two or more coating agents may be used.
The compression molded tablet (molded body) may be subjected to additional coating. Examples of coating agents that may be used in such cases include the coating agents disclosed in "Pharmaceutical Excipients Directory 2016" (published by Yakuji Nippo, Ltd.). One of these coating agents may be used alone, or a combination of two or more coating agents may be used.
[0073]
Date Recue/Date Received 2022-04-20 In those cases the production process includes a granulation step, examples of the granulation method include dry granulation, wet granulation, heat granulation, spray granulation and microencapsulation. More specifically, among the various wet granulation methods, fluidized bed granulation, stirring granulation, extrusion granulation, crushing granulation and rolling granulation are effective. In the fluidized bed granulation method, the granulation is performed in a fluidized bed granulation device by spraying a binder solution onto the fluidized powder. In the stirring granulation method, mixing, kneading and granulation of the powder are conducted simultaneously in a sealed structure by rotating a stirring blade inside a mixing tank while a binding solution is added. In the extrusion granulation method, granulation is performed by forcefully extruding a wet mass which has been kneaded by adding a binder solution through a screen of a suitable size using a screw method or basket method. In the crushing granulation method, granulation is performed by shearing and crushing a wet mass which has been kneaded by adding a binder solution using the rotating blade of a granulator, and the resulting centrifugal force forces the crushed wet mass through an outer peripheral screen. In the rolling granulation method, spherical granules are rolled by the centrifugal force of a rotating rotor while a binder solution is sprayed from a spray gun, thereby growing spherical granules having uniform particle size in a snowball-like manner.
Date Recue/Date Received 2022-04-20 In those cases the production process includes a granulation step, examples of the granulation method include dry granulation, wet granulation, heat granulation, spray granulation and microencapsulation. More specifically, among the various wet granulation methods, fluidized bed granulation, stirring granulation, extrusion granulation, crushing granulation and rolling granulation are effective. In the fluidized bed granulation method, the granulation is performed in a fluidized bed granulation device by spraying a binder solution onto the fluidized powder. In the stirring granulation method, mixing, kneading and granulation of the powder are conducted simultaneously in a sealed structure by rotating a stirring blade inside a mixing tank while a binding solution is added. In the extrusion granulation method, granulation is performed by forcefully extruding a wet mass which has been kneaded by adding a binder solution through a screen of a suitable size using a screw method or basket method. In the crushing granulation method, granulation is performed by shearing and crushing a wet mass which has been kneaded by adding a binder solution using the rotating blade of a granulator, and the resulting centrifugal force forces the crushed wet mass through an outer peripheral screen. In the rolling granulation method, spherical granules are rolled by the centrifugal force of a rotating rotor while a binder solution is sprayed from a spray gun, thereby growing spherical granules having uniform particle size in a snowball-like manner.
[0074]
The method used for drying the granules may employ any of various methods, including hot air heating (shelf drying, vacuum drying, fluidized bed drying), conduction heat transfer (flat pan drying, shelf box drying, drum drying), and freeze drying. In hot air heating, hot air is brought into direct contact with the additive, and the evaporated water is removed at the same time. In conduction heat transfer, the additive is heated Date Recue/Date Received 2022-04-20 indirectly through a heat transfer wall. In freeze drying, the additive is frozen at a temperature of at least -10 C but not more than 40 C, and water is then removed by sublimation by heating under high vacuum (of at least 1.3x 1 0-5 MPa but not higher than 2.6x10-4 MPa).
EXAMPLES
The method used for drying the granules may employ any of various methods, including hot air heating (shelf drying, vacuum drying, fluidized bed drying), conduction heat transfer (flat pan drying, shelf box drying, drum drying), and freeze drying. In hot air heating, hot air is brought into direct contact with the additive, and the evaporated water is removed at the same time. In conduction heat transfer, the additive is heated Date Recue/Date Received 2022-04-20 indirectly through a heat transfer wall. In freeze drying, the additive is frozen at a temperature of at least -10 C but not more than 40 C, and water is then removed by sublimation by heating under high vacuum (of at least 1.3x 1 0-5 MPa but not higher than 2.6x10-4 MPa).
EXAMPLES
[0075]
Embodiments of the present invention are described below in further detail using a series of examples and comparative examples, but embodiments of the present invention are not limited to these examples. The various physical properties described in the examples and comparative examples and the methods used for measuring those properties are as described below. In those cases where a sample contained a large amount of water, the sample was subjected to preliminary drying to reduce the water content to at least 3.5% by mass but not more than about 4.5% by mass prior to conducting measurement of the various physical properties.
Embodiments of the present invention are described below in further detail using a series of examples and comparative examples, but embodiments of the present invention are not limited to these examples. The various physical properties described in the examples and comparative examples and the methods used for measuring those properties are as described below. In those cases where a sample contained a large amount of water, the sample was subjected to preliminary drying to reduce the water content to at least 3.5% by mass but not more than about 4.5% by mass prior to conducting measurement of the various physical properties.
[0076]
<Method for Analyzing Cellulose Compositions>
[Analysis 1]
(Method for Measuring Water-Soluble Substance Content in Cellulose Composition) The water-soluble substance content in the cellulose composition was measured in accordance with the crystalline cellulose purity test (2) method described in the 17th edition of the Japanese Pharmacopoeia.
Specifically, 80 raL of purified water was added to 5.0 g of the cellulose composition, and the mixture was shaken and mixed for 10 minutes.
Subsequently, the cellulose composition-containing solution was suction-filtered using a filter paper for Date Recue/Date Received 2022-04-20 quantitative analysis (Type 5C). The filtrate was evaporated to dryness without charring in a beaker of known mass, subsequently dried at 105 C for one hour, and then left to cool in a desiccator to obtain a residue. The mass of the thus obtained residue was then weighed to determine the mass of the residue. Each powder was measured twice and the average value was used. Further, a blank test was also conducted via the above operations using only 80 mL of purified water, without adding 5.0 g of the cellulose composition, and the water-soluble substance content detected in the blank test was subtracted from the measured value to obtain a value. This value was rounded to the second decimal place to obtain a measured value for the water-soluble substance content.
The water-soluble substance content detennined by this test method represents the amount of water-soluble substances contained in 5 g of the cellulose composition.
<Method for Analyzing Cellulose Compositions>
[Analysis 1]
(Method for Measuring Water-Soluble Substance Content in Cellulose Composition) The water-soluble substance content in the cellulose composition was measured in accordance with the crystalline cellulose purity test (2) method described in the 17th edition of the Japanese Pharmacopoeia.
Specifically, 80 raL of purified water was added to 5.0 g of the cellulose composition, and the mixture was shaken and mixed for 10 minutes.
Subsequently, the cellulose composition-containing solution was suction-filtered using a filter paper for Date Recue/Date Received 2022-04-20 quantitative analysis (Type 5C). The filtrate was evaporated to dryness without charring in a beaker of known mass, subsequently dried at 105 C for one hour, and then left to cool in a desiccator to obtain a residue. The mass of the thus obtained residue was then weighed to determine the mass of the residue. Each powder was measured twice and the average value was used. Further, a blank test was also conducted via the above operations using only 80 mL of purified water, without adding 5.0 g of the cellulose composition, and the water-soluble substance content detected in the blank test was subtracted from the measured value to obtain a value. This value was rounded to the second decimal place to obtain a measured value for the water-soluble substance content.
The water-soluble substance content detennined by this test method represents the amount of water-soluble substances contained in 5 g of the cellulose composition.
[0077]
[Analysis 2]
(Method for Measuring Cellooligosaccharide (3 to 7) Content) The total mass of dried solid of water-soluble substances obtained in the above "Analysis 1" was redissolved in 10 mL of a 50% (v/v) aqueous solution of acetonitrile, the resulting solution was filtered through a filter (0.20 m), and LC/MS was then used to measure the cellooligosaccharide (3 to 7) content.
A precision balance was used during preparation and dilution of the measurement solution, and the measured weight was used to determine the sample concentration and dilution ratio.
Further, for the measurement of the cellooligosaccharide content, solutions of known concentrations prepared using commercially available products of cellotriose (trisaccharide), cellotetraose (tetrasaccharide) and cellopentaose (pentasaccharide) were analyzed by LC/MS, the retention time and m/z ion chromatogram peak surface area for Date Recue/Date Received 2022-04-20 each cellooligosaccharide were determined, and calibration curves (sample concentration vs. peak surface area) were produced. Using these calibration curves, the amount of each cellooligosaccharide in the water-soluble substances (of 5 g of the cellulose composition) was determined.
The amounts of cellohexaose (hexasaccharide) and celloheptaose (heptasaccharide), for which commercially available products are unavailable, were determined by the following calculation method using the trends observed in peak surface area when previously measured glucose (monosaccharide) to cellopentaose (pentasaccharide) solutions were analyzed at the same concentrations. The total amount of each oligosaccharide was recorded as a value rounded to the second decimal place.
[Analysis 2]
(Method for Measuring Cellooligosaccharide (3 to 7) Content) The total mass of dried solid of water-soluble substances obtained in the above "Analysis 1" was redissolved in 10 mL of a 50% (v/v) aqueous solution of acetonitrile, the resulting solution was filtered through a filter (0.20 m), and LC/MS was then used to measure the cellooligosaccharide (3 to 7) content.
A precision balance was used during preparation and dilution of the measurement solution, and the measured weight was used to determine the sample concentration and dilution ratio.
Further, for the measurement of the cellooligosaccharide content, solutions of known concentrations prepared using commercially available products of cellotriose (trisaccharide), cellotetraose (tetrasaccharide) and cellopentaose (pentasaccharide) were analyzed by LC/MS, the retention time and m/z ion chromatogram peak surface area for Date Recue/Date Received 2022-04-20 each cellooligosaccharide were determined, and calibration curves (sample concentration vs. peak surface area) were produced. Using these calibration curves, the amount of each cellooligosaccharide in the water-soluble substances (of 5 g of the cellulose composition) was determined.
The amounts of cellohexaose (hexasaccharide) and celloheptaose (heptasaccharide), for which commercially available products are unavailable, were determined by the following calculation method using the trends observed in peak surface area when previously measured glucose (monosaccharide) to cellopentaose (pentasaccharide) solutions were analyzed at the same concentrations. The total amount of each oligosaccharide was recorded as a value rounded to the second decimal place.
[0078]
(Calculation Method) Cellohexaose (hexasaccharide): Using the calibration curve for cellopentaose (pentasaccharide), the peak surface area was substituted with the peak surface area for cellohexaose (hexasaccharide), and the thus obtained cellooligosaccharide content was multiplied by a correction coefficient (0.729) to calculate the amount of cellohexaose (hexasaccharide).
Celloheptaose (heptasaccharide): Using the calibration curve for cellopentaose (pentasaccharide), the peak surface area was substituted with the peak surface area for celloheptaose (heptasaccharide), and the thus obtained cellooligosaccharide content was multiplied by a correction coefficient (0.531) to calculate the amount of celloheptaose (heptasaccharide).
(Calculation Method) Cellohexaose (hexasaccharide): Using the calibration curve for cellopentaose (pentasaccharide), the peak surface area was substituted with the peak surface area for cellohexaose (hexasaccharide), and the thus obtained cellooligosaccharide content was multiplied by a correction coefficient (0.729) to calculate the amount of cellohexaose (hexasaccharide).
Celloheptaose (heptasaccharide): Using the calibration curve for cellopentaose (pentasaccharide), the peak surface area was substituted with the peak surface area for celloheptaose (heptasaccharide), and the thus obtained cellooligosaccharide content was multiplied by a correction coefficient (0.531) to calculate the amount of celloheptaose (heptasaccharide).
[0079]
The LC/MS measurements were conducted in accordance with the measurement conditions listed below. If measurements are conducted with a portion of the following Date Recue/Date Received 2022-04-20 conditions altered, then the cellooligosaccharide calibration curves described above must be reproduced in accordance with the altered conditions.
The LC/MS measurements were conducted in accordance with the measurement conditions listed below. If measurements are conducted with a portion of the following Date Recue/Date Received 2022-04-20 conditions altered, then the cellooligosaccharide calibration curves described above must be reproduced in accordance with the altered conditions.
[0080]
(Measurement Conditions) LC apparatus: Nexera, manufactured by Shimadzu Corporation Column: Asahipak NH2P-50 2D (2 mm 1.D. x 150 nun), manufactured by Shodex K.K.
Column temperature: 40 C
Detector: PDA detector 200 to 400 nm Flow rate: 0.3 mL/min Mobile phase: A = purified water, B = acetonitrile Gradient: gradient conditions are shown below in Table 1 Injection volume: 10 [I L
MS apparatus: Synapt G2, manufactured by Waters Corporation Ionization conditions: E51 Scan range: ni/z 50 to 2,000
(Measurement Conditions) LC apparatus: Nexera, manufactured by Shimadzu Corporation Column: Asahipak NH2P-50 2D (2 mm 1.D. x 150 nun), manufactured by Shodex K.K.
Column temperature: 40 C
Detector: PDA detector 200 to 400 nm Flow rate: 0.3 mL/min Mobile phase: A = purified water, B = acetonitrile Gradient: gradient conditions are shown below in Table 1 Injection volume: 10 [I L
MS apparatus: Synapt G2, manufactured by Waters Corporation Ionization conditions: E51 Scan range: ni/z 50 to 2,000
[0081]
[Table 1]
Time (min) A (%) B (%) 15.1 10 90
[Table 1]
Time (min) A (%) B (%) 15.1 10 90
[0082]
Date Recue/Date Received 2022-04-20 For reference purposes, the detected ion (m/z) and retention time for each structural component observed under the measurement conditions described above are shown below in Table 2.
Date Recue/Date Received 2022-04-20 For reference purposes, the detected ion (m/z) and retention time for each structural component observed under the measurement conditions described above are shown below in Table 2.
[0083]
[Table 2]
Detected ion m/z Retention time (min) Cellotriose trisaccharide 549.17 [M+HC00]- 9.2 Cellotetraose tetrasaccharide 711.22 [M+HCOO] 10.3 Cellopentaose pentasaccharide 873.28 [M+HC00]- 11.2 Cellohexaose hexasaccharide 989.32 [m-HT 11.9 Celloheptaose heptasaccharide 1151.38 [M-Hr 12.5
[Table 2]
Detected ion m/z Retention time (min) Cellotriose trisaccharide 549.17 [M+HC00]- 9.2 Cellotetraose tetrasaccharide 711.22 [M+HCOO] 10.3 Cellopentaose pentasaccharide 873.28 [M+HC00]- 11.2 Cellohexaose hexasaccharide 989.32 [m-HT 11.9 Celloheptaose heptasaccharide 1151.38 [M-Hr 12.5
[0084]
<Methods for Measuring Powder Physical Properties>
Methods for measuring the powder physical properties in those cases where the cellulose composition is a cellulose powder are described below.
<Methods for Measuring Powder Physical Properties>
Methods for measuring the powder physical properties in those cases where the cellulose composition is a cellulose powder are described below.
[0085]
[Physical Property 1]
(Average Particle Size) Using a laser diffraction particle size distribution meter (LA-950 V2 (brand name), manufactured by Floriba, Ltd.), measurement was conducted in the dry measurement mode at a compressed air pressure of 0.10 MPa, a feeder speed of 160, a feeder initial speed coefficient of 1.2, and a refractive index of 1.51. The particle size at a cumulative volume of 50% in the distribution obtained from the measurement was deemed the average particle size ( m) of the cellulose powder.
[Physical Property 1]
(Average Particle Size) Using a laser diffraction particle size distribution meter (LA-950 V2 (brand name), manufactured by Floriba, Ltd.), measurement was conducted in the dry measurement mode at a compressed air pressure of 0.10 MPa, a feeder speed of 160, a feeder initial speed coefficient of 1.2, and a refractive index of 1.51. The particle size at a cumulative volume of 50% in the distribution obtained from the measurement was deemed the average particle size ( m) of the cellulose powder.
[0086]
Date Recue/Date Received 2022-04-20 [Physical Property 2]
(Loose Bulk Density) For this measurement, a cellulose powder for which the water content had been adjusted to a value of at least 3.5% by mass but not more than 4.5% by mass was used.
In those cases where the water content of the cellulose powder was lower than this range, the water content of the cellulose powder was adjusted by allowing the powder to absorb moisture in a constant temperature and humidity chamber or the like. In those cases where the water content exceeded the above range, the water content was adjusted to a value within the range by blowing hot air at 60 C evenly onto the cellulose powder in a hot air oven.
Date Recue/Date Received 2022-04-20 [Physical Property 2]
(Loose Bulk Density) For this measurement, a cellulose powder for which the water content had been adjusted to a value of at least 3.5% by mass but not more than 4.5% by mass was used.
In those cases where the water content of the cellulose powder was lower than this range, the water content of the cellulose powder was adjusted by allowing the powder to absorb moisture in a constant temperature and humidity chamber or the like. In those cases where the water content exceeded the above range, the water content was adjusted to a value within the range by blowing hot air at 60 C evenly onto the cellulose powder in a hot air oven.
[0087]
Subsequently, a Scott Volumeter (model ASTM B-329-85, manufactured by Tsutsui Rikagaku Kikai) was used to measure the loose bulk density of the cellulose powder, by passing the cellulose powder through a sieve (mesh size: 1 mm) and filling a 25 mL cylindrical metal container. The powder at the top of the 25 mL
cylindrical metal container containing the cellulose powder was leveled off, and the mass (g) of the cellulose powder inside the container was divided by 25 nth to determine the loose bulk density (g/mL). The measurement was conducted 5 times and the average value was determined.
Subsequently, a Scott Volumeter (model ASTM B-329-85, manufactured by Tsutsui Rikagaku Kikai) was used to measure the loose bulk density of the cellulose powder, by passing the cellulose powder through a sieve (mesh size: 1 mm) and filling a 25 mL cylindrical metal container. The powder at the top of the 25 mL
cylindrical metal container containing the cellulose powder was leveled off, and the mass (g) of the cellulose powder inside the container was divided by 25 nth to determine the loose bulk density (g/mL). The measurement was conducted 5 times and the average value was determined.
[0088]
[Physical Property 3]
(Packed Bulk Density) For this measurement, a cellulose powder for which the water content had been adjusted to a value of at least 3.5% by mass but not more than 4.5% by mass was used.
The water content was adjusted to a value within this range using the methods described Date Recue/Date Received 2022-04-20 above in "Physical Property 2". The packed bulk density (packed apparent specific gravity) (g/mL) was calculated using a powder physical property tester (PT-R, manufactured by Hosokawa Micron Corporation). The sieve used had a mesh size of 710 pm, and the funnel used was made of metal (coated with an antistatic spray) and had an inner diameter of 0.8 cm. Testing was conducted with Vibration set to 2.0 (power supply: AC 100V, 60 Hz).
[Physical Property 3]
(Packed Bulk Density) For this measurement, a cellulose powder for which the water content had been adjusted to a value of at least 3.5% by mass but not more than 4.5% by mass was used.
The water content was adjusted to a value within this range using the methods described Date Recue/Date Received 2022-04-20 above in "Physical Property 2". The packed bulk density (packed apparent specific gravity) (g/mL) was calculated using a powder physical property tester (PT-R, manufactured by Hosokawa Micron Corporation). The sieve used had a mesh size of 710 pm, and the funnel used was made of metal (coated with an antistatic spray) and had an inner diameter of 0.8 cm. Testing was conducted with Vibration set to 2.0 (power supply: AC 100V, 60 Hz).
[0089]
[Physical Property 4]
(Compressibility) The compressibility of each cellulose powder was calculated using the following formula.
[Physical Property 4]
(Compressibility) The compressibility of each cellulose powder was calculated using the following formula.
[0090]
Compressibility (%) = ([packed bulk density] - [loose bulk density]) / [packed bulk density] x 100
Compressibility (%) = ([packed bulk density] - [loose bulk density]) / [packed bulk density] x 100
[0091]
[Physical Property 5]
(Primary Particle-Equivalent Particle Size) First. 0.5 g of the cellulose powder was placed in 10 mL of pure water, and following ultrasonic irradiation (600 W, 40 kHz) for 10 minutes, a laser diffraction particle size distribution meter (LA-950 V2 (brand name), manufactured by Horiba, Ltd.) was used to conduct measurement in the wet measurement mode under conditions including a refractive index of 1.20 (cellulose refractive index: 1.59, water refractive index: 1.33), pretreatment conditions (ultrasonic irradiation: 1 minute, ultrasonic wave intensity: 1), a circulation speed of 7, and a stirring speed of 5. The particle size at a cumulative volume of 50% in the distribution obtained from the measurement was Date Recue/Date Received 2022-04-20 deemed the cellulose primary particle-equivalent average particle size (primary particle-equivalent particle size) (pm).
[Physical Property 5]
(Primary Particle-Equivalent Particle Size) First. 0.5 g of the cellulose powder was placed in 10 mL of pure water, and following ultrasonic irradiation (600 W, 40 kHz) for 10 minutes, a laser diffraction particle size distribution meter (LA-950 V2 (brand name), manufactured by Horiba, Ltd.) was used to conduct measurement in the wet measurement mode under conditions including a refractive index of 1.20 (cellulose refractive index: 1.59, water refractive index: 1.33), pretreatment conditions (ultrasonic irradiation: 1 minute, ultrasonic wave intensity: 1), a circulation speed of 7, and a stirring speed of 5. The particle size at a cumulative volume of 50% in the distribution obtained from the measurement was Date Recue/Date Received 2022-04-20 deemed the cellulose primary particle-equivalent average particle size (primary particle-equivalent particle size) (pm).
[0092]
[Physical Property 61 (Ratio UD of Long Axis to Short Axis for Cellulose Particles) The cellulose powder was dispersed on a glass plate and an image was acquired with a microscope (VHX-1000, manufactured by Keyence Corporation) at a magnification of 500x. The captured image was analyzed with image processing analysis system software (Image Hyper II, manufactured by DigiMo Ltd.) using the procedures described below, and the aspect ratio of the particles (the ratio of the long axis to the short axis; UD) was measured. Measurements were conducted for at least 50 particles, and the average value was determined.
[Physical Property 61 (Ratio UD of Long Axis to Short Axis for Cellulose Particles) The cellulose powder was dispersed on a glass plate and an image was acquired with a microscope (VHX-1000, manufactured by Keyence Corporation) at a magnification of 500x. The captured image was analyzed with image processing analysis system software (Image Hyper II, manufactured by DigiMo Ltd.) using the procedures described below, and the aspect ratio of the particles (the ratio of the long axis to the short axis; UD) was measured. Measurements were conducted for at least 50 particles, and the average value was determined.
[0093]
(1) Procedure I: Binarization Processing The image captured by the microscope was imported as a monochrome image into analysis software, and the scale of the image was set using the distance between two points method. Next, the "Otsu method" was selected for the binarization process, and the threshold value was set. Because the optimum threshold value differs for each image, the threshold value was selected by comparison with the original image to ensure the best possible match with the shape of the original particle.
(1) Procedure I: Binarization Processing The image captured by the microscope was imported as a monochrome image into analysis software, and the scale of the image was set using the distance between two points method. Next, the "Otsu method" was selected for the binarization process, and the threshold value was set. Because the optimum threshold value differs for each image, the threshold value was selected by comparison with the original image to ensure the best possible match with the shape of the original particle.
[0094]
(2) Procedure 2: Binarization with Manual Correction By comparison with the originally acquired image, particles for which a suitable measurement result could not be obtained, such as overlapping particles, particles Date Recue/Date Received 2022-04-20 protruding beyond the image edges, and particles with indistinct or blurred outlines were deleted and removed from the measurement target image.
(2) Procedure 2: Binarization with Manual Correction By comparison with the originally acquired image, particles for which a suitable measurement result could not be obtained, such as overlapping particles, particles Date Recue/Date Received 2022-04-20 protruding beyond the image edges, and particles with indistinct or blurred outlines were deleted and removed from the measurement target image.
[0095]
(3) Procedure (3): Hole Filling Hole filling was conducted using the "hole filling" mode with a value of "8"
was selected for the "neighborhood" setting. Subsequently, a second comparison with the original image was conducted by "binarization with manual correction", and a confirmation was made as to whether the correction was able to be conducted normally.
When normal correction could not be achieved, another manual correction was conducted.
(3) Procedure (3): Hole Filling Hole filling was conducted using the "hole filling" mode with a value of "8"
was selected for the "neighborhood" setting. Subsequently, a second comparison with the original image was conducted by "binarization with manual correction", and a confirmation was made as to whether the correction was able to be conducted normally.
When normal correction could not be achieved, another manual correction was conducted.
[0096]
(4) Procedure 4: Image Measurement The number of deleted pixels was set to "100" and the "neighborhood" was set to "8", and "image measurement" was then executed. The measurement results for the "long axis" and the "short axis" for each measured particle are displayed on a computer.
The numerical value obtained by dividing the "long axis" by the "short axis"
was used as the aspect ratio.
(4) Procedure 4: Image Measurement The number of deleted pixels was set to "100" and the "neighborhood" was set to "8", and "image measurement" was then executed. The measurement results for the "long axis" and the "short axis" for each measured particle are displayed on a computer.
The numerical value obtained by dividing the "long axis" by the "short axis"
was used as the aspect ratio.
[0097]
<Tablet Evaluation Methods>
Tablets were produced and subjected to a number of evaluations using the methods described below.
<Tablet Evaluation Methods>
Tablets were produced and subjected to a number of evaluations using the methods described below.
[0098]
[Preparation of Tableting Powder]
Date Recue/Date Received 2022-04-20 The blend raw materials described below (excluding the magnesium stearate lubricant) were placed in a V-type mixer (V-5, manufactured by Tokuju Corporation) and mixed for 60 minutes.
[Preparation of Tableting Powder]
Date Recue/Date Received 2022-04-20 The blend raw materials described below (excluding the magnesium stearate lubricant) were placed in a V-type mixer (V-5, manufactured by Tokuju Corporation) and mixed for 60 minutes.
[0099]
[Table 3]
Blend 1 Blend 2 Blend 3 Blend 4 Chlorpheniramine d-maleate 20 0 20 0 20 g Folic acid 4g Cellulose composition 200 g 200 g 200 g 200 g Mannitol 1760g 1776g 1720g 1770g Magnesium stearate 20 g 20 g 60 g 10 g
[Table 3]
Blend 1 Blend 2 Blend 3 Blend 4 Chlorpheniramine d-maleate 20 0 20 0 20 g Folic acid 4g Cellulose composition 200 g 200 g 200 g 200 g Mannitol 1760g 1776g 1720g 1770g Magnesium stearate 20 g 20 g 60 g 10 g
[0100]
Subsequently, the magnesium stearatc was added as a lubricant, and mixing was conducted for either 5 minutes or 30 minutes to obtain a tableting powder (mixing time:
minutes or 30 minutes).
Subsequently, the magnesium stearatc was added as a lubricant, and mixing was conducted for either 5 minutes or 30 minutes to obtain a tableting powder (mixing time:
minutes or 30 minutes).
[0101]
[Production of Tablets]
The tableting powder (mixing time: 5 minutes or 30 minutes) was tableted for minutes using a rotary tableting machine (Clean Press Correct 12HUK, manufactured by Kikusui Seisakusho Ltd., 12 stations, turntable: 54 rpm, open feeder, applied pressure: 7 kN), thus obtaining 200 mg 08 mm-12R tablets.
[Production of Tablets]
The tableting powder (mixing time: 5 minutes or 30 minutes) was tableted for minutes using a rotary tableting machine (Clean Press Correct 12HUK, manufactured by Kikusui Seisakusho Ltd., 12 stations, turntable: 54 rpm, open feeder, applied pressure: 7 kN), thus obtaining 200 mg 08 mm-12R tablets.
[0102]
[Evaluation 1]
(Tablet Hardness and Tablet Hardness Reduction Rate) Date Recue/Date Received 2022-04-20 The tablets for measuring hardness were tablets sampled within the 30 seconds immediately prior to stopping operation of the rotary tableting machine. The hardness of each tablet was measured at least 20 hours but not more than 48 hours after tableting using a hardness meter (Dr. Schleuniger Tablet Tester 8M). The average value for 10 tablets at each tableting pressure was deemed the tablet hardness. Tablets for which the tablet hardness was at least 55 N were deemed favorable.
[Evaluation 1]
(Tablet Hardness and Tablet Hardness Reduction Rate) Date Recue/Date Received 2022-04-20 The tablets for measuring hardness were tablets sampled within the 30 seconds immediately prior to stopping operation of the rotary tableting machine. The hardness of each tablet was measured at least 20 hours but not more than 48 hours after tableting using a hardness meter (Dr. Schleuniger Tablet Tester 8M). The average value for 10 tablets at each tableting pressure was deemed the tablet hardness. Tablets for which the tablet hardness was at least 55 N were deemed favorable.
[0103]
Further, the tablet hardness reduction rate was determined using the following formula, based on the difference between the hardness (Ni) of tablets produced from the tableting powder (mixing time: 5 minutes) and the hardness (N2) of tablets produced from the tableting powder (mixing time: 30 minutes).
Further, the tablet hardness reduction rate was determined using the following formula, based on the difference between the hardness (Ni) of tablets produced from the tableting powder (mixing time: 5 minutes) and the hardness (N2) of tablets produced from the tableting powder (mixing time: 30 minutes).
[0104]
Tablet Hardness Reduction Rate (%) = (1-N2/N1) x 100
Tablet Hardness Reduction Rate (%) = (1-N2/N1) x 100
[0105]
[Evaluation 2]
(Active Component Content CV value) First, a calibration curve was produced for the active component.
Specifically.
the absorption spectrum of the active component was measured using an absorption spectrometer, and a calibration curve was produced based on the peak top wavelength (for example, chlorpheniramine d-maleate: 264 nm, folic acid: 290 nm).
[Evaluation 2]
(Active Component Content CV value) First, a calibration curve was produced for the active component.
Specifically.
the absorption spectrum of the active component was measured using an absorption spectrometer, and a calibration curve was produced based on the peak top wavelength (for example, chlorpheniramine d-maleate: 264 nm, folic acid: 290 nm).
[0106]
The tablets for measuring the active component content CV value were tablets sampled within the 30 seconds immediately prior to stopping operation of the tableting machine. A single tablet was weighed, and then placed in a 100 niL measuring flask, which was subsequently filled to 100 mL with pure water. The resulting aqueous Date Recue/Date Received 2022-04-20 solution was filtered through a resin filter to remove the insoluble fraction, and the amount of the active component in the filtrate was quantified by absorptiometry. The active component content in the single tablet was calculated. In the case of tablets, a total of ten tablets were measured, and the average value and standard deviation for the active component content were determined.
The tablets for measuring the active component content CV value were tablets sampled within the 30 seconds immediately prior to stopping operation of the tableting machine. A single tablet was weighed, and then placed in a 100 niL measuring flask, which was subsequently filled to 100 mL with pure water. The resulting aqueous Date Recue/Date Received 2022-04-20 solution was filtered through a resin filter to remove the insoluble fraction, and the amount of the active component in the filtrate was quantified by absorptiometry. The active component content in the single tablet was calculated. In the case of tablets, a total of ten tablets were measured, and the average value and standard deviation for the active component content were determined.
[0107]
Subsequently, using the formula below, the coefficient of variation (also referred to as the "active component content CV value") which acts as a measure of the uniformity was determined. A lower coefficient of variation was evaluated as indicating favorable uniformity in the active component content.
Subsequently, using the formula below, the coefficient of variation (also referred to as the "active component content CV value") which acts as a measure of the uniformity was determined. A lower coefficient of variation was evaluated as indicating favorable uniformity in the active component content.
[0108]
Active component content CV value (%) = ([standard deviation] / [average value for active component content]) x 100
Active component content CV value (%) = ([standard deviation] / [average value for active component content]) x 100
[0109]
[Evaluation 3]
(Tableting Failure) In the "Production of Tablets" described above, the lower pestles of the rotary tableting machine were inspected visually after the 10-minute tableting operation, and the level of pestle clouding (powder adhesion) was evaluated. The evaluation criteria used were as follows.
[Evaluation 3]
(Tableting Failure) In the "Production of Tablets" described above, the lower pestles of the rotary tableting machine were inspected visually after the 10-minute tableting operation, and the level of pestle clouding (powder adhesion) was evaluated. The evaluation criteria used were as follows.
[0110]
(Evaluation Criteria) o: no powder adhesion A: a thin layer of powder adhesion, producing a slightly clouded state (with no metallic luster visible on the pestle surface) Date Recue/Date Received 2022-04-20 x: adhesion of powder clearly visible
(Evaluation Criteria) o: no powder adhesion A: a thin layer of powder adhesion, producing a slightly clouded state (with no metallic luster visible on the pestle surface) Date Recue/Date Received 2022-04-20 x: adhesion of powder clearly visible
[0111]
[Evaluation 4]
(Storage Stability (Cellulose Composition and Active Component Reactivity Evaluation)) Using aminophylline as the active component, the reactivity with the cellulose composition was evaluated in the manner described below.
First, a powder prepared by mixing the cellulose composition and aminophylline in a ratio of 1:1 (parts by mass) in a plastic bag was tableted in a static pressure tableting machine (applied pressure: 7 kN, holding time: 10 seconds), thus forming 011.3 mm 500 mg flat tablets.
Immediately following tableting, a tablet obtained using the above production method was analyzed using a spectroscopic colorimeter (SE-2000, manufactured by Nippon Denshoku Industries Co., Ltd.) to determine values for the lightness (L), the saturation (green to red) (a), and the saturation (blue to yellow) (b). The whiteness was then calculated using the following formula.
[Evaluation 4]
(Storage Stability (Cellulose Composition and Active Component Reactivity Evaluation)) Using aminophylline as the active component, the reactivity with the cellulose composition was evaluated in the manner described below.
First, a powder prepared by mixing the cellulose composition and aminophylline in a ratio of 1:1 (parts by mass) in a plastic bag was tableted in a static pressure tableting machine (applied pressure: 7 kN, holding time: 10 seconds), thus forming 011.3 mm 500 mg flat tablets.
Immediately following tableting, a tablet obtained using the above production method was analyzed using a spectroscopic colorimeter (SE-2000, manufactured by Nippon Denshoku Industries Co., Ltd.) to determine values for the lightness (L), the saturation (green to red) (a), and the saturation (blue to yellow) (b). The whiteness was then calculated using the following formula.
[0112]
Whiteness = 100 - R100-L)2 a2 b210.5
Whiteness = 100 - R100-L)2 a2 b210.5
[0113]
Further, a tableted tablet was placed in a glass bottle, the bottle was sealed and stored for one month in a constant temperature and humidity chamber set to a temperature of 40 C and a humidity of 75% RH, and then following storage, the L, a and b values were remeasured using the spectroscopic colorimeter, and the above formula was used to calculate the whiteness following the storage stability test.
Further, a tableted tablet was placed in a glass bottle, the bottle was sealed and stored for one month in a constant temperature and humidity chamber set to a temperature of 40 C and a humidity of 75% RH, and then following storage, the L, a and b values were remeasured using the spectroscopic colorimeter, and the above formula was used to calculate the whiteness following the storage stability test.
[0114]
Date Recue/Date Received 2022-04-20 The change in whiteness between immediately following tableting (before storage) and following the storage stability test (after storage) was calculated using the formula shown below, and this change in whiteness was deemed to indicate the reactivity between the cellulose composition and the active component.
Date Recue/Date Received 2022-04-20 The change in whiteness between immediately following tableting (before storage) and following the storage stability test (after storage) was calculated using the formula shown below, and this change in whiteness was deemed to indicate the reactivity between the cellulose composition and the active component.
[0115]
Change in whiteness whiteness (before storage) - whiteness (after storage)
Change in whiteness whiteness (before storage) - whiteness (after storage)
[0116]
If the absolute value of the change in whiteness exceeds 10%, then the color change is discernible even visually, and therefore tablets for which the absolute value of the change in whiteness was 10% or less were evaluated as having favorable storage stability.
If the absolute value of the change in whiteness exceeds 10%, then the color change is discernible even visually, and therefore tablets for which the absolute value of the change in whiteness was 10% or less were evaluated as having favorable storage stability.
[0117]
<Preparation of Wet Floc>
[Preparation Example I]
(Preparation of Wet Floc X) Two kg of shredded commercially available pulp and 30 L of an aqueous solution of hydrochloric acid were placed in a low-speed stirrer (30 LGL reactor (trade name) manufactured by lkebukuro Horo Kogyo Co., Ltd.) and hydrolyzed under stirring (reaction conditions: hydrochloric acid concentration of 0.5%, reaction temperature of 120 C, reaction time of 1.0 hours, and stirring speed of 220 rpm), thus obtaining an acid-insoluble residue. The obtained acid-insoluble residue was washed thoroughly with pure water until the electrical conductivity of the filtrate fell to less than 100 uS/cm, and then filtered to obtain a wet floc X. Measurement of the average degree of polymerization of the wet floc X using the copper ethylenediamine solution viscosity method disclosed in Date Recue/Date Received 2022-04-20 confirmation test (3) for crystalline cellulose in the Japanese Pharmacopoeia revealed an average degree of polymerization of 170.
<Preparation of Wet Floc>
[Preparation Example I]
(Preparation of Wet Floc X) Two kg of shredded commercially available pulp and 30 L of an aqueous solution of hydrochloric acid were placed in a low-speed stirrer (30 LGL reactor (trade name) manufactured by lkebukuro Horo Kogyo Co., Ltd.) and hydrolyzed under stirring (reaction conditions: hydrochloric acid concentration of 0.5%, reaction temperature of 120 C, reaction time of 1.0 hours, and stirring speed of 220 rpm), thus obtaining an acid-insoluble residue. The obtained acid-insoluble residue was washed thoroughly with pure water until the electrical conductivity of the filtrate fell to less than 100 uS/cm, and then filtered to obtain a wet floc X. Measurement of the average degree of polymerization of the wet floc X using the copper ethylenediamine solution viscosity method disclosed in Date Recue/Date Received 2022-04-20 confirmation test (3) for crystalline cellulose in the Japanese Pharmacopoeia revealed an average degree of polymerization of 170.
[0118]
<Preparation of Cellooligosaccharide Extract>
In the preparation of the wet floc X, the filtrate from the hydrolysis reaction that was separated from the acid-insoluble residue was collected. This filtrate was neutralized using a strongly basic anion exchange resin, and then concentrated with an evaporator to precipitate the insoluble matter (cellooligosaccharides).
Concentration was continued until the concentrate reached a slurry-like state, at which point concentration was halted before the concentrate dried to form a solid. The thus obtained concentrate was cooled in ice and subjected to suction filtration using a glass filter, and the insoluble matter retained on the glass filter was washed with cold water.
The washed insoluble matter was dried by vacuum drying under reduced pressure, obtaining a cellooligosaccharide extract.
The amount of cellooligosaccharides from trisaccharides to heptasaccharides in the cellooligosaccharide extract was 72% by mass.
<Preparation of Cellooligosaccharide Extract>
In the preparation of the wet floc X, the filtrate from the hydrolysis reaction that was separated from the acid-insoluble residue was collected. This filtrate was neutralized using a strongly basic anion exchange resin, and then concentrated with an evaporator to precipitate the insoluble matter (cellooligosaccharides).
Concentration was continued until the concentrate reached a slurry-like state, at which point concentration was halted before the concentrate dried to form a solid. The thus obtained concentrate was cooled in ice and subjected to suction filtration using a glass filter, and the insoluble matter retained on the glass filter was washed with cold water.
The washed insoluble matter was dried by vacuum drying under reduced pressure, obtaining a cellooligosaccharide extract.
The amount of cellooligosaccharides from trisaccharides to heptasaccharides in the cellooligosaccharide extract was 72% by mass.
[0119]
<Production of Cellulose Compositions>
[Example 11 (Production of Cellulose Powder A) The wet floc X was introduced into a 90 L plastic bucket, pure water was added to adjust the total solid fraction concentration to 10% by mass, and the mixture was dispersed using a three-one motor to prepare 30 kg of a dispersion. With the dispersion undergoing constant stirring, a neutralization was conducted with aqueous ammonia (pH
after neutralization: at least 7.5 but not more than 8.0), 5.56 g of the cellooligosaccharide Date Recue/Date Received 2022-04-20 extract (proportion of trisaccharides to heptasaccharides: 72%) was added and stirred, and the resulting mixture was spray dried (drying conditions: a dispersion supply rate of 6 kg/hour, an inlet temperature at least 180 C but not more than 220 C, and an outlet temperature at least 50 C but not more than 70 C), thus obtaining a cellulose composition A. The water-soluble substance content of the obtained powder was 11.3 mg, the amount of cellooligosaccharides from trisaccharides to heptasaccharides was 7.5 mg, and the proportion of trisaccharides to heptasaccharides within the water-soluble substances was 66% by mass.
<Production of Cellulose Compositions>
[Example 11 (Production of Cellulose Powder A) The wet floc X was introduced into a 90 L plastic bucket, pure water was added to adjust the total solid fraction concentration to 10% by mass, and the mixture was dispersed using a three-one motor to prepare 30 kg of a dispersion. With the dispersion undergoing constant stirring, a neutralization was conducted with aqueous ammonia (pH
after neutralization: at least 7.5 but not more than 8.0), 5.56 g of the cellooligosaccharide Date Recue/Date Received 2022-04-20 extract (proportion of trisaccharides to heptasaccharides: 72%) was added and stirred, and the resulting mixture was spray dried (drying conditions: a dispersion supply rate of 6 kg/hour, an inlet temperature at least 180 C but not more than 220 C, and an outlet temperature at least 50 C but not more than 70 C), thus obtaining a cellulose composition A. The water-soluble substance content of the obtained powder was 11.3 mg, the amount of cellooligosaccharides from trisaccharides to heptasaccharides was 7.5 mg, and the proportion of trisaccharides to heptasaccharides within the water-soluble substances was 66% by mass.
[0120]
[Example 21 (Production of Cellulose Powder B) The wet floc X was introduced into a 90 L plastic bucket, pure water was added to adjust the total solid fraction concentration to 10% by mass, and the mixture was dispersed using a three-one motor to prepare 30 kg of a dispersion. With the dispersion undergoing constant stirring, a neutralization was conducted with aqueous ammonia (pH
after neutralization: at least 7.5 but not more than 8.0), 3.39 g of the cellooligosaccharide extract (proportion of trisaccharides to heptasaccharides: 72%) was added and stirred, and the resulting mixture was spray dried (drying conditions: a dispersion supply rate of 6 kg/hour, an inlet temperature at least 180 C but not more than 220 C, and an outlet temperature at least 50 C but not more than 70 C), thus obtaining a cellulose composition B. The water-soluble substance content of the obtained powder was 7.8 lug, the amount of cellooligosaccharides from trisaccharides to heptasaccharides was 5.0 nig, and the proportion of trisaccharides to heptasaccharides within the water-soluble substances was 64% by mass.
[Example 21 (Production of Cellulose Powder B) The wet floc X was introduced into a 90 L plastic bucket, pure water was added to adjust the total solid fraction concentration to 10% by mass, and the mixture was dispersed using a three-one motor to prepare 30 kg of a dispersion. With the dispersion undergoing constant stirring, a neutralization was conducted with aqueous ammonia (pH
after neutralization: at least 7.5 but not more than 8.0), 3.39 g of the cellooligosaccharide extract (proportion of trisaccharides to heptasaccharides: 72%) was added and stirred, and the resulting mixture was spray dried (drying conditions: a dispersion supply rate of 6 kg/hour, an inlet temperature at least 180 C but not more than 220 C, and an outlet temperature at least 50 C but not more than 70 C), thus obtaining a cellulose composition B. The water-soluble substance content of the obtained powder was 7.8 lug, the amount of cellooligosaccharides from trisaccharides to heptasaccharides was 5.0 nig, and the proportion of trisaccharides to heptasaccharides within the water-soluble substances was 64% by mass.
[0121]
Date Recue/Date Received 2022-04-20 [Example 3]
(Production of Cellulose Powder C) A high-speed stirring granulator was charged with 800 g of the cellulose composition B obtained in Example 2, and following granulation and subsequent drying in a fluidized bed, the granules were sieved through a 500 pm mesh to obtain a cellulose composition C (granulation conditions: amount of added water 600 g, granulation time 20 minutes, main blade 400 rpm, cross screw 500 rpm drying conditions: drying temperature 80 C). The water-soluble substance content of the obtained powder was 7.4 mg, the amount of cellooligosaccharides from trisaccharides to heptasaccharides was 4.7 mg, and the proportion of trisaccharides to heptasaccharides within the water-soluble substances was 64% by mass.
Date Recue/Date Received 2022-04-20 [Example 3]
(Production of Cellulose Powder C) A high-speed stirring granulator was charged with 800 g of the cellulose composition B obtained in Example 2, and following granulation and subsequent drying in a fluidized bed, the granules were sieved through a 500 pm mesh to obtain a cellulose composition C (granulation conditions: amount of added water 600 g, granulation time 20 minutes, main blade 400 rpm, cross screw 500 rpm drying conditions: drying temperature 80 C). The water-soluble substance content of the obtained powder was 7.4 mg, the amount of cellooligosaccharides from trisaccharides to heptasaccharides was 4.7 mg, and the proportion of trisaccharides to heptasaccharides within the water-soluble substances was 64% by mass.
[0122]
[Example 4]
(Production of Cellulose Composition D) The cellulose composition B obtained in Example 2 was ground with a Jet Mill pulverizer to obtain a cellulose composition D. The water-soluble substance content of the obtained powder was 8.9 mg, the amount of cellooligosaccharides from trisaccharides to heptasaccharides was 5.8 mg, and the proportion of trisaccharides to heptasaccharides within the water-soluble substances was 65% by mass.
[Example 4]
(Production of Cellulose Composition D) The cellulose composition B obtained in Example 2 was ground with a Jet Mill pulverizer to obtain a cellulose composition D. The water-soluble substance content of the obtained powder was 8.9 mg, the amount of cellooligosaccharides from trisaccharides to heptasaccharides was 5.8 mg, and the proportion of trisaccharides to heptasaccharides within the water-soluble substances was 65% by mass.
[0123]
[Example 5]
(Production of Cellulose Composition E) The wet floc X was introduced into a 90 L plastic bucket, pure water was added to adjust the total solid fraction concentration to 10% by mass, and the mixture was dispersed using a three-one motor to prepare 30 kg of a dispersion. With the dispersion Date Recue/Date Received 2022-04-20 undergoing constant stirring, a neutralization was conducted with aqueous ammonia (pH
after neutralization: at least 7.5 but not more than 8.0), 2.52 g of the cellooligosaccharide extract (proportion of trisaccharides to heptasaccharides: 72%) was added and stirred, and the resulting mixture was spray dried (drying conditions: a dispersion supply rate of 6 kg/hour, an inlet temperature at least 180 C but not more than 220 C, and an outlet temperature at least 50 C but not more than 70 C), thus obtaining a cellulose composition E. The water-soluble substance content of the obtained powder was 6.4 mg, the amount of cellooligosaccharides from trisaccharides to heptasaccharides was 4.0 mg, and the proportion of trisaccharides to heptasaccharides within the water-soluble substances was 62% by mass.
[Example 5]
(Production of Cellulose Composition E) The wet floc X was introduced into a 90 L plastic bucket, pure water was added to adjust the total solid fraction concentration to 10% by mass, and the mixture was dispersed using a three-one motor to prepare 30 kg of a dispersion. With the dispersion Date Recue/Date Received 2022-04-20 undergoing constant stirring, a neutralization was conducted with aqueous ammonia (pH
after neutralization: at least 7.5 but not more than 8.0), 2.52 g of the cellooligosaccharide extract (proportion of trisaccharides to heptasaccharides: 72%) was added and stirred, and the resulting mixture was spray dried (drying conditions: a dispersion supply rate of 6 kg/hour, an inlet temperature at least 180 C but not more than 220 C, and an outlet temperature at least 50 C but not more than 70 C), thus obtaining a cellulose composition E. The water-soluble substance content of the obtained powder was 6.4 mg, the amount of cellooligosaccharides from trisaccharides to heptasaccharides was 4.0 mg, and the proportion of trisaccharides to heptasaccharides within the water-soluble substances was 62% by mass.
[0124]
[Comparative Example 1]
(Production of Cellulose Composition F) The wet floc X was introduced into a 90 L plastic bucket, pure water was added to adjust the total solid fraction concentration to 10% by mass, and the mixture was dispersed using a three-one motor to prepare 30 kg of a dispersion. With the dispersion undergoing constant stirring, a neutralization was conducted with aqueous ammonia (pH
after neutralization: at least 7.5 but not more than 8.0), and then without adding any cellooligosaccharide extract, the dispersion was spray dried (drying conditions: a dispersion supply rate of 6 kg/hour, an inlet temperature at least 180 C but not more than 220 C, and an outlet temperature at least 50 C but not more than 70 C), thus obtaining a cellulose composition F. The water-soluble substance content of the obtained powder was 2.4 mg, the amount of cellooligosaccharides from trisaccharides to heptasaccharides was 1.1 mg, and the proportion of trisaccharides to heptasaccharides within the water-soluble substances was 46% by mass.
Date Recue/Date Received 2022-04-20
[Comparative Example 1]
(Production of Cellulose Composition F) The wet floc X was introduced into a 90 L plastic bucket, pure water was added to adjust the total solid fraction concentration to 10% by mass, and the mixture was dispersed using a three-one motor to prepare 30 kg of a dispersion. With the dispersion undergoing constant stirring, a neutralization was conducted with aqueous ammonia (pH
after neutralization: at least 7.5 but not more than 8.0), and then without adding any cellooligosaccharide extract, the dispersion was spray dried (drying conditions: a dispersion supply rate of 6 kg/hour, an inlet temperature at least 180 C but not more than 220 C, and an outlet temperature at least 50 C but not more than 70 C), thus obtaining a cellulose composition F. The water-soluble substance content of the obtained powder was 2.4 mg, the amount of cellooligosaccharides from trisaccharides to heptasaccharides was 1.1 mg, and the proportion of trisaccharides to heptasaccharides within the water-soluble substances was 46% by mass.
Date Recue/Date Received 2022-04-20
[0125]
[Comparative Example 2]
(Production of Cellulose Composition G) The wet floc X was introduced into a 90 L plastic bucket, pure water was added to adjust the total solid fraction concentration to 10% by mass, and the mixture was dispersed using a three-one motor to prepare 30 kg of a dispersion. With the dispersion undergoing constant stirring, a neutralization was conducted with aqueous ammonia (pH
after neutralization: at least 7.5 but not more than 8.0), 7.29 g of the cellooligosaccharide extract (proportion of trisaccharides to heptasaccharides: 72%) was added and stirred, and the resulting mixture was spray dried (drying conditions: a dispersion supply rate of 6 kg/hour, an inlet temperature at least 180 C but not more than 220 C, and an outlet temperature at least 50 C but not more than 70 C), thus obtaining a cellulose composition G. The water-soluble substance content of the obtained powder was 14.1 mg, the amount of cellooligosaccharides from trisaccharides to heptasaccharides was 9.5 mg, and the proportion of trisaccharides to heptasaccharides within the water-soluble substances was 68% by mass.
[Comparative Example 2]
(Production of Cellulose Composition G) The wet floc X was introduced into a 90 L plastic bucket, pure water was added to adjust the total solid fraction concentration to 10% by mass, and the mixture was dispersed using a three-one motor to prepare 30 kg of a dispersion. With the dispersion undergoing constant stirring, a neutralization was conducted with aqueous ammonia (pH
after neutralization: at least 7.5 but not more than 8.0), 7.29 g of the cellooligosaccharide extract (proportion of trisaccharides to heptasaccharides: 72%) was added and stirred, and the resulting mixture was spray dried (drying conditions: a dispersion supply rate of 6 kg/hour, an inlet temperature at least 180 C but not more than 220 C, and an outlet temperature at least 50 C but not more than 70 C), thus obtaining a cellulose composition G. The water-soluble substance content of the obtained powder was 14.1 mg, the amount of cellooligosaccharides from trisaccharides to heptasaccharides was 9.5 mg, and the proportion of trisaccharides to heptasaccharides within the water-soluble substances was 68% by mass.
[0126]
Using each of the cellulose compositions obtained in the examples and comparative examples, the physical properties were measured using the methods described above, and tablets were produced and subjected to various evaluations. The results of measuring the physical properties are shown in Table 4, and the evaluation results are shown in Table 5. In Table 5, "d-MC" is an abbreviation for chlorpheniraniine d-maleate.
Using each of the cellulose compositions obtained in the examples and comparative examples, the physical properties were measured using the methods described above, and tablets were produced and subjected to various evaluations. The results of measuring the physical properties are shown in Table 4, and the evaluation results are shown in Table 5. In Table 5, "d-MC" is an abbreviation for chlorpheniraniine d-maleate.
[0127]
Date Recue/Date Received 2022-04-20 [Table 4]
Comparative Comparative Example 1 Example 2 Example 3 Example 4 Example 5 Example 1 Example 2 Cellulose composition A B C D
E F G
Water-soluble substance content [mg] 11.3 7.8 7.4 8.9 6.4 2.4 14.1 g Cellooligosaccharides (3 to 7) [mg] 7.5 5.0 4.7 5.8 4.0 1.1 9.5 tl content -4:
o Proportion of cellooligosaccharides P
(3 to 7) within water-soluble [% by mash] 66 64 64 65 62 46 68 ' ,..
, substances ,.., h, Average particle size birnl 62 59 134 26 h, h, , Loose bulk density [g/mL] 0.23 0.26 0.31 0.15 0.27 0.29 0.19 , r., '-o ....' Packed bulk density [g/mL] 0.42 0.41 0.41 0.32 0.40 0.41 0.39 i=-)(4' _ 1:0 "c3 Compressibility [7] 45 36 25 53 a Primary particle-equivalent 5" [pm] 24 23 20 24 particle size _ L/D Li 2.3 2.2 1.9 2.7 2.1 2.1 2.4 Reactivity with active component 1%l -8 -5 -4 -6 Date Recue/Date Received 2022-04-20
Date Recue/Date Received 2022-04-20 [Table 4]
Comparative Comparative Example 1 Example 2 Example 3 Example 4 Example 5 Example 1 Example 2 Cellulose composition A B C D
E F G
Water-soluble substance content [mg] 11.3 7.8 7.4 8.9 6.4 2.4 14.1 g Cellooligosaccharides (3 to 7) [mg] 7.5 5.0 4.7 5.8 4.0 1.1 9.5 tl content -4:
o Proportion of cellooligosaccharides P
(3 to 7) within water-soluble [% by mash] 66 64 64 65 62 46 68 ' ,..
, substances ,.., h, Average particle size birnl 62 59 134 26 h, h, , Loose bulk density [g/mL] 0.23 0.26 0.31 0.15 0.27 0.29 0.19 , r., '-o ....' Packed bulk density [g/mL] 0.42 0.41 0.41 0.32 0.40 0.41 0.39 i=-)(4' _ 1:0 "c3 Compressibility [7] 45 36 25 53 a Primary particle-equivalent 5" [pm] 24 23 20 24 particle size _ L/D Li 2.3 2.2 1.9 2.7 2.1 2.1 2.4 Reactivity with active component 1%l -8 -5 -4 -6 Date Recue/Date Received 2022-04-20
[0128]
[Table 5]
Comparative Comparative Example 1 Example 2 Example 3 Example 4 Example 5 Example 1 Example 2 Cellulose composition A B C D
E F G
Blend blend I blend I blend I blend I blend 1 blend I blend I
¨3 Active component d-MC d-MC d-MC d-MC
d-MC d-MC d-MC
w r7 Active component content [c7c by mass] 1 1 0 .
Cellulose composition [c7c by mass] 10 10 10 10 o content .
,..
u., Mannitol content [% by mass] 88 88 88 88 ,..
_ - r., Lubricant content [% by mass] 1 1 1 1 1 1 1 N) N) I
.
Tablet hardness [N] 78 67 60 96 65 56 84 .T.
N) (..,, .
i. Active component content CV value [% by mass] 1.9 1.7 1.3 2.0 1.6 1.5 2.5 c 7, rn Tableting failure [-] 0 0 0 0 <
C
=
= Tablet hardness [N] 75 62 55 90 = Active component content [% by mass] 1.8 1.7 1.4 1.7 2.0 3.5 2.4 CV value FD
vD
Tableting failure [-] o o o o o o o Tablet hardness reduction rate [To] 3.8 7.5 8.3 6.3 10.8 16.1 2.4 _ Date Recue/Date Received 2022-04-20
[Table 5]
Comparative Comparative Example 1 Example 2 Example 3 Example 4 Example 5 Example 1 Example 2 Cellulose composition A B C D
E F G
Blend blend I blend I blend I blend I blend 1 blend I blend I
¨3 Active component d-MC d-MC d-MC d-MC
d-MC d-MC d-MC
w r7 Active component content [c7c by mass] 1 1 0 .
Cellulose composition [c7c by mass] 10 10 10 10 o content .
,..
u., Mannitol content [% by mass] 88 88 88 88 ,..
_ - r., Lubricant content [% by mass] 1 1 1 1 1 1 1 N) N) I
.
Tablet hardness [N] 78 67 60 96 65 56 84 .T.
N) (..,, .
i. Active component content CV value [% by mass] 1.9 1.7 1.3 2.0 1.6 1.5 2.5 c 7, rn Tableting failure [-] 0 0 0 0 <
C
=
= Tablet hardness [N] 75 62 55 90 = Active component content [% by mass] 1.8 1.7 1.4 1.7 2.0 3.5 2.4 CV value FD
vD
Tableting failure [-] o o o o o o o Tablet hardness reduction rate [To] 3.8 7.5 8.3 6.3 10.8 16.1 2.4 _ Date Recue/Date Received 2022-04-20
[0129]
From the results in Tables 4 and 5, it is evident that reactivity with the active component was suppressed in the cellulose compositions A to E (Examples I to 5), in which the amount of cellooligosaccharides from trisaccharides to heptasaccharides per 5 g of the cellulose composition was at least 4.0 mg but not more than 7.5 mg, and that for the tablets produced using those cellulose compositions, the results for the tablet hardness, the reduction rate in the tablet hardness and the active component content CV
value were all favorable, and tableting failure during molding was able to be suppressed.
From the results in Tables 4 and 5, it is evident that reactivity with the active component was suppressed in the cellulose compositions A to E (Examples I to 5), in which the amount of cellooligosaccharides from trisaccharides to heptasaccharides per 5 g of the cellulose composition was at least 4.0 mg but not more than 7.5 mg, and that for the tablets produced using those cellulose compositions, the results for the tablet hardness, the reduction rate in the tablet hardness and the active component content CV
value were all favorable, and tableting failure during molding was able to be suppressed.
[0130]
In contrast, in the case of the cellulose composition F (Comparative Example 1), in which the amount of cellooligosaccharides from trisaccharides to heptasaccharides per g of the cellulose composition was less than 4.0 mg, although reactivity with the active component was low, in the tablets produced using the cellulose composition, tablets having favorable results for the tablet hardness, the reduction rate in the tablet hardness and the active component content CV value could not be obtained.
In the case of the tablets produced using the cellulose composition G
(Comparative Example 2), in which the amount of cellooligosaccharides from trisaccharides to heptasaccharides per 5 g of the cellulose composition exceeded 7.5 mg, although the tablet hardness and the reduction rate in the tablet hardness were favorable, the reactivity between the cellulose composition and the active component and the active component content CV value were unsatisfactory.
In contrast, in the case of the cellulose composition F (Comparative Example 1), in which the amount of cellooligosaccharides from trisaccharides to heptasaccharides per g of the cellulose composition was less than 4.0 mg, although reactivity with the active component was low, in the tablets produced using the cellulose composition, tablets having favorable results for the tablet hardness, the reduction rate in the tablet hardness and the active component content CV value could not be obtained.
In the case of the tablets produced using the cellulose composition G
(Comparative Example 2), in which the amount of cellooligosaccharides from trisaccharides to heptasaccharides per 5 g of the cellulose composition exceeded 7.5 mg, although the tablet hardness and the reduction rate in the tablet hardness were favorable, the reactivity between the cellulose composition and the active component and the active component content CV value were unsatisfactory.
[0131]
[Examples 6 to 8]
Using the cellulose composition B obtained in Example 2, tablets having the blend formulation shown below in Table 6 were produced using the method described Date Recue/Date Received 2022-04-20 above, and then subjected to each of the various evaluations. The results are shown in Table 6. In Table 6, "d-MC" is an abbreviation for chlorpheniramine d-maleate.
[Examples 6 to 8]
Using the cellulose composition B obtained in Example 2, tablets having the blend formulation shown below in Table 6 were produced using the method described Date Recue/Date Received 2022-04-20 above, and then subjected to each of the various evaluations. The results are shown in Table 6. In Table 6, "d-MC" is an abbreviation for chlorpheniramine d-maleate.
[0132]
[Table 6]
Example 6 Example 7 Example 8 Cellulose composition B B B
Blend blend 3 blend 4 blend 2 Active component d-MC d-MC folic acid o-F Active component content 1% by mass] 1 1 0.2 4 Cellulose composition [% by mass] 10 10 10 5 content '`:..". Mannitol content [% by mass] 86 88.5 88.8 Lubricant content [% by mass] 3 0.5 1 _ Tablet hardness [N] 62 68 66 (..., ' Active component content B. [% by mass] 2.0 1.7 2.0 = CV value F
, rn Tableting failure [-] o A o k F. ,, Tablet hardness [N] 57 65 62 o¨=
o L7.., Active component content - CV value [% by mass] 1.7 1.7 1.9 , C.7 Tableting failure [-] o A o Tablet hardness reduction rate [TeJ 8.1 4.4 6.1
[Table 6]
Example 6 Example 7 Example 8 Cellulose composition B B B
Blend blend 3 blend 4 blend 2 Active component d-MC d-MC folic acid o-F Active component content 1% by mass] 1 1 0.2 4 Cellulose composition [% by mass] 10 10 10 5 content '`:..". Mannitol content [% by mass] 86 88.5 88.8 Lubricant content [% by mass] 3 0.5 1 _ Tablet hardness [N] 62 68 66 (..., ' Active component content B. [% by mass] 2.0 1.7 2.0 = CV value F
, rn Tableting failure [-] o A o k F. ,, Tablet hardness [N] 57 65 62 o¨=
o L7.., Active component content - CV value [% by mass] 1.7 1.7 1.9 , C.7 Tableting failure [-] o A o Tablet hardness reduction rate [TeJ 8.1 4.4 6.1
[0133]
From Table 6, it is evident that in those tablets in which the lubricant content was at least 0.3% by mass but not more than 5% by mass (Examples 6 to 8), the tablet hardness, the reduction rate in the tablet hardness, the active component content CV
value, and the tableting failure rate during molding were all favorable.
Furthermore, based on a comparison of tablets that used the cellulose composition B but contained differing amounts of the lubricant (Examples 2, 6 and 7), a tendency was Date Recue/Date Received 2022-04-20 observed for better suppression of tableting failure during molding as the amount of the lubricant was increased.
On the other hand, reducing the amount of the lubricant yielded a tendency for more favorable results for the tablet hardness and the tablet hardness reduction rate.
INDUSTRIAL APPLICABILITY
From Table 6, it is evident that in those tablets in which the lubricant content was at least 0.3% by mass but not more than 5% by mass (Examples 6 to 8), the tablet hardness, the reduction rate in the tablet hardness, the active component content CV
value, and the tableting failure rate during molding were all favorable.
Furthermore, based on a comparison of tablets that used the cellulose composition B but contained differing amounts of the lubricant (Examples 2, 6 and 7), a tendency was Date Recue/Date Received 2022-04-20 observed for better suppression of tableting failure during molding as the amount of the lubricant was increased.
On the other hand, reducing the amount of the lubricant yielded a tendency for more favorable results for the tablet hardness and the tablet hardness reduction rate.
INDUSTRIAL APPLICABILITY
[0134]
By using the cellulose composition of an embodiment of the present invention, a cellulose composition can be provided that has favorable hardness and good suppression of both deviation in the active component content and tableting failure during molding.
A tablet of an embodiment of the present invention contains the cellulose composition, and exhibits favorable hardness, and good suppression of both deviation in the active component content and tableting failure during molding.
Date Recue/Date Received 2022-04-20
By using the cellulose composition of an embodiment of the present invention, a cellulose composition can be provided that has favorable hardness and good suppression of both deviation in the active component content and tableting failure during molding.
A tablet of an embodiment of the present invention contains the cellulose composition, and exhibits favorable hardness, and good suppression of both deviation in the active component content and tableting failure during molding.
Date Recue/Date Received 2022-04-20
Claims (10)
1. A cellulose cornposition comprising cellulose and cellooligosaccharides from trisaccharides to heptasaccharides, wherein a cellooligosaccharide content per 5 g of the cellulose composition is at least 1.5 mg but not more than 9.0 rng.
2. The cellulose composition according to Claim 1, wherein a water-soluble substance content per 5 g of the cellulose composition is at least 2.5 mg but not rnore than 12.5 mg.
3. The cellulose composition according to Claim 2, wherein a proportion of the cellooligosaccharides relative to the water-soluble substances is at least 47%
by mass but not more than 67% by mass.
by mass but not more than 67% by mass.
4. The cellulose composition according to any one of Claims 1 to 3, wherein the cellulose cornposition is a powder, and an average particle size of the powder is at least prn but not more than 200 pm.
5. The cellulose composition according to Claim 4, wherein an aspect ratio L/D of the powder is at least 1.8 but not more than 4Ø
6. A tablet comprising the cellulose composition of any one of Claims 1 to 5, and at least one active cornponent.
7. The tablet according to Claim 6, wherein a lubricant content, relative to a total mass of the tablet, is at least 0.3% by mass but not more than 5% by mass.
8. The tablet according to Claim 7, wherein the lubricant is at least one substance selected from the group consisting of fatty acid metal salts, fatty acid esters, and fatty acid ester metal salts.
9. The tablet according to Claim 7 or 8, wherein the lubricant is at least one substance selected from the group consisting of magnesium stearate, calcium stearate, sodium stearyl fumarate, stearic acid, sucrose fatty acid esters, and talc.
10. The tablet according to any one of Claims 6 to 9, wherein the active component content, relative to a total mass of the tablet, is at least 0.01% by mass less than 50% by mass.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2019/043583 WO2021090422A1 (en) | 2019-11-07 | 2019-11-07 | Cellulose composition and tablet |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3158394A1 true CA3158394A1 (en) | 2021-05-14 |
Family
ID=72048018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3158394A Pending CA3158394A1 (en) | 2019-11-07 | 2019-11-07 | Cellulose composition and tablet |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230055674A1 (en) |
EP (1) | EP4056637A4 (en) |
JP (1) | JP6744518B1 (en) |
CN (1) | CN112996850B (en) |
BR (1) | BR112022007431A2 (en) |
CA (1) | CA3158394A1 (en) |
WO (1) | WO2021090422A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114948765B (en) * | 2022-05-27 | 2023-07-07 | 王孟华 | Mouthwash and preparation method thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010200720A (en) * | 2009-03-06 | 2010-09-16 | Asahi Kasei Chemicals Corp | Taste quality improver |
JP2010215556A (en) * | 2009-03-17 | 2010-09-30 | Asahi Kasei Chemicals Corp | External composition for skin, improved in skin permeability |
SE536746C2 (en) * | 2010-05-12 | 2014-07-08 | Stora Enso Oyj | A composition containing microfibrillated cellulose and a process for making a composition |
WO2013180248A1 (en) * | 2012-05-31 | 2013-12-05 | 旭化成ケミカルズ株式会社 | Cellulose powder |
SG10201913076PA (en) * | 2013-12-12 | 2020-02-27 | Almirall Sa | Pharmaceutical compositions comprising dimethyl fumarate |
-
2019
- 2019-11-07 JP JP2020506361A patent/JP6744518B1/en active Active
- 2019-11-07 US US17/767,996 patent/US20230055674A1/en active Pending
- 2019-11-07 CA CA3158394A patent/CA3158394A1/en active Pending
- 2019-11-07 WO PCT/JP2019/043583 patent/WO2021090422A1/en unknown
- 2019-11-07 EP EP19951364.9A patent/EP4056637A4/en active Pending
- 2019-11-07 CN CN201980044853.6A patent/CN112996850B/en active Active
- 2019-11-07 BR BR112022007431A patent/BR112022007431A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021090422A1 (en) | 2021-05-14 |
EP4056637A4 (en) | 2022-11-16 |
BR112022007431A2 (en) | 2022-07-12 |
CN112996850B (en) | 2022-06-03 |
CN112996850A (en) | 2021-06-18 |
US20230055674A1 (en) | 2023-02-23 |
JPWO2021090422A1 (en) | 2021-11-25 |
EP4056637A1 (en) | 2022-09-14 |
JP6744518B1 (en) | 2020-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9446137B2 (en) | Composite particles which contain both cellulose and inorganic compound | |
JP7332549B2 (en) | How to suppress mount occurrence | |
JP7028927B2 (en) | How to reduce the capacitance of granules | |
JP2021075686A (en) | Cellulose composition, tablet, and orally disintegrating tablet | |
CA3158394A1 (en) | Cellulose composition and tablet | |
RU2798266C1 (en) | Cellulose-containing composition and tablet | |
JP6744517B1 (en) | Cellulose composition, tablet and orally disintegrating tablet | |
WO2019130701A1 (en) | Cellulose powder | |
RU2796502C1 (en) | Cellulose-containing composition, tablet and tablet with intraoral disintegration | |
TWI734247B (en) | Cellulose composition and lozenge | |
TWI723621B (en) | Cellulose composition, lozenge and orally disintegrating tablet | |
JP2021075687A (en) | Cellulose composition and tablet | |
JP2022139962A (en) | Granules, method for producing granules, and tablet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20220420 |
|
EEER | Examination request |
Effective date: 20220420 |
|
EEER | Examination request |
Effective date: 20220420 |
|
EEER | Examination request |
Effective date: 20220420 |
|
EEER | Examination request |
Effective date: 20220420 |
|
EEER | Examination request |
Effective date: 20220420 |